

Bibliography

- Aarons, G. A., M. Hurlburt, and S. M. Howitz. 2011. Advancing a Conceptual Model of Evidence-Based Practice Implementation in Public Service Sectors. *Adm. Policy Ment. Health* **38**:4–23. [15]
- Abbott, A. 2008. Psychiatric Genetics: The Brains of the Family. *Nature* **454**:154–157. [08]
- . 2010. Schizophrenia: The Drug Deadlock. *Nature* **468**:158–159. [13, 17]
- Abel, K. M., M. P. Allin, D. R. Hemsley, and M. A. Geyer. 2003. Low Dose Ketamine Increases Prepulse Inhibition in Healthy Men. *Neuropharmacology* **44**:729–737. [07]
- Abi-Dargham, A., and H. Moore. 2003. Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia. *Neuroscientist* **9**:404–416. [12]
- Addington, J., B. A. Cornblatt, K. S. Cadenhead, et al. 2011. At Clinical High Risk for Psychosis: Outcome for Nonconverters. *Am. J. Psychiatr.* **168**:800–805. [02]
- Addington, J., H. Saeedi, and D. Addington. 2005. The Course of Cognitive Functioning in First Episode Psychosis: Changes over Time and Impact on Outcome. *Schizophr. Res.* **78**:35–43. [07]
- Addington, J., S. Van Mastrigt, and D. Addington. 2004. Duration of Untreated Psychosis: Impact on 2-Year Outcome. *Psychol. Med.* **34**:277–284. [07]
- Aggernaes, B., B. Y. Glenthøj, B. H. Ebdrup, et al. 2010. Sensorimotor Gating and Habituation in Antipsychotic-Naive, First-Episode Schizophrenia Patients before and after 6 Months' Treatment with Quetiapine. *Int. J. Neuropsychopharmacol.* **13**:1383–1395. [07]
- Agid, O., S. Kapur, T. Arenovich, and R. B. Zipursky. 2003. Delayed Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected. *Arch. Gen. Psychiatry* **60**:1228–1235. [17]
- Aguilar-Valles, A., C. Flores, and G. N. Luheshi. 2010. Prenatal Inflammation-Induced Hypoferremia Alters Dopamine Function in the Adult Offspring in Rat: Relevance for Schizophrenia. *PLoS One* **5**:e10967. [07]
- Ahveninen, J., S. Kahkonen, S. Pennanen, et al. 2002. Tryptophan Depletion Effects on EEG and MEG Responses Suggest Serotonergic Modulation of Auditory Involuntary Attention in Humans. *NeuroImage* **16**:1052–1061. [07]
- Aleman, A., R. Higman, E. H. F. de Haan, and R. S. Kahn. 1999. Memory Impairment in Schizophrenia: A Meta-Analysis. *Am. J. Psychiatr.* **156**:1358–1366. [04]
- Alexander-Bloch, A. F., P. E. Vértes, R. Stidd, et al. 2012. The Anatomical Distance of Functional Connections Predicts Brain Network Topology in Health and Schizophrenia. *Cereb. Cortex* **23**:127–138. [06]
- Allardyce, J., and J. Boydell. 2006. Review: The Wider Social Environment and Schizophrenia. *Schizophr. Bull.* **32**:592–598. [01]
- Allen, P., J. Luigjes, O. D. Howes, et al. 2012. Transition to Psychosis Associated with Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals. *Schizophr. Bull.* **38**:1268–1276. [07]
- Allen, P., M. L. Seal, I. Valli, et al. 2011. Altered Prefrontal and Hippocampal Function During Verbal Encoding and Recognition in People with Prodromal Symptoms of Psychosis. *Schizophr. Bull.* **37**:746–756. [07]

- Allon Therapeutics Inc. 2009. Press Release (May 11, 2013): Phase IIA Clinical Data Confirms Potential of Allon's Davunetide as a Treatment for Cognitive Impairment in Schizophrenia Patients. <http://www.allontherapeutics.com/2009/12/phase-ii-clinical-data-confirms-potential-of-allon%e2%80%99s-davunetide-as-a-treatment-for-cognitive-impairment-in-schizophrenia-patients/>. (accessed June 14, 2013). [04]
- Allport, G. 1962. The General and the Unique in Psychological Science. *J. Pers.* **30**:405–422. [01]
- Alonso, J., M. C. Angermeyer, S. Bernert, et al. 2004. Use of Mental Health Services in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. *Acta Psychiatr. Scand.* **420**:47–54. [16]
- Alonso, J., M. Codony, V. Kovess, et al. 2007. Population Level of Unmet Need for Mental Healthcare in Europe. *Br. J. Psychiatry* **190**:299–306. [16]
- American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders (DSM IV). Arlington, VA: APA Publishing. [05]
- . 2013. DSM-5. Arlington, VA: APA Publishing. [02, 03]
- Amminger, G. P., M. R. Schäfer, K. Papageorgiou, et al. 2010. Long-Chain Omega-3 Fatty Acids for Indicated Prevention of Psychotic Disorders: A Randomized, Placebo-Controlled Trial. *Arch. Gen. Psychiatry* **67**:146–154. [01, 07]
- Anderson, C. M., D. J. Reiss, and G. E. Hogarty, eds. 1986. Schizophrenia and the Family. New York: Guilford Press. [15]
- Ando, J., Y. Ono, and M. J. Wright. 2001. Genetic Structure of Spatial and Verbal Working Memory. *Behav. Genet.* **31**:615–624. [07]
- Andrade, L., J. J. Caraveo-Anduaga, P. Berglund, et al. 2003. The Epidemiology of Major Depressive Episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. *Int. J. Meth. Psychiatr. Res.* **12**:3–21. [16]
- Andreasen, N. C. 1982. Negative Symptoms in Schizophrenia. Definition and Reliability. *Arch. Gen. Psychiatry* **39**:784–788. [10, 17]
- Andreasen, N. C., W. T. Carpenter, Jr., J. M. Kane, et al. 2005. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus. *Am. J. Psychiatr.* **162**:441–449. [17]
- Andreasson, S., P. Allebeck, A. Engstrom, and U. Rydberg. 1987. Cannabis and Schizophrenia. A Longitudinal Study of Swedish Conscripts. *Lancet* **2**:1483–1486. [07]
- Andrews, A., M. Knapp, P. McCrone, M. Parsonage, and M. Trachtenberg. 2012. Effective Interventions in Schizophrenia: The Economic Case. A Report Prepared for the Schizophrenia Commission. London: Rethink Mental Illness. <http://www2.lse.ac.uk/LSEHealthAndSocialCare/pdf/LSE-economic-report-FINAL-12-Nov.pdf> (accessed 25 May, 2013). [01]
- Andrews, G., S. Henderson, and W. Hall. 2001. Prevalence, Comorbidity, Disability and Service Utilisation: Overview of the Australian National Mental Health Survey. *Br. J. Psychiatry* **178**:145–153. [16]
- Angst, J., A. Gamma, F. Benazzi, et al. 2003. Toward a Re-Definition of Subthreshold Bipolarity: Epidemiology and Proposed Criteria for Bipolar-II, Minor Bipolar Disorders and Hypomania. *J. Affect. Disord.* **73**:133–146. [16]
- Anthony, W. 1993. Recovery from Mental Illness: The Guiding Vision of the Mental Health Service System in the 1990s. *Psychosocial Rehab. J.* **16**:11–23. [15, 17]
- Anthony, W., M. Cohen, M. Farkas, and C. Gagne. 2002. Psychiatric Rehabilitation (2nd edition). Boston: Boston Univ. Center for Psychiatric Rehabilitation. [15]
- Archer, T. 2010. Neurodegeneration in Schizophrenia. *Expert. Rev. Neurother.* **10**:1131–1141. [07]

- Arguello, P. A., and J. A. Gogos. 2006. Modeling Madness in Mice: One Piece at a Time. *Neuron* **52**:179–196. [08]
- Arnold, S. E., L. Y. Han, P. J. Moberg, et al. 2001. Dysregulation of Olfactory Receptor Neuron Lineage in Schizophrenia. *Arch. Gen. Psychiatry* **58**:829–835. [10]
- Arnold, S. E., E. B. Lee, P. J. Moberg, et al. 2010. Olfactory Epithelium Amyloid-Beta and Paired Helical Filament-Tau Pathology in Alzheimer Disease. *Ann. Neurol.* **67**:462–469. [10]
- Arranz, M. J., and J. de Leon. 2007. Pharmacogenetics and Pharmacogenomics of Schizophrenia: A Review of Last Decade of Research. *Mol. Psychiatry* **12**:707–747. [07, 08]
- Arseneault, L., M. Cannon, R. Poulton, et al. 2002. Cannabis Use in Adolescence and Risk for Adult Psychosis: Longitudinal Prospective Study. *BMJ* **325**:1212–1213. [07]
- Arseneault, L., M. Cannon, J. Witton, and R. M. Murray. 2004. Causal Association between Cannabis and Psychosis: Examination of the Evidence. *Br. J. Psychiatry* **184**:110–117. [09]
- AstraZeneca and Targacept. 2008. Astrazeneca and Targacept Announce Results from Trial of AZD3480 for Cognitive Dysfunction in Schizophrenia. <http://www.news-medical.net/news/2008/12/10/43968.aspx>. (accessed June 16, 2013). [04]
- Atkins, D. 2009. Queri and Implementation Research: Emerging from Adolescence into Adulthood: Queri Series. *Implement. Sci.* **4**:12. [15]
- Atkinson, R. J., P. T. Michie, and U. Schall. 2012. Duration Mismatch Negativity and P3a in First-Episode Psychosis and Individuals at Ultra-High Risk of Psychosis. *Biol. Psychiatry* **71**:98–104. [07, 09]
- Aukes, M. F., B. Z. Alizadeh, M. M. Sitskoorn, et al. 2009. Genetic Overlap among Intelligence and Other Candidate Endophenotypes for Schizophrenia. *Biol. Psychiatry* **65**:527–534. [14]
- Averbeck, B. B., T. Bobin, S. Evans, and S. S. Shergill. 2011. Emotion Recognition and Oxytocin in Patients with Schizophrenia. *Psychol. Med.* **42**:1–8. [07]
- Ayllon, T., and N. Azrin. 1968. *The Token Economy: A Motivational System for Therapy and Rehabilitation*. New York: Appleton-Century-Crofts. [15]
- Balaguer-Ballester, E., C. Lapish, J. Seamans, and D. Durstewitz. 2011. Attracting Dynamics of Frontal Cortex Ensembles During Memory-Guided Decision Making. *PLoS Comput. Biol.* **7**:e1002057. [12]
- Baldeweg, T., D. Wong, and K. E. Stephan. 2006. Nicotinic Modulation of Human Auditory Sensory Memory: Evidence from Mismatch Negativity Potentials. *Int. J. Psychophysiol.* **59**:49–58. [07]
- Bandura, A. 1969. *Principles of Behavior Modification*. New York: Holt, Rinehart and Winston, Inc. [15]
- Barak, S., and I. Weiner. 2011. Putative Cognitive Enhancers in Preclinical Models Related to Schizophrenia: The Search for an Elusive Target. *Pharmacol. Biochem. Behav.* **99**:164–189. [07]
- Barbato, A., and B. D'Avanzo. 2000. Family Interventions in Schizophrenia and Related Disorders: A Critical Review of Clinical Trials. *Acta Psychiatr. Scand.* **102**:81–97. [17]
- Barch, D. M. 2010. Pharmacological Strategies for Enhancing Cognition in Schizophrenia. *Curr. Top. Behav. Neurosci.* **4**:43–96. [07]
- Barch, D. M., and A. Ceaser. 2012. Cognition in Schizophrenia: Core Psychological and Neural Mechanisms. *Trends Cogn. Sci.* **16**:27–34. [01]
- Barger, S. W., and A. S. Basile. 2001. Activation of Microglia by Secreted Amyloid Precursor Protein Evokes Release of Glutamate by Cystine Exchange and Attenuates Synaptic Function. *J. Neurochem.* **76**:846–854. [07]

- Barlati, S., L. De Peri, G. Deste, P. Fusar-Poli, and A. Vita. 2012. Cognitive Remediation in the Early Course of Schizophrenia: A Critical Review. *Curr. Pharm. Des.* **18**:534–541. [07]
- Barnett, J. H., F. McDougall, M. K. Xu, et al. 2012. Childhood Cognitive Function and Adult Psychopathology: Associations with Psychotic and Non-Psychotic Symptoms in the General Population. *Br. J. Psychiatry* **201**:124–130. [06]
- Barnett, J. H., C. H. Salmond, P. B. Jones, and B. J. Sahakian. 2006. Cognitive Reserve in Neuropsychiatry. *Psychol. Med.* **36**:1053–1064. [06]
- Barnsley, N., J. H. McAuley, R. Mohan, et al. 2011. The Rubber Hand Illusion Increases Histamine Reactivity in the Real Arm. *Curr. Biol.* **21**:R945–R946. [01]
- Barr, M. S., F. Farzan, T. K. Rajji, et al. 2013. Can Repetitive Magnetic Stimulation Improve Cognition in Schizophrenia? Pilot Data from a Randomized Controlled Trial. *Biol. Psychiatry* **73**:510–517. [09]
- Barr, R. S., D. A. Pizzagalli, M. A. Culhane, D. C. Goff, and A. E. Evins. 2008. A Single Dose of Nicotine Enhances Reward Responsiveness in Nonsmokers: Implications for Development of Dependence. *Biol. Psychiatry* **63**:1061–1065. [17]
- Barrowclough, C., G. Haddock, T. Wykes, et al. 2010. Integrated Motivational Interviewing and Cognitive Behavioural Therapy for People with Psychosis and Comorbid Substance Misuse: Randomised Controlled Trial. *BMJ* **341**:c6325. [15, 17]
- Barrowclough, C., and N. Tarrow. 1992. Families of Schizophrenic Patients: Cognitive Behavioural Intervention. London: Chapman & Hall. [15]
- Bar-Yam, Y. 1997. Dynamics of Complex Systems. Cambridge, MA: Perseus. [01]
- . 2002. Unifying Principles in Complex Systems. *N. Engl. Complex Sys. Inst.* <http://necsi.edu/projects/yaneer/complexsystems.pdf>. (accessed December 31, 2012). [01]
- Basar-Eroglu, C., A. Brand, H. Hildebrandt, et al. 2007. Working Memory Related Gamma Oscillations in Schizophrenia Patients. *Int. J. Psychophysiol.* **64**:39–45. [04]
- Bassett, D. S., D. L. Greenfield, A. Meyer-Lindenberg, et al. 2010. Efficient Physical Embedding of Topologically Complex Information Processing Networks in Brains and Computer Circuits. *PLoS Comput. Biol.* **6**:e1000748. [08]
- Baxter, L. R., Jr., J. M. Schwartz, K. S. Bergman, et al. 1992. Caudate Glucose Metabolic Rate Changes with Both Drug and Behavior Therapy for Obsessive-Compulsive Disorder. *Arch. Gen. Psychiatry* **49**:681–689. [07]
- Bazan, N. G. 2005. Neuroprotectin D1 (NPD1): A DHA-Derived Mediator That Protects Brain and Retina against Cell Injury-Induced Oxidative Stress. *Brain Pathol.* **15**:159–166. [07]
- Bearden, C. E., P. M. Thompson, M. Dalwani, et al. 2007. Greater Cortical Gray Matter Density in Lithium-Treated Patients with Bipolar Disorder. *Biol. Psychiatry* **62**:7–16. [07]
- Bebbington, P., S. Jonas, E. Kuipers, et al. 2011. Childhood Sexual Abuse and Psychosis: Data from a Cross-Sectional National Psychiatric Survey in England. *Br. J. Psychiatry* **199**:29–37. [09]
- Beck, A. T., N. A. Rector, N. Stolar, and P. Grant. 2009. Schizophrenia: Cognitive Theory, Research, and Therapy. New York: Guilford Press. [15]
- Beck, A. T., A. J. Rush, B. F. Shaw, and G. Emery. 1979. Cognitive Therapy of Depression. New York: Guilford Press. [15]
- Becker, D. R., and R. E. Drake. 2003. A Working Life for People with Severe Mental Illness. New York: Oxford Univ. Press. [15]

- Behrens, M. M., S. S. Ali, and L. L. Dugan. 2008. Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of Schizophrenia. *J. Neurosci.* **28**:13,957–13,966. [11]
- Behrens, M. M., and T. J. Sejnowski. 2009. Does Schizophrenia Arise from Oxidative Dysregulation of Parvalbumin-Interneurons in the Developing Cortex? *Neuropharmacology* **57**:193–200. [13]
- Belforte, J. E., V. Zsiros, E. R. Sklar, et al. 2010. Postnatal NMDA Receptor Ablation in Corticolimbic Interneurons Confers Schizophrenia-Like Phenotypes. *Nat. Neurosci.* **13**:76–83. [11, 13]
- Bellack, A. S., K. T. Mueser, S. Gingerich, and J. Agresta. 2004a. Social Skills Training for Schizophrenia: A Step-by-Step Guide (2nd edition). New York: Guilford Press. [15]
- Bellack, A. S., N. R. Schooler, S. R. Marder, et al. 2004b. Do Clozapine and Risperidone Affect Social Competence and Problem Solving? *Am. J. Psychiatr.* **161**:364–367. [04]
- Belsky, J., C. Jonassaint, M. Pluess, et al. 2009. Vulnerability Genes or Plasticity Genes? *Mol. Psychiatry* **14**:746–754. [09]
- Ben-Ari, Y. 2008. Neuro-Archaeology: Pre-Symptomatic Architecture and Signature of Neurological Disorders. *Trends Neurosci.* **31**:626–636. [13]
- Ben-Ari, Y., and N. C. Spitzer. 2010. Phenotypic Checkpoints Regulate Neuronal Development. *Trends Neurosci.* **33**:485–492. [13]
- Bender, L. 1959. The Concept of Pseudopsychopathic Schizophrenia in Adolescents. *Am. J. Orthopsychiat.* **29**:491–512. [01]
- . 1966. The Concept of Plasticity in Childhood Schizophrenia. *Proc. Annu. Meet. Am. Psychopathol. Assoc.* **54**:354–365. [01]
- Benes, F. M., and S. Berretta. 2001. Gabaergic Interneurons: Implications for Understanding Schizophrenia and Bipolar Disorder. *Neuropsychopharmacology* **25**:1–27. [12]
- Bentall, R. P. 1993. Deconstructing the Concept of “Schizophrenia.” *J. Ment. Health* **2**:223–228. [15]
- Ben-Zeev, D., R. E. Drake, P. W. Corrigan, et al. 2012. Using Contemporary Technologies in the Assessment and Treatment of Serious Mental Illness. *Am. J. Psychiatr. Rehabil.* **15**:357–376. [15]
- Berger, G. E., S. Wood, and P. D. McGorry. 2003. Incipient Neurovulnerability and Neuroprotection in Early Psychosis. *Psychopharmacol. Bull.* **37**:79–101. [07]
- Berger, G. E., S. J. Wood, M. Ross, et al. 2012. Neuroprotective Effects of Low-Dose Lithium in Individuals at Ultra-High Risk for Psychosis. A Longitudinal MRI/MRS Study. *Curr. Pharm. Des.* **18**:570–575. [07]
- Berger, G. E., S. J. Wood, R. M. Wellard, et al. 2008. Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study. *Neuropsychopharmacology* **33**:2467–2473. [07]
- Bertolino, A., G. Caforio, G. Blasi, et al. 2004. Interaction of COMT (Val(108/158)Met) Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients with Schizophrenia. *Am. J. Psychiatr.* **161**:1798–1805. [07]
- Bertram, L., C. M. Lill, and R. E. Tanzi. 2010. The Genetics of Alzheimer Disease: Back to the Future. *Neuron* **68**:270–281. [13]
- Betancur, C., T. Sakurai, and J. D. Buxbaum. 2009. The Emerging Role of Synaptic Cell-Adhesion Pathways in the Pathogenesis of Autism Spectrum Disorders. *Trends Neurosci.* **32**:402–412. [13]
- Bickman, L. 2008. A Measurement Feedback System (MFS) Is Necessary to Improve Mental Health Outcomes. *J. Am. Acad. Child Adolesc. Psychiatry* **47**:1114–1119. [15]

- Bigos, K. L., V. S. Mattay, J. H. Callicott, et al. 2010. Genetic Variation in CACNA1C Affects Brain Circuitries Related to Mental Illness. *Arch. Gen. Psychiatry* **67**:939–945. [08]
- Bigos, K. L., and D. R. Weinberger. 2010. Imaging Genetics: Days of Future Past. *NeuroImage* **53**:804–809. [08]
- Bijl, R. V., R. de Graaf, E. Hiripi, et al. 2003. The Prevalence of Treated and Untreated Mental Disorders in Five Countries. *Health Affairs* **22**:122–133. [16]
- Bijl, R. V., and A. Ravelli. 2000. Psychiatric Morbidity, Service Use, and Need for Care in the General Population: Results of the Netherlands Mental Health Survey and Incidence Study. *Am. J. Public Health* **90**:602–607. [16]
- Bijou, S. W., and R. F. Peterson. 1971. Functional Analysis in the Assessment of Children. In: *Advances in Psychological Assessment*, ed. P. McReynolds, vol. 2, pp. 63–78. Palo Alto: Science and Behavior Books. [15]
- Bilbo, S. D., and J. M. Schwarz. 2009. Early-Life Programming of Later-Life Brain and Behavior: A Critical Role for the Immune System. *Front. Behav. Neurosci.* **3**:14. [07]
- Bilder, R. M., L. Lipschutz-Broch, G. Reiter, et al. 1992. Intellectual Deficits in First-Episode Schizophrenia: Evidence for Progressive Deterioration. *Schizophr. Bull.* **18**:437–448. [04]
- Bilder, R. M., G. Reiter, J. Bates, et al. 2006. Cognitive Development in Schizophrenia: Follow-Back from the First Episode. *J. Clin. Exp. Neuropsychol.* **28**:270–282. [07]
- Birchwood, M., R. Mason, F. MacMillian, and J. Healy. 1993. Depression, Demoralization and Control over Psychotic Illness: A Comparison and Non-Depressed Patients with a Chronic Psychosis. *Psychol. Med.* **23**:387–395. [15]
- Bittner, R. 2003. Notebook 10 (1887). In: *Friedrich Nietzsche: Writings from the Late Notebooks*, p. 188. Cambridge: Cambridge Univ. Press. [06]
- Blackwood, D. H., A. Fordyce, M. T. Walker, et al. 2001. Schizophrenia and Affective Disorders: Cosegregation with a Translocation at Chromosome 1q42 That Directly Disrupts Brain-Expressed Genes: Clinical and P300 Findings in a Family. *Am. J. Hum. Genet.* **69**:428–433. [08]
- Blake, R., and M. Shiffrar. 2007. Perception of Human Motion. *Annu. Rev. Psychol.* **58**:47–73. [07]
- Bleuler, E. 1911/1950. *Dementia Praecox or the Group of Schizophrenias* (translated by J. Zinkin). New York: Intl. Universities Press. [02, 03, 14]
- Bleuler, M. 1972. *Die Schizophrenen Geistesstörungen: Im Lichte Langjähriger Kranken und Familiengeschichten*. Stuttgart: Georg Thieme Verlag. [06]
- . 1974. The Offspring of Schizophrenics. *Schizophr. Bull.* **8**:93–107. [06]
- Block, M. L., and J. S. Hong. 2007. Chronic Microglial Activation and Progressive Dopaminergic Neurotoxicity. *Biochem. Soc. Trans.* **35**:1127–1132. [07]
- Bodatsch, M., S. Ruhmann, M. Wagner, et al. 2011. Prediction of Psychosis by Mismatch Negativity. *Biol. Psychiatry* **69**:959–966. [07, 09]
- Bond, G. R. 1992. Vocational Rehabilitation. In: *Handbook of Psychiatric Rehabilitation*, ed. R. P. Liberman, pp. 244–275. New York: MacMillan. [15]
- . 2004. Supported Employment: Evidence for an Evidence-Based Practice. *Psychiatr. Rehabil. J.* **27**:345–359. [15]
- Bond, G. R., R. E. Drake, and D. R. Becker. 2008. An Update on Randomized Controlled Trials of Evidence-Based Supported Employment. *Psychiatr. Rehabil. J.* **31**:280–290. [15]
- . 2012. Generalizability of the Individual Placement and Support (IPS) Model of Supported Employment Outside the US. *World Psychiatry* **11**:32–39. [15]

- Bond, G. R., R. E. Drake, G. J. McHugo, C. A. Rapp, and E. Whitley. 2009. Strategies for Improving Fidelity in the National Evidence-Based Practices Project. *Res. Social Work Prac.* **19**:569–581. [15]
- Bond, G. R., L. Evans, M. P. Salyers, J. Williams, and H.-W. Kim. 2000. Measurement of Fidelity in Psychiatric Rehabilitation. *Ment. Health Serv. Res.* **2**:75–87. [15]
- Bond, G. R., and M. Kukla. 2011. Impact of Follow-Along Support on Job Tenure in IPS Supported Employment. *J. Nerv. Ment. Dis.* **199**:150–155. [15]
- Bonini, L., and P. F. Ferrari. 2011. Evolution of Mirror Systems: A Simple Mechanism for Complex Cognitive Functions. *Ann. NY Acad. Sci.* **1225**:166–175. [07]
- Borgmann-Winter, K. E., N. E. Rawson, H. Y. Wang, et al. 2009. Human Olfactory Epithelial Cells Generated *in Vitro* Express Diverse Neuronal Characteristics. *Neuroscience* **158**:642–653. [10]
- Borgwardt, S. J., A. Riecher-Rossler, P. Dazzan, et al. 2007. Regional Gray Matter Volume Abnormalities in the at Risk Mental State. *Biol. Psychiatry* **61**:1148–1156. [07]
- Borkovec, T. D. 2004. Research in Training Clinics and Practice Research Networks: A Route to the Integration of Science and Practice. *Clin. Psychol.* **11**:211–215. [15]
- Borojerdj, B., M. Phipps, L. Kopylev, et al. 2001. Enhancing Analogic Reasoning with rTMS over the Left Prefrontal Cortex. *Neurology* **56**:526–528. [09]
- Bosker, F. J., C. A. Hartman, I. M. Nolte, et al. 2011. Poor Replication of Candidate Genes for Major Depressive Disorder Using Genome-Wide Association Data. *Mol. Psychiatry* **16**:516–532. [08]
- Bouffard, L. A., and L. R. Muftić. 2006. The “Rural Mystique”: Social Disorganization and Violence Beyond Urban Communities. *West. Crim. Rev.* **7**:56–66. [01]
- Boulanger, L. M. 2009. Immune Proteins in Brain Development and Synaptic Plasticity. *Neuron* **64**:93–109. [08]
- Bourque, F., E. van der Ven, and A. Malla. 2011. A Meta-Analysis of the Risk for Psychotic Disorders among First- and Second-Generation Immigrants. *Psychol. Med.* **41**:897–910. [08]
- Bowie, C. R., A. Reichenberg, T. L. Patterson, R. K. Heaton, and P. D. Harvey. 2006. Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations with Cognition, Functional Capacity, and Symptoms. *Am. J. Psychiatr.* **163**:418–425. [14]
- Bowlby, J. 1969. Attachment and Loss I: Attachment. London: Hogarth Press. [06]
- . 1973. Attachment and Loss II: Separation, Anxiety and Anger. London: Hogarth Press. [06]
- . 1980. Attachment and Loss III: Loss, Sadness, and Depression. New York: Basic Books. [06]
- Boyle, D. J., and C. Hassett-Walker. 2008. Individual-Level and Socio-Structural Characteristics of Violence. *J. Interpers. Violence* **23**:1011–1026. [01]
- Brady, A. M., R. D. Saul, and M. K. Wiest. 2010. Selective Deficits in Spatial Working Memory in the Neonatal Ventral Hippocampal Lesion Rat Model of Schizophrenia. *Neuropharmacology* **59**:605–611. [11]
- Braff, D. L., R. Freedman, N. J. Schork, and I. I. Gottesman. 2007. Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex Disorder. *Schizophr. Bull.* **33**:21–32. [03]
- Braff, D. L., C. Grillon, and M. A. Geyer. 1992. Gating and Habituation of the Startle Reflex in Schizophrenic Patients. *Arch. Gen. Psychiatry* **49**:206–215. [07]
- Brandon, N. J., and A. Sawa. 2011. Linking Neurodevelopmental and Synaptic Theories of Mental Illness through DISC1. *Nat. Rev. Neurosci.* **12**:707–722. [10, 13]

- Brans, R. G., R. S. Kahn, H. G. Schnack, et al. 2010. Brain Plasticity and Intellectual Ability Are Influenced by Shared Genes. *J. Neurosci.* **30**:5519–5524. [17]
- Brase-Smith, S. B. 1995. Restraints: Retraumatization for Rape Victims? *J. Psychosoc. Nurs. Ment. Health Serv.* **33**:24–28. [15]
- Breitborde, N. J., F. A. Moreno, N. Mai-Dixon, et al. 2011. Multifamily Group Psychoeducation and Cognitive Remediation for First-Episode Psychosis: A Randomized Controlled Trial. *BMC Psychiatry* **11**:9. [07]
- Bremner, J. D., M. Vythilingam, E. Vermetten, et al. 2003. MRI and PET Study of Deficits in Hippocampal Structure and Function in Women with Childhood Sexual Abuse and Posttraumatic Stress Disorder. *Am. J. Psychiatr.* **160**:924–932. [01]
- Brenhouse, H. C., K. C. Sonntag, and S. L. Andersen. 2008. Transient D1 Dopamine Receptor Expression on Prefrontal Cortex Projection Neurons: Relationship to Enhanced Motivational Salience of Drug Cues in Adolescence. *J. Neurosci.* **28**:2375–2382. [13]
- Brennan, K. J., A. Simone, J. Jou, et al. 2011. Modelling Schizophrenia Using Human Induced Pluripotent Stem Cells. *Nature* **473**:221–225. [10, 17]
- Brenner, H. D., V. Roder, B. Hodel, et al. 1994. Integrated Psychological Therapy for Schizophrenic Patients. Seattle: Hogrefe & Huber Publishers. [15]
- Brewer, W. J., S. M. Francey, S. J. Wood, et al. 2005. Memory Impairments Identified in People at Ultra-High Risk for Psychosis Who Later Develop First-Episode Psychosis. *Am. J. Psychiatr.* **162**:71–78. [07]
- Brewer, W. J., S. J. Wood, L. J. Phillips, et al. 2006. Generalized and Specific Cognitive Performance in Clinical High-Risk Cohorts: A Review Highlighting Potential Vulnerability Markers for Psychosis. *Schizophr. Bull.* **32**:538–555. [02]
- Brockhaus-Dumke, A., I. Tendolkar, R. Pukrop, et al. 2005. Impaired Mismatch Negativity Generation in Prodromal Subjects and Patients with Schizophrenia. *Schizophr. Res.* **73**:297–310. [07]
- Broen, W. E. J., and L. H. Storms. 1966. Lawful Disorganization: The Process Underlying a Schizophrenic Syndrome. *Psychol. Rev.* **73**:265–279. [01]
- Bromet, E. J., R. Kotov, L. J. Fochtmann, et al. 2011. Diagnostic Shifts During the Decade Following First Admission for Psychosis. *Am. J. Psychiatr.* **168**:1186–1194. [02]
- Broome, M. R., P. Matthiasson, P. Fusar-Poli, et al. 2010. Neural Correlates of Movement Generation in the “At-Risk Mental State.” *Acta Psychiatr. Scand.* **122**:295–301. [07]
- Brown, A. S. 2006. Prenatal Infection as a Risk Factor for Schizophrenia. *Schizophr. Bull.* **32**:200–202. [11]
- Brown, A. S., and E. J. Derkits. 2010. Prenatal Infection and Schizophrenia: A Review of Epidemiologic and Translational Studies. *Am. J. Psychiatr.* **167**:261–280. [08]
- Brown, A. S., and P. H. Patterson. 2011. Maternal Infection and Schizophrenia: Implications for Prevention. *Schizophr. Bull.* **37**:284–290. [07]
- Brown, G. W., J. L. T. Birley, and J. K. Wing. 1972. A Replication Influence of Family Life on the Course of Schizophrenic Disorders: A Replication. *Br. J. Psychiatry* **121**:241–258. [15]
- Brown, G. W., and T. O. Harris. 1978. Social Origins of Depression: A Study of Psychiatric Disorder in Women. London: Tavistock Publications. [09]
- Brown, S., M. Kim, C. Mitchell, and H. Inskip. 2010. Twenty-Five Year Mortality of a Community Cohort with Schizophrenia. *Br. J. Psychiatry* **196**:116–121. [17]
- Brune, M. 2005. Emotion Recognition, “Theory of Mind,” and Social Behavior in Schizophrenia. *Psychiatry Res.* **133**:135–147. [04]

- Bryant, R. A., K. Felmingham, A. Kemp, et al. 2008. Amygdala and Ventral Anterior Cingulate Activation Predicts Treatment Response to Cognitive Behaviour Therapy for Post-Traumatic Stress Disorder. *Psychol. Med.* **38**:555–561. [09]
- Bryson, G., M. Bell, and P. Lysaker. 1997. Affect Recognition in Schizophrenia: A Function of Global Impairment or a Specific Cognitive Deficit. *Psychiatry Res.* **71**:105–113. [04]
- Buchanan, R. W., R. R. Conley, D. Dickinson, et al. 2008. Galantamine for the Treatment of Cognitive Impairments in People with Schizophrenia. *Am. J. Psychiatr.* **165**:82–89. [04]
- Buchanan, R. W., M. Davis, D. Goff, et al. 2005. A Summary of the FDA-NIMH-MATRICES Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. *Schizophr. Bull.* **31**:5–19. [03]
- Buchanan, R. W., D. C. Javitt, S. R. Marder, et al. 2007. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments. *Am. J. Psychiatr.* **164**:1593–1602. [04]
- Buchanan, R. W., R. S. Keefe, J. A. Lieberman, et al. 2011. A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. *Biol. Psychiatry* **69**:442–449. [04, 11]
- Buckholtz, J. W., and A. Meyer-Lindenberg. 2012. Psychopathology and the Human Connectome: Toward a Transdiagnostic Model of Risk for Mental Illness. *Neuron* **74**:990–1004. [17]
- Burdick, K. E., C. B. Gopin, and A. K. Malhotra. 2011. Pharmacogenetic Approaches to Cognitive Enhancement in Schizophrenia. *Harv. Rev. Psychiatry* **19**:102–108. [07]
- Burne, T., E. Scott, B. van Swinderen, et al. 2011. Big Ideas for Small Brains: What Can Psychiatry Learn from Worms, Flies, Bees and Fish? *Mol. Psychiatry* **16**:7–16. [08, 10]
- Burns, T., J. Catty, T. Becker, et al. 2007. The Effectiveness of Supported Employment for People with Severe Mental Illness: A Randomised Controlled Trial. *Lancet* **370**:1146–1152. [17]
- Bustillo, J. R., H. Chen, C. Gasparovic, et al. 2011. Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla. *Biol. Psychiatry* **69**:19–27. [07]
- Bustillo, J. R., L. M. Rowland, P. Mullins, et al. 2010. 1H-MRS at 4 Tesla in Minimally Treated Early Schizophrenia. *Mol. Psychiatry* **15**:629–636. [07]
- Butler, P. D., and D. C. Javitt. 2005. Early-Stage Visual Processing Deficits in Schizophrenia. *Curr. Opin. Psychiatry* **18**:151–157. [13]
- Butler, P. D., S. M. Silverstein, and S. C. Dakin. 2008. Visual Perception and Its Impairment in Schizophrenia. *Biol. Psychiatry* **64**:40–47. [01]
- Byrd, C. A., and P. C. Brunjes. 2001. Neurogenesis in the Olfactory Bulb of Adult Zebrafish. *Neuroscience* **105**:793–801. [07]
- Cabral, P., H. B. Meyer, and D. Ames. 2011. Effectiveness of Yoga Therapy as a Complementary Treatment for Major Psychiatric Disorders: A Meta-Analysis. *Prim. Care Companion CNS Disord.* **13**: [07]
- Cadenhead, K. S. 2011. Startle Reactivity and Prepulse Inhibition in Prodromal and Early Psychosis: Effects of Age, Antipsychotics, Tobacco and Cannabis in a Vulnerable Population. *Psychiatry Res.* **188**:208–216. [07]

- Cadenhead, K. S., B. Carasso, N. R. Swerdlow, M. A. Geyer, and D. L. Braff. 1999a. Prepulse Inhibition and Habituation of the Startle Response Are Stable Neurobiological Measures in a Normal Male Population. *Biol. Psychiatry* **45**:360–364. [07]
- Cadenhead, K. S., M. A. Geyer, and D. L. Braff. 1993. Impaired Startle Prepulse Inhibition and Habituation in Patients with Schizotypal Personality Disorder. *Am. J. Psychiatr.* **150**:1862–1867. [07]
- Cadenhead, K. S., W. Perry, K. Shafer, and D. L. Braff. 1999b. Cognitive Functions in Schizotypal Personality Disordered Subjects. *Schizophr. Res.* **37**:123–132. [07]
- Cadenhead, K. S., N. R. Swerdlow, K. Shafer, M. Diaz, and D. L. Braff. 2000. Modulation of the Startle Response and Startle Laterality in Relatives of Schizophrenia Patients and Schizotypal Personality Disordered Subjects: Evidence of Inhibitory Deficits. *Am. J. Psychiatr.* **157**:1660–1668. [07]
- Caiazzo, M., M. T. Dell’Anno, E. Dvoretzkova, et al. 2011. Direct Generation of Functional Dopaminergic Neurons from Mouse and Human Fibroblasts. *Nature* **476**:224–227. [10]
- Callicott, J. H., A. Bertolino, V. S. Mattay, et al. 2000. Physiological Dysfunction of the Dorsolateral Prefrontal Cortex in Schizophrenia Revisited. *Cereb. Cortex* **10**:1078–1092. [07, 11]
- Callicott, J. H., M. F. Egan, V. S. Mattay, et al. 2003. Abnormal fMRI Response of the Dorsolateral Prefrontal Cortex in Cognitively Intact Siblings of Patients with Schizophrenia. *Am. J. Psychiatr.* **160**:709–719. [07]
- Cannon, T. D., K. Cadenhead, B. Cornblatt, et al. 2008. Prediction of Psychosis in Youth at High Clinical Risk: A Multisite Longitudinal Study in North America. *Arch. Gen. Psychiatry* **65**:28–37. [02, 07, 09]
- Cannon, T. D., and M. C. Keller. 2006. Endophenotypes in the Genetic Analyses of Mental Disorders. *Annu. Rev. Clin. Psychol.* **2**:267–290. [02]
- Cannon, T. D., L. E. Zorrilla, D. Shtasel, et al. 1994. Neuropsychological Functioning in Siblings Discordant for Schizophrenia and Healthy Volunteers. *Arch. Gen. Psychiatry* **51**:651–666. [07]
- Capper, E. A., and L. A. Marshall. 2001. Mammalian Phospholipases A(2): Mediators of Inflammation, Proliferation and Apoptosis. *Prog. Lipid Res.* **40**:167–197. [07]
- Carandini, M., and D. J. Heeger. 2012. Normalization as a Canonical Neural Computation. *Nat. Rev. Neurosci.* **13**:51–62. [01, 02]
- Cardin, J. A., M. Carlen, K. Meletis, et al. 2009. Driving Fast-Spiking Cells Induces Gamma Rhythm and Controls Sensory Responses. *Nature* **459**:663–667. [13]
- Cardno, A. G., E. J. Marshall, B. Coid, et al. 1999. Heritability Estimates for Psychotic Disorders: The Maudsley Twin Psychosis Series. *Arch. Gen. Psychiatry* **56**:162–168. [06]
- Carlsson, A., N. Waters, S. Holm-Waters, et al. 2001. Interactions between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence. *Annu. Rev. Pharmacol. Toxicol.* **41**:237–260. [07]
- Carlsson, M., and A. Carlsson. 1990a. Interactions between Glutamatergic and Monoaminergic Systems within the Basal Ganglia: Implications for Schizophrenia and Parkinson’s Disease. *Trends Neurosci.* **13**:272–276. [07]
- . 1990b. Schizophrenia: A Subcortical Neurotransmitter Imbalance Syndrome? *Schizophr. Bull.* **16**:425–430. [12]

- Carpenter, W. T., Jr., and R. W. Buchanan. 1989. Domains of Psychopathology Relevant to the Study of Etiology and Treatment of Schizophrenia. In: *Schizophrenia: Scientific Progress*, ed. S. C. Schulz and C. T. Tamminga, pp. 13–22. New York: Oxford Univ. Press. [03]
- Carpenter, W. T., Jr., D. W. Heinrichs, and A. M. I. Wagman. 1988. Deficit and Non-Deficit Forms of Schizophrenia: The Concept. *Am. J. Psychiatr.* **145**:578–583. [03, 17]
- Carpenter, W. T., Jr., and J. I. Koenig. 2008. The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. *Neuropsychopharmacology* **33**:2061–2079. [13]
- Carpenter, W. T., Jr., J. S. Strauss, and J. J. Bartko. 1973. Flexible System for the Diagnosis of Schizophrenia: Report from the WHO International Pilot Study of Schizophrenia. *Science* **182**:1275–1278. [03]
- Carrà, G., S. Johnson, P. Bebbington, et al. 2012. The Lifetime and Past-Year Prevalence of Dual Diagnosis in People with Schizophrenia across Europe: Findings from the European Schizophrenia Cohort (EuroSC). *Eur. Arch. Psychiatry Clin. Neurosci.* **262**:607–616. [05]
- Carter, C. S., and D. M. Barch. 2007. Cognitive Neuroscience-Based Approaches to Measuring and Improving Treatment Effects on Cognition in Schizophrenia: The Cntrics Initiative. *Schizophr. Bull.* **33**:1131–1137. [02, 07]
- Cascella, N. G., M. Takaki, S. Lin, and A. Sawa. 2007. Neurodevelopmental Involvement in Schizophrenia: The Olfactory Epithelium as an Alternative Model for Research. *J. Neurochem.* **102**:587–594. [10]
- Casey, B. J., S. Duhoux, and M. Malter Cohen. 2010. Adolescence: What Do Transmission, Transition, and Translation Have to Do with It? *Neuron* **67**:749–760. [13]
- Caspi, A., and T. E. Moffitt. 2006. Gene-Environment Interactions in Psychiatry: Joining Forces with Neuroscience. *Nat. Rev. Neurosci.* **7**:583–590. [08]
- Caspi, A., T. E. Moffitt, M. Cannon, et al. 2005. Moderation of the Effect of Adolescent-Onset Cannabis Use on Adult Psychosis by a Functional Polymorphism in the Catechol-O-Methyltransferase Gene: Longitudinal Evidence of a Gene X Environment Interaction. *Biol. Psychiatry* **57**:1117–1127. [07]
- Catty, J., M. Koletsis, S. White, et al. 2010. Therapeutic Relationships: Their Specificity in Predicting Outcomes for People with Psychosis Using Clinical and Vocational Services. *Soc. Psychiatry Psychiatr. Epidem.* **45**:1187–1193. [16]
- Catty, J., S. White, M. Koletsis, et al. 2011. Therapeutic Relationships in Vocational Rehabilitation: Predicting Good Relationships for People with Psychosis. *Psychiatry Res.* **187**:68–73. [16]
- Cech, T. R., and G. M. Rubin. 2004. Nurturing Interdisciplinary Research. *Nat. Struct. Mol. Biol.* **11**:1166–1169. [08]
- Ceglar, A., and J. F. Roddick. 2006. Association Mining. *ACM Comput. Surveys* **38**:58–64. [05]
- Cephalon Inc. 2010. Treatment of Cognitive Impairment in Men with Schizophrenia (MK5757-005) (Completed). *Natl. Library Med.* <http://www.clinicaltrials.gov/ct2/show/record/NCT00848484?term=NCT00848484&rank=1> (accessed May 11, 2013). [04]
- Chadwick, P. 2006. *Person-Based Cognitive Therapy for Distressing Psychosis*. Chichester: Wiley. [15]
- Chadwick, P., M. J. Birchwood, and P. Trower. 1996. *Cognitive Therapy for Delusions, Voices, and Paranoia*. Chichester: Wiley. [05]
- Chamberlin, J. 1997a. Confessions of a Non-Compliant Patient. *Natl. Empowerment Center Newsletter* **8/9**:13. [15]

- Chamberlin, J. 1997b. A Working Definition of Empowerment. *Psychiatr. Rehabil. J.* **20**:43–46. [17]
- Chambless, D. L., and T. H. Ollendick. 2001. Empirically Supported Psychological Interventions: Controversies and Evidence. *Annu. Rev. Psychol.* **52**:685–716. [15]
- Chang, C.-K., R. D. Hayes, G. Perera, et al. 2011. Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Case Register in London. *PLoS One* **6**:e19590. [05]
- Chapman, L. J., and J. P. Chapman. 1973a. Disordered Thought in Schizophrenia. In: *Century Psychology*, ed. K. MacCorquodale et al. Englewood Cliffs, NJ: Prentice-Hall. [02]
- . 1973b. Problems in the Measurement of Cognitive Deficit. *Psychol. Bull.* **79**:380–385. [02]
- . 1978. The Measurement of Differential Deficit. *J. Psychiatr. Res.* **14**:303–311. [02]
- Chapman, L. J., J. P. Chapman, T. R. Kwapil, M. Eckblad, and M. C. Zinser. 1994. Putative Psychosis-Prone Subjects 10 Years Later. *J. Abnorm. Psychol.* **103**:171–183. [02]
- Charrier, C., K. Joshi, J. Coutinho-Budd, et al. 2012. Inhibition of SRGAP2 Function by Its Human-Specific Paralogs Induces Neoteny During Spine Maturation. *Cell* **149**:923–935. [10]
- Chen, H. H., A. Stoker, and A. Markou. 2010. The Glutamatergic Compounds Sarcosine and N-Acetylcysteine Ameliorate Prepulse Inhibition Deficits in Metabotropic Glutamate 5 Receptor Knockout Mice. *Psychopharmacology* **209**:343–350. [07]
- Chinman, M., A. S. Young, T. Schell, J. Hassell, and J. Mintz. 2004. Computer-Assisted Self-Assessment in Persons with Severe Mental Illness. *J. Clin. Psychiatry* **65**:1343–1351. [15]
- Choi, S. M., H. Liu, P. Chaudhari, et al. 2011. Reprogramming of EBV-Immortalized B-Lymphocyte Cell Lines into Induced Pluripotent Stem Cells. *Blood* **118**:1801–1805. [10]
- Chorpita, B. F., and E. L. Daleiden. 2009. Mapping of Evidence-Based Treatment for Children and Adolescents: Application of the Distillation and Matching Model to 615 Treatments from 22 Randomized Trials. *J. Consult. Clin. Psychol.* **77**:566–579. [15]
- Cicchetti, D., and T. D. Cannon. 1999. Neurodevelopmental Processes in the Ontogenesis and Epigenesis of Psychopathology. *Dev. Psychopathol.* **11**:375–393. [02]
- Cichon, S., N. Craddock, M. Daly, et al. 2009. Genomewide Association Studies: History, Rationale, and Prospects for Psychiatric Disorders. *Am. J. Psychiatry* **166**:540–556. [08]
- Clarke, H., J. Flint, A. S. Attwood, and M. R. Munafo. 2010. Association of the 5-HTTLPR Genotype and Unipolar Depression: A Meta-Analysis. *Psychol. Med.* **40**:1767–1778. [08]
- Clarke, M. C., M. Harley, and M. Cannon. 2006. The Role of Obstetric Events in Schizophrenia. *Schizophr. Bull.* **32**:3–8. [09]
- Cohen, J. 1992. A Power Primer. *Psychol. Bull.* **112**:155–159. [15]
- Cohen, J. D., D. M. Barch, C. Carter, and D. Servan-Schreiber. 1999. Context-Processing Deficits in Schizophrenia: Converging Evidence from Three Theoretically Motivated Cognitive Tasks. *J. Abnorm. Psychol.* **108**:120–133. [02]
- Cohen, J. D., and D. Servan-Schreiber. 1992. Context, Cortex and Dopamine: A Connectionist Approach to Behavior and Biology in Schizophrenia. *Psychol. Rev.* **99**:45–77. [02]

- Coldwell, C. M., and W. S. Bender. 2007. The Effectiveness of Assertive Community Treatment for Homeless Populations with Severe Mental Illness: A Meta-Analysis. *Am. J. Psychiatr.* **164**:393–399. [15]
- Cole, G. M., Q. L. Ma, and S. A. Frautschy. 2009. Omega-3 Fatty Acids and Dementia. *Prostaglandins Leukot. Essent. Fatty Acids* **81**:213–221. [07]
- Collip, D., I. Myin-Germeys, and J. Van Os. 2008. Does the Concept of “Sensitization” Provide a Plausible Mechanism for the Putative Link between the Environment and Schizophrenia? *Schizophr. Bull.* **34**:220–225. [09]
- Conklin, H. M., C. E. Curtis, M. E. Calkins, and W. G. Iacono. 2005. Working Memory Functioning in Schizophrenia Patients and Their First-Degree Relatives: Cognitive Functioning Shedding Light on Etiology. *Neuropsychologia* **43**:930–942. [01]
- Cook, J. A., M. E. Copeland, J. A. Jonikas, et al. 2012. Results of a Randomized Controlled Trial of Mental Illness Self-Management Using Wellness Recovery Action Planning. *Schizophr. Bull.* **38**:881–891. [15]
- Cook, J. A., S. E. Shore, J. K. Burke-Miller, et al. 2010. Participatory Action Research to Establish Self-Directed Care for Mental Health Recovery in Texas. *Psychiatr. Rehabil. J.* **34**:137–144. [15]
- Cools, R., L. Clark, A. M. Owen, and T. W. Robbins. 2002. Defining the Neural Mechanisms of Probabilistic Reversal Learning Using Event-Related Functional Magnetic Resonance Imaging. *J. Neurosci.* **22**:4563–4567. [05]
- Cooper, B., and B. Singh. 2000. Population Research and Mental Health Policy. Bridging the Gap. *Br. J. Psychiatry* **176**:407–411. [16]
- Corey, L. A., J. M. Pellock, M. J. Kjeldsen, and K. O. Nakken. 2011. Importance of Genetic Factors in the Occurrence of Epilepsy Syndrome Type: A Twin Study. *Epilepsy Res.* **97**:103–111. [13]
- Corlett, P. 2013. Sleight of Hand, Sleight of Mind: Illusions, Delusions and the Immune System. Scientific American SciCurious Blog 2013 [cited January 30, 2013 2013]. Available from <http://blogs.scientificamerican.com/scicurious-brain/2013/01/30/scicurious-guest-writer-sleight-of-hand-sleight-of-mind-illusions-delusions-and-the-immune-system/>. [01]
- Cornblatt, B. A., and L. Erlenmeyer-Kimling. 1985. Global Attentional Deviance as a Marker of Risk for Schizophrenia: Specificity and Predictive Validity. *J. Abnorm. Psychol.* **94**:470–486. [02]
- Correll, C. U., and A. K. Malhotra. 2004. Pharmacogenetics of Antipsychotic-Induced Weight Gain. *Psychopharmacology* **174**:477–489. [07]
- Corrigan, P. W., S. G. McCracken, and E. P. Holmes. 2001. Motivational Interviews as Goal Assessment for Persons with Psychiatric Disability. *Commun. Ment. Health J.* **37**:113–122. [15]
- Corrigan, P. W., K. T. Mueser, G. R. Bond, R. E. Drake, and P. Solomon. 2008. *The Principles and Practice of Psychiatric Rehabilitation: An Empirical Approach*. New York: Guilford Press. [15]
- Cosway, R., M. Byrne, R. Clafferty, et al. 2000. Neuropsychological Change in Young People at High Risk for Schizophrenia: Results from the First Two Neuropsychological Assessments of the Edinburgh High Risk Study. *Psychol. Med.* **30**:1111–1121. [07]
- Coyle, P., N. Tran, J. N. Fung, B. L. Summers, and A. M. Rofe. 2009. Maternal Dietary Zinc Supplementation Prevents Aberrant Behaviour in an Object Recognition Task in Mice Offspring Exposed to Lps in Early Pregnancy. *Behav. Brain Res.* **197**:210–218. [07]

- Crespi, B., and C. Badcock. 2008. Psychosis and Autism as Diametrical Disorders of the Social Brain. *Behav. Brain Sci.* **31**:241–261. [01]
- Crossley, N. A., A. Mechelli, P. Fusar-Poli, et al. 2009. Superior Temporal Lobe Dysfunction and Frontotemporal Dysconnectivity in Subjects at Risk of Psychosis and in First-Episode Psychosis. *Hum. Brain Mapp.* **30**:4129–4137. [09]
- Csermely, P. 2008. Creative Elements: Network-Based Predictions of Active Centres in Proteins and Cellular and Social Networks. *Trends Biochem. Sci.* **33**:569–576. [01]
- Cuesta, M. J., and V. Peralta. 1995. Psychopathological Dimensions in Schizophrenia. *Schizophr. Bull.* **21**:473–482. [03]
- Cusin, C., and D. D. Dougherty. 2012. Somatic Therapies for Treatment-Resistant Depression: ECT, TMS, VNS, DBS. *Biol. Mood Anxiety Disord.* **2**:14. [17]
- Cuthbert, B. N., and T. R. Insel. 2010. Toward New Approaches to Psychotic Disorders: The NIMH Research Domain Criteria Project. *Schizophr. Bull.* **36**:1061–1062. [17]
- D’Agostino, R. B., Sr., S. Grundy, L. M. Sullivan, and P. Wilson. 2001. Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. *JAMA* **286**:180–187. [09]
- Das, P., A. H. Kemp, G. Flynn, et al. 2007. Functional Disconnections in the Direct and Indirect Amygdala Pathways for Fear Processing in Schizophrenia. *Schizophr. Res.* **90**:284–294. [04]
- Davey Smith, G., and S. Ebrahim. 2001. Epidemiology: Is It Time to Call It a Day? *Int. J. Epidemiol.* **30**:1–11. [08]
- Davidson, L., M. J. O’Connell, J. Tondora, M. Lawless, and A. C. Evans. 2005. Recovery in Serious Mental Illness: A New Wine or Just a New Bottle? *Prof. Psychol. Res. Pr.* **36** 480–487. [17]
- Davidson, M., S. Galderisi, M. Weiser, et al. 2009. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). *Am. J. Psychiatr.* **166**:675–682. [14]
- Davies, L. M., S. W. Lewis, P. B. Jones, et al. 2007. Cost Effectiveness of First Generation Versus Second Generation Antipsychotic Drugs to Treat Psychosis: Results from a Randomised Controlled Trial in Schizophrenia Responding Poorly to Previous Therapy. *Br. J. Psychiatry* **191** 14–22. [01]
- Decoster, J., J. van Os, I. Myin-Germeys, M. De Hert, and R. van Winkel. 2012. Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Critical Review and Future Directions. *Curr. Pharm. Des.* **18**:5015–5023. [06]
- Deegan, P. E. 1990. Spirit Breaking: When the Helping Professionals Hurt. *Hum. Psychol.* **18**:301–313. [15]
- . 1991. Recovery: The Lived Experience of Rehabilitation. In: *The Psychological and Social Impact of Disability* ed. R. P. Marinelli and A. E. Dell Orto, pp. 47–54. New York: Springer. [17]
- Degenhardt, L., W. D. Hall, M. Lynskey, et al. 2009. Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis? *PLoS Med.* **6**:e1000133. [09]
- De Hert, M., J. Detraux, R. van Winkel, W. Yu, and C. U. Correll. 2012. Metabolic and Cardiovascular Adverse Effects Associated with Antipsychotic Drugs. *Nat. Rev. Endocrinol.* **8**: 114–126. [17]
- De Hert, M., D. Vancampfort, C. U. Correll, et al. 2011. Guidelines for Screening and Monitoring of Cardiometabolic Risk in Schizophrenia: Systematic Evaluation. *Br. J. Psychiatry* **199**:99–105. [17]
- Deisseroth, K. 2012. Optogenetics and Psychiatry: Applications, Challenges, and Opportunities. *Biol. Psychiatry* **71**:1030–1032. [17]

- de la Fuente-Sandoval, C., P. León-Ortiz, M. Azcárraga, et al. 2013a. Glutamate in the Associative Striatum before and after 4 Weeks of Antipsychotic Treatment in First-Episode Psychosis: A Longitudinal Proton Magnetic Resonance Spectroscopy Study. *JAMA Psychiatry*, in press. [07]
- . 2013b. Striatal Glutamate and the Conversion to Psychosis: A Prospective 1H-MRS Imaging Study. *Int. J. Neuropsychopharmacol.* **16**:471–475. [07]
- de la Fuente-Sandoval, C., P. Leon-Ortiz, R. Favila, et al. 2011. Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. *Neuropsychopharmacology* **36**:1781–1791. [07]
- Demjaha, A., J. H. MacCabe, and R. M. Murray. 2012. How Genes and Environmental Factors Determine the Different Neurodevelopmental Trajectories of Schizophrenia and Bipolar Disorder. *Schizophr. Bull.* **38**:209–214. [09]
- De Silva, M. J., K. McKenzie, T. Harpham, and S. R. Huttly. 2005. Social Capital and Mental Illness: A Systematic Review. *J. Epidemiol. Community Health* **59**:619–627. [01]
- Devrim-Ucok, M., H. Y. Keskin-Ergen, and A. Ucok. 2008. Mismatch Negativity at Acute and Post-Acute Phases of First-Episode Schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* **258**:179–185. [07]
- Dickerson, D. D., A. M. Restieaux, and D. K. Bilkey. 2012. Clozapine Administration Ameliorates Disrupted Long-Range Synchrony in a Neurodevelopmental Animal Model of Schizophrenia. *Schizophr. Res.* **135**:112–115. [13]
- Dickerson, D. D., A. R. Wolff, and D. K. Bilkey. 2010. Abnormal Long-Range Neural Synchrony in a Maternal Immune Activation Animal Model of Schizophrenia. *J. Neurosci.* **30**:12,424–12,431. [13]
- Dickinson, D., V. N. Iannone, C. M. Wilk, and J. M. Gold. 2004. General and Specific Cognitive Deficits in Schizophrenia. *Biol. Psychiatry* **55**:826–833. [04]
- Dickinson, D., J. D. Ragland, J. M. Gold, and R. C. Gur. 2008. General and Specific Cognitive Deficits in Schizophrenia: Goliath Defeats David? *Biol. Psychiatry* **64**:823–827. [01]
- Dickinson, D., M. B. Ramsey, and J. M. Gold. 2007. Overlooking the Obvious: A Meta-Analytic Comparison of Digit Symbol Coding Tasks and Other Cognitive Measures in Schizophrenia. *Arch. Gen. Psychiatry* **64**:532–542. [02, 04]
- Dickson, H., K. R. Laurens, A. E. Cullen, and S. Hodgins. 2012. Meta-Analysis of Cognitive and Motor Function in Youth Aged 16 Years and Younger Who Subsequently Develop Schizophrenia. *Psychol. Med.* **42**:743–755. [14]
- Di Costanzo, A., F. Trojsi, M. Tosetti, et al. 2007. Proton Mr Spectroscopy of the Brain at 3 T: An Update. *Eur. Radiol.* **17**:1651–1662. [07]
- Dixon, L., A. Lyles, J. Scott, et al. 1999. Services to Families of Adults with Schizophrenia: From Treatment Recommendations to Dissemination. *Psychiatr. Serv.* **50**:233–238. [16]
- Dixon, L. B., F. Dickerson, A. S. Bellack, et al. 2010. The 2009 PORT Psychosocial Treatment Recommendations and Summary Statements. *Schizophr. Bull.* **36**:48–70. [15, 16]
- Dixon, L. B., W. McFarlane, H. Lefley, et al. 2001. Evidence-Based Practices for Services to Family Members of People with Psychiatric Disabilities. *Psychiatr. Serv.* **52**:903–910. [15]
- Dolmetsch, R., and D. H. Geschwind. 2011. The Human Brain in a Dish: The Promise of iPSC-Derived Neurons. *Cell* **145**:831–834. [10, 17]

- Domingues, I., T. Alderman, and K. S. Cadenhead. 2011. Strategies for Effective Recruitment of Individuals at Risk for Developing Psychosis. *Early Interv. Psychiatry* **5**:233–241. [09]
- Domschke, K., and U. Dannlowski. 2010. Imaging Genetics of Anxiety Disorders. *NeuroImage* **53**:822–831. [08]
- Doty, R. L. 2012. Olfaction in Parkinson's Disease and Related Disorders. *Neurobiol. Dis.* **46**:527–552. [10]
- Downar, J., and Z. J. Daskalakis. 2013. New Targets for rTMS in Depression: A Review of Convergent Evidence. *Brain Stimul.* **6**:231–240. [17]
- Drake, R. E., and S. M. Essock. 2009. The Science-to-Service Gap in Real-World Schizophrenia Treatment: The 95% Problem. *Schizophr. Bull.* **35**:677–678. [15]
- Drake, R. E., H. H. Goldman, H. S. Leff, et al. 2001. Implementing Evidence-Based Practices in Routine Mental Health Service Settings. *Psychiatr. Serv.* **52**:179–182. [15]
- Drake, R. E., G. J. McHugo, R. R. Bebout, et al. 1999. A Randomized Clinical Trial of Supported Employment for Inner-City Patients with Severe Mental Illness. *Arch. Gen. Psychiatry* **56**:627–633. [15]
- Drake, R. E., G. J. McHugo, D. R. Becker, W. A. Anthony, and R. E. Clark. 1996. The New Hampshire Study of Supported Employment for People with Severe Mental Illness: Vocational Outcomes. *J. Consult. Clin. Psychol.* **64**:391–399. [15]
- Drake, R. E., M. R. Merrens, and D. W. Lynde. 2005. Evidence-Based Mental Health Practice: A Textbook. New York: Norton. [15]
- Drake, R. E., E. O'Neal, and M. A. Wallach. 2008. A Systematic Review of Psychosocial Interventions for People with Co-Occurring Severe Mental and Substance Use Disorders. *J. Subst. Abuse Treat.* **34**:123–138. [15]
- Drapalski, A. L., A. Lucksted, P. B. Perrin, et al. 2013. A Model of Internalized Stigma and Its Effects on People with Mental Illness. *Psychiatr. Serv.* **64**:264–269. [15]
- Druss, B. G., W. D. Bradford, R. A. Rosenheck, M. J. Radford, and H. M. Krumholz. 2001. Quality of Medical Care and Excess Mortality in Older Patients with Mental Disorders. *Arch. Gen. Psychiatry* **58**:565–572. [17]
- Drzyzga, L., E. Obuchowicz, A. Marcinowska, and Z. S. Herman. 2006. Cytokines in Schizophrenia and the Effects of Antipsychotic Drugs. *Brain Behav. Immun.* **20**:532–545. [07]
- D'Souza, D. C. 2007. Cannabinoids and Psychosis. *Int. Rev. Neurobiol.* **78**:289–326. [07]
- D'Souza, D. C., W. M. Abi-Saab, S. Madonick, et al. 2005. Delta-9-Tetrahydrocannabinol Effects in Schizophrenia: Implications for Cognition, Psychosis, and Addiction. *Biol. Psychiatry* **57**:594–608. [07]
- Dunaif, S. L., and P. H. Hoch. 1955. Pseudopsychopathic Schizophrenia. *Proc. Annu. Meet. Am. Psychopathol. Assoc.* **1955**:169–195. [01]
- Duncan, E. J., S. H. Madonick, A. Parwani, et al. 2001. Clinical and Sensorimotor Gating Effects of Ketamine in Normals. *Neuropsychopharmacology* **25**:72–83. [07]
- Durlak, J. A., R. P. Weissberg, A. B. Dymnicki, R. D. Taylor, and K. B. Schellinger. 2011. The Impact of Enhancing Students' Social and Emotional Learning: A Meta-Analysis of School-Based Universal Interventions. *Child Dev.* **82**:405–432. [09]
- Durstewitz, D. 2007. Dopaminergic Modulation of Prefrontal Cortex Network Dynamics. In: *Monoaminergic Modulation of Cortical Excitability*, ed. K.-Y. Tseng and M. Atzori. New York: Springer. [12]
- Durstewitz, D., and E. Balaguer-Ballester. 2010. Statistical Approaches for Reconstructing Neuro-Cognitive Dynamics from High-Dimensional Neural Recordings. *NeuroForum* **4**:266–276. [12]

- Durstewitz, D., and J. K. Seamans. 2002. The Computational Role of Dopamine D1 Receptors in Working Memory. *Neural Netw.* **15**:561–572. [12]
- . 2008. The Dual-State Theory of Prefrontal Cortex Dopamine Function with Relevance to COMT Genotypes and Schizophrenia. *Biol. Psychiatry* **64**:739–749. [12]
- Durstewitz, D., J. K. Seamans, and T. J. Sejnowski. 2000. Dopamine-Mediated Stabilization of Delay-Period Activity in a Network Model of Prefrontal Cortex. *J. Neurophysiol.* **83**:1733–1750. [12]
- D’Zurilla, T. J., and M. R. Goldfried. 1971. Problem Solving and Behavior Modification. *J. Abnorm. Psychol.* **78**:107–126. [15]
- Eack, S. M., G. E. Hogarty, R. Y. Cho, et al. 2010. Neuroprotective Effects of Cognitive Enhancement Therapy against Gray Matter Loss in Early Schizophrenia: Results from a 2-Year Randomized Controlled Trial. *Arch. Gen. Psychiatry* **67**:674–682. [01, 07]
- Eastvold, A. D., R. K. Heaton, and K. S. Cadenhead. 2007. Neurocognitive Deficits in the (Putative) Prodrome and First Episode of Psychosis. *Schizophr. Res.* **93**:266–277. [07]
- Eckblad, M., and L. J. Chapman. 1983. Magical Ideation as an Indicator of Schizotypy. *J. Consult. Clin. Psychol.* **51**:215–225. [02]
- Edwards, J., H. J. Jackson, and P. E. Pattison. 2002. Emotion Recognition via Facial Expression and Affective Prosody in Schizophrenia: A Methodological Review. *Clin. Psychol. Rev.* **22**:789–832. [04]
- Egan, M. F., M. Kojima, J. H. Callicott, et al. 2003. The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function. *Cell* **112**:257–269. [09]
- Egerton, A., S. Brugger, M. Raffin, et al. 2012a. Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia. *Neuropsychopharmacology* **37**:2515–2521. [07]
- Egerton, A., P. Fusar-Poli, and J. M. Stone. 2012b. Glutamate and Psychosis Risk. *Curr. Pharm. Des.* **18**:466–478. [07]
- Ehrlichman, R. S., M. J. Gandal, C. R. Maxwell, et al. 2009. N-Methyl-D-Aspartic Acid Receptor Antagonist-Induced Frequency Oscillations in Mice Recreate Pattern of Electrophysiological Deficits in Schizophrenia. *Neuroscience* **158**:705–712. [07]
- Eichenberger, A., and W. Rössler. 2000. Comparison of Self-Ratings and Therapist Ratings of Outpatients’ Psychosocial Status. *J. Nerv. Ment. Dis.* **188**:297–300. [16]
- Eldar, A., and M. B. Elowitz. 2010. Functional Roles for Noise in Genetic Circuits. *Nature* **467**:167–173. [13]
- Ellett, L., D. Freeman, and P. A. Garety. 2008. The Psychological Effect of an Urban Environment on Individuals with Persecutory Delusions: The Camberwell Walk Study. *Schizophr. Res.* **99**:77–84. [01]
- Elliot, A. J., K. M. Sheldon, and M. A. Church. 1997. Avoidance Personal Goals and Subjective Well-Being. *Pers. Soc. Psychol. Bull.* **23**:915–927. [15]
- Engel, A. K., K. Friston, J. A. S. Kelso, et al. 2010. Coordination in Behavior and Cognition. In: *Dynamic Coordination in the Brain: From Molecules to Mind*, ed. C. von der Malsburg et al., Strüngmann Forum Report, J. Lupp, series ed., vol. 5, pp. 267–299. Cambridge, MA: MIT Press. [01]
- Engel, A. K., P. Konig, A. K. Kreiter, and W. Singer. 1991. Interhemispheric Synchronization of Oscillatory Neuronal Responses in Cat Visual Cortex. *Science* **252**:1177–1179. [04]
- Engel, A. K., and W. Singer. 2001. Temporal Binding and the Neural Correlates of Sensory Awareness. *Trends Cogn. Neurosci.* **5**:16–25. [04]

- Erickson, K. I., M. W. Voss, R. S. Prakash, et al. 2011. Exercise Training Increases Size of Hippocampus and Improves Memory. *PNAS* **108**:3017–3022. [17]
- Ericson, C. A., II. 2011. Fault Tree Analysis Primer. Charleston, NC: CreateSpace. [02]
- Ericsson, K. A., and N. Charness. 1994. Expert Performance: Its Structure and Acquisition. *Am. Psychol.* **49**:725–747. [15]
- Erlenmeyer-Kimling, L., and B. Cornblatt. 1987. The New York High-Risk Project: A Follow-Up Report. *Schizophr. Bull.* **13**:451–461. [02]
- Erlenmeyer-Kimling, L., B. A. Cornblatt, and R. Golden. 1984. Early Indicators of Vulnerability to Schizophrenia in Children at High Genetic Risk. In: *Childhood Psychopathology and Development*, ed. S. B. Guze et al., pp. 247–261. New York: Raven Press. [02]
- Esslinger, C., H. Walter, P. Kirsch, et al. 2009. Neural Mechanisms of a Genome-Wide Supported Psychosis Variant. *Science* **324**:605. [08, 09]
- EU-GEI. 2008. Schizophrenia Aetiology: Do Gene-Environment Interactions Hold the Key? *Schizophr. Res.* **102**:21–26. [09]
- Eysenck, S. B. G., H. J. Eysenck, and P. Barrett. 1985. A Revised Version of the Psychoticism Scale. *Pers. Individ. Dif.* **6**:21–29. [02]
- Fadden, G. 1997. Implementation of Family Interventions in Routine Clinical Practice Following Staff Training Programs: A Major Cause for Concern. *J. Ment. Health* **6**:599–612. [15]
- Falloon, I. R. H., J. L. Boyd, and C. W. McGill. 1984. Family Care of Schizophrenia: A Problem-Solving Approach to the Treatment of Mental Illness. New York: Guilford Press. [15]
- Falloon, I. R. H., J. L. Boyd, C. W. McGill, et al. 1985. Family Management in the Prevention of Morbidity of Schizophrenia: Clinical Outcome of a Two Year Longitudinal Study. *Arch. Gen. Psychiatry* **42**:887–896. [15]
- Fan, Y., G. Abrahamsen, J. J. McGrath, and A. Mackay-Sim. 2012. Altered Cell Cycle Dynamics in Schizophrenia. *Biol. Psychiatry* **71**:129–135. [10]
- Fang, G., R. Kuang, G. Pandey, et al. 2010. Subspace Differential Coexpression Analysis: Problem Definition and a General Approach. *Pac. Symp. Biocomput.* **15**:145–156. [05]
- Fang, G., G. Pandey, W. Wang, et al. 2012. Mining Low-Support Discriminative Patterns from Dense and High-Dimensional Data. *IEEE Trans. Knowl. Data Eng.* **24**:279–294. [05]
- Fanous, A. H., F. A. Middleton, K. Gentile, et al. 2012. Genetic Overlap of Schizophrenia and Bipolar Disorder in a High-Density Linkage Survey in the Portuguese Island Population. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **159B**:383–391. [02]
- Fanous, A. H., M. C. Neale, B. T. Webb, et al. 2008. Novel Linkage to Chromosome 20p Using Latent Classes of Psychotic Illness in 270 Irish High-Density Families. *Biol. Psychiatry* **64**:121–127. [03]
- Faraone, S. V., A. I. Green, L. J. Seidman, and M. T. Tsuang. 2001. “Schizotaxia”: Clinical Implications and New Directions for Research. *Schizophr. Bull.* **27**:1–18. [02]
- Faraone, S. V., L. J. Seidman, W. S. Kremen, et al. 1999. Neuropsychological Functioning among the Nonpsychotic Relatives of Schizophrenic Patients: A 4-Year Follow-Up Study. *J. Abnorm. Psychol.* **108**: [07]
- Faris, R. E. L., and H. W. Dunham. 1939. *Mental Disorders in Urban Areas*. Chicago: Univ. of Chicago Press. [01, 16]
- Farkas, M. D. 2007. The Vision of Recovery Today: What It Is and What It Means for Services. *World Psychiatry* **6**:4–10. [15, 16]

- Faulkner, G., A. A. Soundy, and K. Lloyd. 2003. Schizophrenia and Weight Management: A Systematic Review of Interventions to Control Weight. *Acta Psychiatr. Scand.* **108**:324–332. [17]
- Fearon, P., and C. Morgan. 2006. Environmental Factors in Schizophrenia: The Role of Migrant Studies. *Schizophr. Bull.* **32**:405–408. [09]
- Feifel, D., K. Macdonald, A. Nguyen, et al. 2010. Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients. *Biol. Psychiatry* **68**:678–680. [07]
- Feifel, D., and T. Reza. 1999. Oxytocin Modulates Psychotomimetic-Induced Deficits in Sensorimotor Gating. *Psychopharmacology* **141**:93–98. [07]
- Feifel, D., P. D. Shilling, and A. M. Belcher. 2012. The Effects of Oxytocin and Its Analog, Carbetocin, on Genetic Deficits in Sensorimotor Gating. *Eur. Neuropsychopharmacol.* **22**:374–378. [07]
- Feinberg, I. 1982. Schizophrenia: Caused by a Fault in Programmed Synaptic Elimination During Adolescence? *J. Psychiatr. Res.* **17**:319–334. [07]
- Fenko, L., O. Yizhar, and K. Deisseroth. 2011. The Development and Application of Optogenetics. *Annu. Rev. Neurosci.* **34**:389–412. [12]
- Feron, F., C. Perry, M. H. Hirning, J. McGrath, and A. Mackay-Sim. 1999. Altered Adhesion, Proliferation and Death in Neural Cultures from Adults with Schizophrenia. *Schizophr. Res.* **40**:211–218. [10]
- Feron, F., C. Perry, J. J. McGrath, and A. Mackay-Sim. 1998. New Techniques for Biopsy and Culture of Human Olfactory Epithelial Neurons. *Arch. Otolaryngol. Head Neck Surg.* **124**:861–866. [10]
- Fish, B., and K. S. Kendler. 2005. Abnormal Infant Neurodevelopment Predicts Schizophrenia Spectrum Disorders. *J. Child Adolesc. Psychopharmacol.* **15**:348–361. [01]
- Fisher, M., C. Holland, M. M. Merzenich, and S. Vinogradov. 2009. Using Neuroplasticity-Based Auditory Training to Improve Verbal Memory in Schizophrenia. *Am. J. Psychiatr.* **166**:805–811. [07]
- Flagstad, P., A. Mork, B. Y. Glenhoj, et al. 2004. Disruption of Neurogenesis on Gestational Day 17 in the Rat Causes Behavioral Changes Relevant to Positive and Negative Schizophrenia Symptoms and Alters Amphetamine-Induced Dopamine Release in Nucleus Accumbens. *Neuropsychopharmacology* **29**:2052–2064. [11]
- Flatscher-Bader, T., C. J. Foldi, S. Chong, et al. 2011. Increased *De Novo* Copy Number Variants in the Offspring of Older Males. *Translat. Psychiatry* **1**:e34. [08]
- Fletcher, P. C., and C. D. Frith. 2009. Perceiving Is Believing: A Bayesian Approach to Explaining the Positive Symptoms of Schizophrenia. *Nat. Rev. Neurosci.* **10**:48–58. [13]
- Foldi, C. J., D. W. Eyles, J. J. McGrath, and T. H. Burne. 2010. Advanced Paternal Age Is Associated with Alterations in Discrete Behavioural Domains and Cortical Neuroanatomy of C57BL/6J Mice. *Eur. J. Neurosci.* **31**:556–564. [08]
- Folwell, K. 1995. Single Measures of Deprivation. *J. Epidemiol. Community Health* **49(Suppl. 2)**:S51–S56. [16]
- Foster, A., J. Gable, and J. Buckley. 2012. Homelessness in Schizophrenia. *Psychiatr. Clin. North Am.* **35**:717–734. [05]
- Foster, A., D. D. Miller, and P. Buckley. 2010. Pharmacogenetics and Schizophrenia. *Clin. Lab. Med.* **30**:975–993. [07]
- Fowler, T., S. Zammit, M. J. Owen, and F. Rasmussen. 2012. A Population-Based Study of Shared Genetic Variation between Premorbid IQ and Psychosis among Male Twin Pairs and Sibling Pairs from Sweden. *Arch. Gen. Psychiatry* **69**:460–466. [02]

- Frangou, S., M. Lewis, J. Wollard, and A. Simmons. 2007. Preliminary *in Vivo* Evidence of Increased N-Acetyl-Aspartate Following Eicosapentanoic Acid Treatment in Patients with Bipolar Disorder. *J. Psychopharmacol.* **21**:435–439. [07]
- Frank, M. G., M. V. Baratta, D. B. Sprunger, L. R. Watkins, and S. F. Maier. 2007. Microglia Serve as a Neuroimmune Substrate for Stress-Induced Potentiation of CNS Pro-Inflammatory Cytokine Responses. *Brain Behav. Immun.* **21**:47–59. [07]
- Freeman, D. 2008. Studying and Treating Schizophrenia Using Virtual Reality: A New Paradigm. *Schizophr. Bull.* **34**:605–610. [17]
- Frese, F. J. I. 2008. Self-Help Activities. In: *Clinical Handbook of Schizophrenia*, ed. K. T. Mueser and D. V. Jeste, pp. 298–305. New York: Guilford Press. [15]
- Freudenreich, O., D. C. Henderson, E. A. Macklin, and A. E. Evins. 2009. Modafinil for Clozapine-Treated Schizophrenia Patients: A Double-Blind, Placebo-Controlled Pilot Trial. *J. Clin. Psychiatry* **70**:1674–1680. [04]
- Freyer, F., J. A. Roberts, P. Ritter, and B. M. 2012. A Canonical Model of Multistability and Scale-Invariance in Biological Systems. *PLoS Comput. Biol.* **8**:e1002634. [01]
- Friedman, J. I., D. N. Adler, E. Howanitz, et al. 2002. A Double Blind Placebo Controlled Trial of Donepezil Adjunctive Treatment to Risperidone for the Cognitive Impairment of Schizophrenia. *Biol. Psychiatry* **51**:349–357. [04]
- Friedman, J. I., D. N. Adler, H. D. Temporini, et al. 2001a. Guanfacine Treatment of Cognitive Impairment in Schizophrenia. *Neuropsychopharmacology* **25**:402–409. [04]
- Friedman, J. I., D. Carpenter, J. Lu, et al. 2008. A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. *J. Clin. Psychopharmacol.* **28**:59–63. [04]
- Friedman, J. J., P. D. Harvey, T. Coleman, et al. 2001b. Six-Year Follow-up Study of Cognitive and Functional Status across the Lifespan in Schizophrenia: A Comparison with Alzheimer's Disease and Normal Aging. *Am. J. Psychiatr.* **158**:1441–1448. [04]
- Fuller, R., P. Nopoulos, S. Arndt, et al. 2002. Longitudinal Assessment of Premorbid Cognitive Functioning in Patients with Schizophrenia through Examination of Standardized Scholastic Test Performance. *Am. J. Psychiatr.* **159**:1183–1189. [14, 17]
- Fusar-Poli, P., M. R. Broome, J. B. Woolley, et al. 2011a. Altered Brain Function Directly Related to Structural Abnormalities in People at Ultra High Risk of Psychosis: Longitudinal VBM-fMRI Study. *J. Psychiatr. Res.* **45**:190–198. [07]
- Fusar-Poli, P., O. D. Howes, P. Allen, et al. 2010. Abnormal Frontostriatal Interactions in People with Prodromal Signs of Psychosis: A Multimodal Imaging Study. *Arch. Gen. Psychiatry* **67**:683–691. [07]
- . 2011b. Abnormal Prefrontal Activation Directly Related to Pre-Synaptic Striatal Dopamine Dysfunction in People at Clinical High Risk for Psychosis. *Mol. Psychiatry* **16**:67–75. [07]
- Fusar-Poli, P., J. Perez, M. Broome, et al. 2007. Neurofunctional Correlates of Vulnerability to Psychosis: A Systematic Review and Meta-Analysis. *Neurosci. Biobehav. Rev.* **31**:465–484. [07]
- Fuster, J. 2003. *Cortex and Mind: Unifying Cognition*. New York: Oxford Univ. Press. [01]
- Gaebel, W., T. Becker, B. Janssen, et al. 2012. EPA Guidance on the Quality of Mental Health Services. *Eur. Psychiatry* **27**(2):87–113. [16]
- Gale, C. R., G. D. Batty, A. M. McIntosh, et al. 2013. Is Bipolar Disorder More Common in Highly Intelligent People? A Cohort Study of a Million Men. *Molecular Psychiatry* **18**:190–194. [14]

- Gale, C. R., G. D. Batty, D. P. J. Osborn, et al. 2012. Association of Mental Disorders in Early Adulthood and Later Psychiatric Hospital Admissions and Mortality in a Cohort Study of More Than 1 Million Men. *Arch. Gen. Psychiatry* **69**:823–831. [17]
- Gallinat, J., G. Winterer, C. S. Herrmann, and D. Senkowski. 2004. Reduced Oscillatory Gamma-Band Responses in Unmedicated Schizophrenic Patients Indicate Impaired Frontal Network Processing. *Clin. Neurophysiol.* **115**:1863–1874. [04, 07]
- Galvan, A. 2010. Adolescent Development of the Reward System. *Front. Hum. Neurosci.* **4**:6. [13]
- Gandal, M. J., J. C. Edgar, K. Klook, and S. J. Siegel. 2012. Gamma Synchrony: Towards a Translational Biomarker for the Treatment-Resistant Symptoms of Schizophrenia. *Neuropharmacology* **62**:1504–1518. [07]
- Ganju, V. 2003. Implementation of Evidence-Based Practices in State Mental Health Systems: Implications for Research and Effectiveness Studies. *Schizophr. Bull.* **29**:125–131. [15]
- Ganter, B., R. Wille, and C. Franzke. 1999. Formal Concept Analysis: Mathematical Foundations. Heidelberg: Springer. [05]
- Gao, W. J., and P. S. Goldman-Rakic. 2003. Selective Modulation of Excitatory and Inhibitory Microcircuits by Dopamine. *PNAS* **100**:2836–2841. [12]
- Garcia-Bueno, B., J. R. Caso, and J. C. Leza. 2008. Stress as a Neuroinflammatory Condition in Brain: Damaging and Protective Mechanisms. *Neurosci. Biobehav. Rev.* **32**:1136–1151. [07]
- Garcia-Palomares, S., J. F. Pertusa, J. Minarro, et al. 2009. Long-Term Effects of Delayed Fatherhood in Mice on Postnatal Development and Behavioral Traits of Offspring. *Biol. Reprod.* **80**:337–342. [08]
- Garety, P. A., E. Kuipers, D. Fowler, D. Freeman, and P. E. Bebbington. 2001. A Cognitive Model of the Positive Symptoms of Psychosis. *Psychol. Med.* **31**:189–195. [09]
- Garnezy, N. 1977. On Some Risks in Risk Research. *Psychol. Med.* **7**:1–6. [06]
- Geyer, M. A., K. Krebs-Thomson, D. L. Braff, and N. R. Swerdlow. 2001. Pharmacological Studies of Prepulse Inhibition Models of Sensorimotor Gating Deficits in Schizophrenia: A Decade in Review. *Psychopharmacology* **156**:117–154. [07]
- Gill, K. M., D. J. Lodge, J. M. Cook, S. Aras, and A. A. Grace. 2011. A Novel alpha5GABA(A)R-Positive Allosteric Modulator Reverses Hyperactivation of the Dopamine System in the MAM Model of Schizophrenia. *Neuropsychopharmacology* **36**:1903–1911. [11]
- Gilligan, J. 1996. *Violence: Reflections on a National Epidemic*. New York: Putnam. [01]
- Gilmore, J. H., C. Kang, D. D. Evans, et al. 2010. Prenatal and Neonatal Brain Structure and White Matter Maturation in Children at High Risk for Schizophrenia. *Am. J. Psychiatr.* **167**:1083–1091. [01]
- Gingerich, S., and K. T. Mueser. 2011. *Illness Management and Recovery: Personalized Skills and Strategies for Those with Mental Illness* (3rd edition). Center City, MN: Hazelden. [15]
- Girard, S., L. Tremblay, M. Lepage, and G. Sebire. 2010. Il-1 Receptor Antagonist Protects against Placental and Neurodevelopmental Defects Induced by Maternal Inflammation. *J. Immunol.* **184**:3997–4005. [07]
- Girirajan, S., J. A. Rosenfeld, B. P. Coe, et al. 2012. Phenotypic Heterogeneity of Genomic Disorders and Rare Copy-Number Variants. *N. Engl. J. Med.* **367**:1321–1331. [13]

- Giuffrida, A., F. M. Leweke, C. W. Gerth, et al. 2004. Cerebrospinal Anandamide Levels Are Elevated in Acute Schizophrenia and Are Inversely Correlated with Psychotic Symptoms. *Neuropsychopharmacology* **29**:2108–2114. [07]
- Gladso, J. A., L. A. McAdams, B. W. Palmer, et al. 2004. A Six-Factor Model of Cognition in Schizophrenia and Related Psychotic Disorders: Relationships with Clinical Symptoms and Functional Capacity. *Schizophr. Bull.* **30**:739–754. [04]
- Glasgow, R. E., E. Lichtenstein, and A. C. Marcus. 2003. Why Don't We See More Translation of Health Promotion Research to Practice? Rethinking the Efficacy-to-Effectiveness Transition. *Am. J. Public Health* **93**:1261–1267. [15]
- Glisson, C., and S. K. Schoenwald. 2005. The Arc Organizational and Community Intervention Strategy for Implementing Evidence-Based Children's Mental Health Treatments. *Ment. Health Serv. Res.* **7**:243–259. [15]
- Goff, D., C. Cather, O. Freudenreich, et al. 2009. A Placebo-Controlled Study of Sildenafil Effects on Cognition in Schizophrenia. *Psychopharmacology* **202**:411–417. [04]
- Goff, D. C., C. Cather, J. D. Gottlieb, et al. 2008a. Once-Weekly D-Cycloserine Effects on Negative Symptoms and Cognition in Schizophrenia: An Exploratory Study. *Schizophr. Res.* **106**:320–327. [04]
- Goff, D. C., M. Hill, and D. Barch. 2011. The Treatment of Cognitive Impairment in Schizophrenia. *Pharmacol. Biochem. Behav.* **99**:245–253. [04, 07]
- Goff, D. C., J. S. Lamberti, A. C. Leon, et al. 2008b. A Placebo-Controlled Add-on Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia. *Neuropsychopharmacology* **33**:465–472. [04]
- Goffman, E. 1963. *Stigma: Notes on the Management of Spoiled Identity*. Englewood Cliffs, NY: Prentice-Hall. [17]
- Gold, J. M., D. M. Barch, C. S. Carter, et al. 2012. Clinical, Functional and Inter-Task Correlations of Measures Developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. *Schizophr. Bull.* [02]
- Gold, S., S. Arndt, P. Nopoulos, D. S. O'Leary, and N. C. Andreasen. 1999. Longitudinal Study of Cognitive Function in First-Episode and Recent-Onset Schizophrenia. *Am. J. Psychiatr.* **156**:1342–1348. [04]
- Goldberg, T. E., R. S. Goldman, K. E. Burdick, et al. 2007. Cognitive Improvement after Treatment with Second-Generation Antipsychotic Medications in First-Episode Schizophrenia. *Arch. Gen. Psychiatry* **64**:1115–1122. [14]
- Goldberg, T. E., R. S. E. Keefe, R. S. Goldman, D. G. Robinson, and P. D. Harvey. 2010. Circumstances under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies. *Neuropsychopharmacology* **35**:1053–1062. [14]
- Goldman, H. H., A. E. Skodol, and T. R. Lave. 1992. Revising Axis V for DSM-IV: A Review of Measures of Social Functioning. *Am. J. Psychiatr.* **149**:1148–1156. [04]
- Goldman-Rakic, P. S. 1991. Prefrontal Cortical Dysfunction in Schizophrenia: The Relevance of Working Memory. In: *Psychopathology and the Brain*, ed. B. J. Carroll and J. E. Barrett, pp. 1–23. New York: Raven Press. [02]
- Goldstein, J. M., S. L. Buka, L. J. Seidman, and M. T. Tsuang. 2010. Specificity of Familial Transmission of Schizophrenia Psychosis Spectrum and Affective Psychoses in the New England Family Study's High-Risk Design. *Arch. Gen. Psychiatry* **67**:458–467. [02]
- Golzio, C., J. Willer, M. E. Talkowski, et al. 2012. KCTD13 Is a Major Driver of Mirrored Neuroanatomical Phenotypes of the 16p11.2 Copy Number Variant. *Nature* **485**:363–367. [10]

- Gonzales, J. J., H. L. Ringeisen, and D. A. Chambers. 2002. The Tangled and Thorny Path of Science to Practice: Tensions in Interpreting and Applying “Evidence.” *Clin. Psychol.* **9**:204–209. [15]
- Gonzalez-Burgos, G., K. N. Fish, and D. A. Lewis. 2011. GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia. *Neural Plast.* **2011**:Article ID 723184. [05, 13]
- González-Pinto, A., S. Ruiz de Azúa, B. Ibáñez, et al. 2011. Can Positive Family Factors Be Protective against the Development of Psychosis? *Psychiatry Res.* **186**:28–33. [01]
- Goodwin, N., N. Curry, C. Naylor, P. Ross, and D. W. 2010. Managing People with Long-Term Conditions. http://www.kingsfund.org.uk/sites/files/kf/field/field_document/managing-people-long-term-conditions-gp-inquiry-research-paper-mar11.pdf. (accessed 11 March, 2013). [06]
- Gorzynski, P., and G. Faulkner. 2010. Exercise Therapy for Schizophrenia. *Schizophr. Bull.* **36**:665–666. [17]
- Gorelova, N., J. K. Seamans, and C. R. Yang. 2002. Mechanisms of Dopamine Activation of Fast-Spiking Interneurons That Exert Inhibition in Rat Prefrontal Cortex. *J. Neurophysiol.* **88**:3150–3166. [12]
- Gottesman, I. I., and A. Bertelsen. 1989. Confirming Unexpressed Genotypes for Schizophrenia. Risks in the Offspring of Fischer’s Danish Identical and Fraternal Discordant Twins. *Arch. Gen. Psychiatry* **46**:867–872. [06]
- Gottesman, I. I., and T. D. Gould. 2003. The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions. *Am. J. Psychiatr.* **160**:636–645. [02, 06, 08]
- Gottesman, I. I., T. M. Laursen, A. Bertelsen, and P. B. Mortensen. 2010. Severe Mental Disorders in Offspring with 2 Psychiatrically Ill Parents. *Arch. Gen. Psychiatry* **160**:252–257. [06]
- Gottesman, I. I., and J. Shields. 1967. A Polygenic Theory of Schizophrenia. *PNAS* **58**:199–205. [02, 08]
- . 1972. *Schizophrenia and Genetics: A Twin Study Vantage Point*. New York: Academic Press. [02]
- Gourevitch, R., C. Rocher, G. L. Pen, M. O. Krebs, and T. M. Jay. 2004. Working Memory Deficits in Adult Rats after Prenatal Disruption of Neurogenesis. *Behav. Pharmacol.* **15**:287–292. [11]
- Grace, A. A. 2000. Gating of Information Flow within the Limbic System and the Pathophysiology of Schizophrenia. *Brain. Res. Rev.* **31**:330–341. [02]
- Grace, A. A. 2010. Dopamine System Dysregulation by the Ventral Subiculum as the Common Pathophysiological Basis for Schizophrenia Psychosis, Psychostimulant Abuse, and Stress. *Neurotox. Res.* **18**:367–376. [13]
- Graf, J., C. Lauber, C. Nordt, et al. 2004. Perceived Stigmatization of Mentally Ill People and Its Consequences for the Quality of Life in a Swiss Population. *J. Nerv. Ment. Dis.* **192**:542–547. [17]
- Graham, F. K. 1975. Presidential Address, 1974. The More or Less Startling Effects of Weak Prestimulation. *Psychophysiology* **12**:238–248. [07]
- Granholm, E., D. Ben-Zeev, and P. C. Link. 2009. Social Disinterest Attitudes and Group Cognitive-Behavioral Social Skills Training for Functional Disability in Schizophrenia. *Schizophr. Bull.* **35**:874–883. [15]
- Granholm, E., J. R. McQuaid, F. S. McClure, et al. 2007. Randomized Controlled Trial of Cognitive Behavioral Social Skills Training for Older People with Schizophrenia: 12-Month Follow-Up. *J. Clin. Psychiatry* **68**:730–737. [07]

- Grant, P. M., and A. T. Beck. 2009. Defeatist Beliefs as a Mediator of Cognitive Impairment, Negative Symptoms, and Functioning in Schizophrenia. *Schizophr. Bull.* **35**:798–806. [15]
- Green, M. F. 1996. What Are the Functional Consequences of Neurocognitive Deficits in Schizophrenia? *Am. J. Psychiatr.* **153**:321–330. [04, 07, 17]
- . 2006. Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder. *J. Clin. Psychiatry* **67**(Suppl. 9):3–8. [15]
- Green, M. F., R. S. Kern, D. L. Braff, and J. Mintz. 2000. Neurocognitive Deficits and Functional Outcome in Schizophrenia: Are We Measuring the “Right Stuff”? *Schizophr. Bull.* **26**:119–136. [07]
- Green, M. F., R. S. Kern, and R. K. Heaton. 2004a. Longitudinal Studies of Cognition and Functional Outcome in Schizophrenia: Implications for MATRICS. *Schizophr. Res.* **72**:41–51. [02, 04]
- Green, M. F., and K. H. Nuechterlein. 1999a. Cortical Oscillations and Schizophrenia: Timing Is of the Essence. *Arch. Gen. Psychiatry* **56**:1007–1008. [07]
- . 1999b. Should Schizophrenia Be Treated as a Neurocognitive Disorder? *Schizophr. Bull.* **25**:309–319. [07]
- Green, M. F., K. H. Nuechterlein, J. M. Gold, et al. 2004b. Approaching a Consensus Cognitive Battery for Clinical Trials in Schizophrenia: The NIMH-MATRICES Conference to Select Cognitive Domains and Test Criteria. *Biol. Psychiatry* **56**:301–307. [04]
- Green, M. F., K. H. Nuechterlein, R. S. Kern, et al. 2008. Functional Co-Primary Measures for Clinical Trials in Schizophrenia: Results from the MATRICS Psychometric and Standardization Study. *Am. J. Psychiatr.* **165**:221–228. [04]
- Green, M. F., B. Olivier, J. N. Crawley, D. L. Penn, and S. Silverstein. 2005. Social Cognition in Schizophrenia: Recommendations from the Measurement and Treatment Research to Improve Cognition in Schizophrenia New Approaches Conference. *Schizophr. Bull.* **31**:882–887. [04]
- Greenberg, D. A., and R. Subaran. 2011. Blinders, Phenotype, and Fashionable Genetic Analysis: A Critical Examination of the Current State of Epilepsy Genetic Studies. *Epilepsia* **52**:1–9. [13]
- Greenhalgh, T., G. Robert, F. MacFarlane, P. Bate, and O. Kyriakidou. 2004. Diffusion of Innovations in Service Organizations: Systematic Review and Recommendations. *Milbank Q.* **82**:581–629. [15]
- Greenwood, K., C. F. Hung, M. Tropeano, P. McGuffin, and T. Wykes. 2011. No Association between the Catechol-O-Methyltransferase (COMT) val158met Polymorphism and Cognitive Improvement Following Cognitive Remediation Therapy (CRT) in Schizophrenia. *Neurosci. Lett.* **496**:65–69. [06]
- Greenwood, T. A., D. L. Braff, G. A. Light, et al. 2007. Initial Heritability Analyses of Endophenotypic Measures for Schizophrenia: The Consortium on the Genetics of Schizophrenia. *Arch. Gen. Psychiatry* **64**:1242–1250. [07]
- Gromann, P. M., D. K. Tracy, V. Giampietro, et al. 2012. Examining Frontotemporal Connectivity and rTMS in Healthy Controls: Implications for Auditory Hallucinations in Schizophrenia. *Neuropsychology* **26**:127–132. [09]
- Gross, G., and G. Huber. 2010. The History of the Basic Symptom Concept. *Acta Clinica Croatica* **49**:47–59. [17]
- Gruber, A. J., G. G. Calhoun, I. Shusterman, et al. 2010. More Is Less: A Disinhibited Prefrontal Cortex Impairs Cognitive Flexibility. *J. Neurosci.* **30**:17,102–17,110. [11]

- Guest, P. C., E. Schwarz, D. Krishnamurthy, et al. 2011. Altered Levels of Circulating Insulin and Other Neuroendocrine Hormones Associated with the Onset of Schizophrenia. *Psychoneuroendocrinology* **36**:1092–1096. [07]
- Guilmatre, A., D. C., A. L. Mosca, et al. 2009. Recurrent Rearrangements in Synaptic and Neurodevelopmental Genes and Shared Biologic Pathways in Schizophrenia, Autism, and Mental Retardation. *Arch. Gen. Psychiatry* **66**:947–956. [06]
- Gur, R. E., M. E. Calkins, R. C. Gur, et al. 2007. The Consortium on the Genetics of Schizophrenia: Neurocognitive Endophenotypes. *Schizophr. Bull.* **33**:49–68. [03]
- Gur, R. E., P. Cowell, B. I. Turetsky, et al. 1998. A Follow-up Magnetic Resonance Imaging Study of Schizophrenia. Relationship of Neuroanatomical Changes to Clinical and Neurobehavioral Measures. *Arch. Gen. Psychiatry* **55**:145–152. [07]
- Gustavsson, A. M. Svensson, F. Jacobi, et al. 2011. Cost of disorders of the brain in Europe 2010. *Eur. Neuropsychopharm.* **21**(10):718–779. [16]
- GWAS Consortium. 2011. Genome-Wide Association Study Identifies Five New Schizophrenia Loci. *Nat. Genet.* **43**:969–976. [09]
- Hagan, J., R. MacMillan, and B. Wheaton. 1996. New Kid in Town: Social Capital and the Life Course Effects of Family Migration on Children. *Am. Sociol. Rev.* **61**:368–385. [01]
- Hahn, C. G., G. Gomez, D. Restrepo, et al. 2005. Aberrant Intracellular Calcium Signaling in Olfactory Neurons from Patients with Bipolar Disorder. *Am. J. Psychiatr.* **162**:616–618. [10]
- Hakami, T., N. C. Jones, E. A. Tolmacheva, et al. 2009. NMDA Receptor Hypofunction Leads to Generalized and Persistent Aberrant Gamma Oscillations Independent of Hyperlocomotion and the State of Consciousness. *PLoS One* **4**:e6755. [07]
- Hall, J., L. Romaniuk, A. M. McIntosh, et al. 2009. Associative Learning and the Genetics of Schizophrenia. *Trends Neurosci.* **32**:359–365. [02]
- Hallak, J. E., S. M. Dursun, D. C. Bosi, et al. 2011. The Interplay of Cannabinoid and NMDA Glutamate Receptor Systems in Humans: Preliminary Evidence of Interactive Effects of Cannabidiol and Ketamine in Healthy Human Subjects. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **35**:198–202. [07]
- Hambrecht, M., M. Lammertink, J. Klosterkotter, E. Matuschek, and R. Pukrop. 2002. Subjective and Objective Neuropsychological Abnormalities in a Psychosis Prodrome Clinic. *Br. J. Psychiatry Suppl.* **43**:30–37. [07]
- Han, J., H. Cheng, D. Xin, and X. Yan. 2007. Frequent Pattern Mining: Current Status and Future Directions. *Data Min. Knowl. Discov.* **15**:55–86. [05]
- Han, S. S., L. A. Williams, and K. C. Eggen. 2011. Constructing and Deconstructing Stem Cell Models of Neurological Disease. *Neuron* **70**:626–644. [10]
- Hansen, D. V., J. H. Lui, P. R. Parker, and A. R. Kriegstein. 2010. Neurogenic Radial Glia in the Outer Subventricular Zone of Human Neocortex. *Nature* **464**:554–561. [10]
- Hansen, D. V., J. L. Rubenstein, and A. R. Kriegstein. 2011. Deriving Excitatory Neurons of the Neocortex from Pluripotent Stem Cells. *Neuron* **70**:645–660. [10]
- Harding, C. M., G. W. Brooks, T. Ashikaga, J. S. Strauss, and A. Breier. 1987. The Vermont Longitudinal Study of Persons with Severe Mental Illness: II. Long-Term Outcome of Subjects Who Retrospectively Met DSM-III Criteria for Schizophrenia. *Am. J. Psychiatr.* **144**:727–735. [15]
- Hare, R. D. 1993. *Without Conscience: The Disturbing World of the Psychopaths among Us*. New York: Guilford Press. [01]
- Harrison, B. J., M. Yücel, J. Pujol, and C. Pantelis. 2007. Task-Induced Deactivation of Midline Cortical Regions in Schizophrenia Assessed with fMRI. *Schizophr. Res.* **91**:82–86. [04]

- Harrison, P. J., and D. R. Weinberger. 2005. Schizophrenia Genes, Gene Expression, and Neuropathology: On the Matter of Their Convergence. *Mol. Psychiatry* **10**:40–68; image 45. [09]
- Harvey, P. D., and R. S. E. Keefe. 2012. Technology, Society, and Mental Illness: Challenges and Opportunities for Assessment and Treatment. *Innov. Clin. Neurosci.* **9**:47–50. [17]
- Harvey, P. D., J. Lombardi, M. Leibman, et al. 1996. Cognitive Impairment and Negative Symptoms in Geriatric Chronic Schizophrenic Patients: A Follow-up Study. *Schizophr. Res.* **22**:223–231. [04]
- Harvey, P. D., T. L. Patterson, L. S. Potter, K. Zhong, and M. Brecher. 2006. Improvement in Social Competence with Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition and Neuropsychological Functioning. *Am. J. Psychiatr.* **163**:1918–1925. [04]
- Hawkins, K. A., J. Addington, R. S. Keefe, et al. 2004. Neuropsychological Status of Subjects at High Risk for a First Episode of Psychosis. *Schizophr. Res.* **67**:115–122. [07]
- Hayashi-Takagi, A., M. Takaki, N. Graziane, et al. 2010. Disrupted-in-Schizophrenia 1 (DISC1) Regulates Spines of the Glutamate Synapse via Rac1. *Nat. Neurosci.* **13**:327–332. [08]
- Heaton, R., J. S. Paulsen, L. A. McAdams, et al. 1994. Neuropsychological Deficits in Schizophrenics: Relationship to Age, Chronicity, and Dementia. *Arch. Gen. Psychiatry* **51**:469–476. [15, 17]
- Heaton, R. K., J. A. Gladsjo, B. W. Palmer, et al. 2001. Stability and Course of Neuropsychological Deficits in Schizophrenia. *Arch. Gen. Psychiatry* **58**:24–32. [04, 07]
- Hedman, A. M., N. E. M. van Haren, C. G. M. van Baal, R. S. Kahn, and H. E. Hulshoff Pol. 2013. IQ Change over Time in Schizophrenia and Healthy Individuals: A Meta-Analysis, in Revision. *Schizophr. Res.* **146**:201–208. [14]
- Hegarty, J. D., R. J. Baldessarini, M. Tohen, C. Watermaux, and G. Oepen. 1994. One Hundred Years of Schizophrenia: A Meta-Analysis of the Outcome Literature. *Am. J. Psychiatr.* **151**:1409–1416. [14]
- Hegelstad, W. T. V., T. K. Larsen, B. Auestad, et al. 2012. Long-Term Follow-up of the TIPS Early Detection in Psychosis Study: Effects on 10-Year Outcome. *Am. J. Psychiatr.* **169**:374–380. [17]
- Heinrichs, R., and K. Zakanis. 1998. Neurocognitive Deficit in Schizophrenia: A Quantitative Review of the Evidence. *Neuropsychology* **12**:426–445. [04, 07]
- Heinrichs, R. W. 2001. In *Search of Madness*. Oxford: Oxford Univ. Press. [01]
- . 2005. The Primacy of Cognition in Schizophrenia. *Am. Psychol.* **60**:229–242. [02]
- Heinz, A., D. Goldman, D. W. Jones, et al. 2000. Genotype Influences *In Vivo* Dopamine Transporter Availability in Human Striatum. *Neuropsychopharmacology* **22**:133–139. [08]
- Heinze, S., G. Sartory, B. W. Müller, et al. 2006. Neural Activation During Successful and Unsuccessful Verbal Learning in Schizophrenia. *Schizophr. Res.* **83**:121–130. [04]
- Hencliff, C., and M. F. Beal. 2008. Mitochondrial Biology and Oxidative Stress in Parkinson Disease Pathogenesis. *Nat. Clin. Pract. Neurol.* **4**:600–609. [10]
- Hennekens, C. H., A. R. Hennekens, D. Hollar, and D. E. Casey. 2005. Schizophrenia and Increased Risks of Cardiovascular Disease. *Am. Heart J.* **150**:1115–1121. [05]

- Herbert, J. D. 2000. Defining Empirically Supported Treatments: Pitfalls and Possible Solutions. *Behav. Ther.* **23**:113–134. [15]
- Hermens, D. F., P. B. Ward, M. A. Hodge, et al. 2010. Impaired MMN/P3a Complex in First-Episode Psychosis: Cognitive and Psychosocial Associations. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **34**:822–829. [07]
- Hertz, J., A. Krogh, and G. Palmer. 1991. Introduction to the Theory of Neural Computation. Reading, MA: Addison-Wesley. [12]
- Hickie, I. B., E. M. Scott, D. F. Hermens, et al. 2013. Applying Clinical Staging to Young People Who Present for Mental Health Care. *Early Interv. Psychiatry* **7**:31–43. [05]
- Hickman, M., P. Vickerman, J. Macleod, et al. 2009. If Cannabis Caused Schizophrenia: How Many Cannabis Users May Need to Be Prevented in Order to Prevent One Case of Schizophrenia? England and Wales Calculations. *Addiction* **104**:1856–1861. [09]
- Higuchi, Y., T. Sumiyoshi, Y. Kawasaki, et al. 2010. Effect of Tansospirone on Mismatch Negativity and Cognitive Performance in Schizophrenia: A Case Report. *J. Clin. Psychopharmacol.* **30**:732–734. [07]
- Hikida, T., H. Jaaro-Peled, S. Seshadri, et al. 2007. Dominant-Negative DISC1 Transgenic Mice Display Schizophrenia-Associated Phenotypes Detected by Measures Translatable to Humans. *PNAS* **104**:14501–14506. [11, 13]
- Hill, S. K., J. L. Reilly, M. S. H. Harris, T. Khine, and J. A. Sweeney. 2008. Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia. *Schizophrenia Bulletin. Schizophr. Bull.* **34**:494–506. [04]
- Ho, B. C., N. C. Andreasen, P. Nopoulos, et al. 2003. Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome: A Longitudinal Magnetic Resonance Imaging Study Early in Schizophrenia. *Arch. Gen. Psychiatry* **60**:585–594. [07]
- Hodge, M. A. R., D. Siciliano, P. Withey, et al. 2010. A Randomized Controlled Trial of Cognitive Remediation in Schizophrenia. *Schizophr. Bull.* **36**:419–427. [04]
- Hodgins, S. 2008. Violent Behaviour among People with Schizophrenia: A Framework for Investigations of Causes, and Effective Treatment, and Prevention. *Phil. Trans. R. Soc. Lond. B* **363**:2505–2518. [01]
- Hoexter, M. Q., F. L. de Souza Duran, C. C. D'Alcante, et al. 2012. Gray Matter Volumes in Obsessive-Compulsive Disorder before and after Fluoxetine or Cognitive-Behavior Therapy: A Randomized Clinical Trial. *Neuropsychopharmacology* **37**:734–745. [07]
- Hoff, A. L., M. Sakuma, M. Wieneke, et al. 1999. Longitudinal Neuropsychological Follow-up Study of Patients with First-Episode Schizophrenia. *Am. J. Psychiatr.* **156**:1336–1341. [04]
- Hoffman, R. E., and T. H. McGlashan. 1993. Parallel Distributed Processing and the Emergence of Schizophrenic Symptoms. *Schizophr. Bull.* **19**:119–140. [01]
- Hogarty, G. E. 2002. Personal Therapy for Schizophrenia and Related Disorders: A Guide to Individualized Treatment. New York: Guilford Press. [15]
- Hogarty, G. E., S. Flesher, R. F. Ulrich, et al. 2004. Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior. *Arch. Gen. Psychiatry* **61**:866–876. [15]
- Hogarty, G. E., S. J. Kornblith, D. Greenwald, et al. 1995. Personal Therapy: A Disorder-Relevant Psychotherapy for Schizophrenia. *Schizophr. Bull.* **21**:379–393. [03]

- Holliday, E. G., D. E. McLean, D. R. Nyholt, and B. J. Mowry. 2009. Susceptibility Locus on Chromosome 1q23-25 for a Schizophrenia Subtype Resembling Deficit Schizophrenia Identified by Latent Class Analysis. *Arch. Gen. Psychiatry* **66**:1058–1067. [03]
- Hollingshead, A. B., and F. C. Redlich. 1958. *Social Class and Mental Illness: A Community Study*. New York: Wiley. [09]
- Homayoun, H., and B. Moghaddam. 2007. NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons. *J. Neurosci.* **27**:11,496–11,500. [11]
- Honer, W. G., A. E. Thornton, E. Y. H. Chen, et al. 2006. Clozapine Alone Versus Clozapine and Risperidone with Refractory Schizophrenia. *N. Engl. J. Med.* **354**:472–482. [04]
- Hong, L. E., A. Summerfelt, R. W. Buchanan, et al. 2010. Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine. *Neuropsychopharmacology* **35**:632–640. [07]
- Horn, S. D., and J. Gassaway. 2007. Practice-Based Evidence Study Design for Comparative Effectiveness Research. *Medical Care* **45**:S50–S57. [15]
- Horn, S. D., J. Gassaway, L. Pentz, and R. James. 2010. Practice-Based Evidence for Clinical Practice Improvement: An Alternative Study Design for Evidence-Based Medicine. *Stud. Health Tech. Inform.* **151**:446–460. [15]
- Horrobin, D. F., A. I. Glen, and C. J. Hudson. 1995. Possible Relevance of Phospholipid Abnormalities and Genetic Interactions in Psychiatric Disorders: The Relationship between Dyslexia and Schizophrenia. *Med. Hypotheses* **45**:605–613. [01]
- Horvath, S., Z. Janka, and K. Mircics. 2011. Analyzing Schizophrenia by DNA Microarrays. *Biol. Psychiatry* **69**:157–162. [10]
- Howes, O. D., A. Egerton, V. Allan, et al. 2009. Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. *Curr. Pharm. Des.* **15**:2550–2559. [07]
- Howes, O. D., J. Kambeitz, E. Kim, et al. 2012a. The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment. *Arch. Gen. Psychiatry* **69**:776–786. [13]
- Howes, O. D., and S. Kapur. 2009. The Dopamine Hypothesis of Schizophrenia, Version III: The Final Common Pathway. *Schizophr. Bull.* **35**:549–562. [02, 09, 13]
- Howes, O. D., P. Shotbolt, M. Bloomfield, et al. 2012b. Dopaminergic Function in the Psychosis Spectrum: An [18f]-Dopa Imaging Study in Healthy Individuals with Auditory Hallucinations. *Schizophr. Bull.* [09]
- Huddy, V., C. Reeder, D. Kontis, T. Wykes, and D. Stahl. 2012. The Effect of Working Alliance on Adherence and Outcome in Cognitive Remediation Therapy. *J. Nerv. Ment. Dis.* **200**:614–619. [06]
- Huot, P., and J. M. Brotchie. 2011. 5-Ht(1a) Receptor Stimulation and L-Dopa-Induced Dyskinesia in Parkinson's Disease: Bridging the Gap between Serotonergic and Glutamatergic Mechanisms. *Exp. Neurol.* **231**:195–198. [07]
- Huttenlocker, P. 1979. Synaptic Density in the Human Frontal Cortex: Developmental Changes and Effects of Aging. *Brain. Res.* **163**:195–205. [07]
- Huttenlocker, P., and A. Dabhakar. 1997. Regional Differences in Synaptogenesis in Human Cerebral Cortex. *J. Comp. Neurol.* **387**:167–178. [07]
- Huttunen, M. O., and P. Niskanen. 1978. Prenatal Loss of Father and Psychiatric Disorders. *Arch. Gen. Psychiatry* **35**:429–431. [06]
- Hyman, S. E. 2007. Can Neuroscience Be Integrated into the DSM-V? *Nat. Rev. Neurosci.* **8**:725–732. [08]

- Hyman, S. E., and W. S. Fenton. 2003. What Are the Right Targets for Psychopharmacology? *Science* **299**:350–351. [04]
- Insel, T. R. 2009. Translating Scientific Opportunity into Public Health Impact. *Arch. Gen. Psychiatry* **66**:128–133. [01, 15]
- . 2010. From Prevention to Preemption. *Biol. Psychiatry* **67**:188S. [01]
- Insel, T. R., and B. N. Cuthbert. 2011. Endophenotypes: Bridging Genomic Complexity and Disorder Heterogeneity. *Biol. Psychiatry* **66**:988–989. [02]
- Insel, T. R., B. Cuthbert, M. Garvey, et al. 2010. Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders. *Am. J. Psychiatr.* **167**:748–751. [01, 07]
- Inskip, H. M., E. C. Harris, and C. Barraclough. 1998. Lifetime Risk of Suicide for Alcoholism, Affective Disorder and Schizophrenia. *Br. J. Psychiatry* **172**:35–37. [17]
- Institute of Medicine. 2001. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: Natl. Academies Press. [15]
- . 2006. Improving the Quality of Health Care for Mental and Substance-Use Conditions. Washington, DC: Natl. Academies Press. [15]
- International Electrotechnical Commission. 1990. Chapter 191: Dependability and Quality of Service. *Electropedia: The World's Online Electrotechnical Vocabulary* <http://www.electropedia.org/iev/iev.nsf/index?openform&part=191>. (accessed March 27, 2013). [02]
- International Schizophrenia Consortium. 2009. Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder. *Nature* **460**:748–752. [05]
- Isohanni, I., M. R. Järvelin, P. Jones, Jokelainen J, and I. M. 1999. Can Excellent School Performance Be a Precursor of Schizophrenia? A 28-Year Follow-up in the Northern Finland 1966 Birth Cohort. *Acta Psychiatr. Scand.* **100**:17–26. [06]
- Isohanni, M., P. B. Jones, K. Moilanen, et al. 2001. Early Developmental Milestones in Adult Schizophrenia and Other Psychoses. A 31-Year Follow-up of the Northern Finland 1966 Birth Cohort. *Schizophr. Res.* **52**:1–19. [06]
- Ison, J. R., and H. S. Hoffman. 1983. Reflex Modification in the Domain of Startle: II. The Anomalous History of a Robust and Ubiquitous Phenomenon. *Psychol. Bull.* **94**:3–17. [07]
- Iyer, S. N., T. L. Rothmann, J. E. Vogler, and W. D. Spaulding. 2005. Evaluating Outcomes of Rehabilitation for Severe Mental Illness. *Rehab. Psychol.* **50**:43–55. [15]
- Jackson, H. J., H. L. Whiteside, G. W. Bates, et al. 1991. Diagnosing Personality Disorders in Psychiatric Inpatients. *Acta Psychiatr. Scand.* **83**:206–213. [01]
- Jacobs, B. L., H. Praag, and F. H. Gage. 2000. Adult Brain Neurogenesis and Psychiatry: A Novel Theory of Depression. *Mol. Psychiatry* **5**:262–269. [07]
- Jacobsen, L. K., J. N. Giedd, F. X. Castellanos, et al. 1998. Progressive Reduction of Temporal Lobe Structures in Childhood-Onset Schizophrenia. *Am. J. Psychiatry.* **155**:678–685. [07]
- Jaeger, M., and W. Rössler. 2010. Attitudes Towards Long-Acting Depot Antipsychotics: A Survey of Patients, Relatives and Psychiatrists. *Psychiatry Res.* **175**:58–62. [16]
- Jaffee, S. R., T. E. Moffitt, A. Caspi, and A. Taylor. 2003. Life with (or without) Father: The Benefits of Living with Two Biological Parents Depend on the Father's Antisocial Behavior. *Child Dev.* **74**:109–126. [09]
- Jahshan, C., K. S. Cadenhead, A. J. Risling, et al. 2012. Automatic Sensory Information Processing Abnormalities across the Illness Course of Schizophrenia. *Psychol. Med.* **42**:85–97. [07, 09]

- Jahshan, C., R. K. Heaton, S. Golshan, and K. S. Cadenhead. 2010. Course of Neurocognitive Deficits in the Prodrome and First Episode of Schizophrenia. *Neuropsychology* **24**:109–120. [07]
- Jansma, J. M., N. F. Ramsey, N. J. van der Wee, and R. S. Kahn. 2004. Working Memory Capacity in Schizophrenia: A Parametric fMRI Study. *Schizophr. Res.* **68**:159–171. [04]
- Jaspers, K. 1946/1997. *General Psychopathology* (translated by J. Hoenig and Marian W. Hamilton). Baltimore: Johns Hopkins Univ. Press. [05]
- . 1963. *General Psychopathology* (translated by J. Hoenig and M. W. Hamilton). Manchester: Manchester Univ. Press. [03]
- Javitt, D. C., R. W. Buchanan, R. S. E. Keefe, et al. 2012. Effect of the Neuroprotective Peptide Davunetide (AL-108) on Cognition and Functional Capacity in Schizophrenia. *Schizophr. Res.* **136**:25–31. [04]
- Javitt, D. C., A. Shelley, and W. Ritter. 2000. Associated Deficits in Mismatch Negativity Generation and Tone Matching in Schizophrenia. *Clin. Neurophysiol.* **111**:1733–1737. [07]
- Javitt, D. C., and S. R. Zukin. 1991. Recent Advances in the Phencyclidine Model of Schizophrenia. *Am. J. Psychiatr.* **148**:1301–1308. [07]
- Jenkins, R., G. Lewis, P. Bebbington, et al. 1997. The National Psychiatric Morbidity Surveys of Great Britain Initial Findings from the Household Survey. *Psychol. Med.* **27**:777–789. [16]
- Jennings, A. F. 1994. On Being Invisible in the Mental Health System. *J. Ment. Health Adm.* **21**:374–387. [15]
- Johnson, A. B. 1990. *Out of Bedlam: The Truth About Deinstitutionalization*. New York: Basic Books. [15]
- Johnson, S. C., A. J. Saykin, L. A. Flashman, T. W. McAllister, and M. B. Sparling. 2001. Brain Activation on fMRI and Verbal Memory Ability: Functional Neuroanatomic Correlates of CVLT Performance. *J. Int. Neuropsychol. Soc.* **7**:55–62. [04]
- Johnston, P. J., H. Devir, and F. Karayanidis. 2006. Facial Emotion Processing in Schizophrenia: No Evidence for a Deficit Specific to Negative Emotions in a Differential Deficit Design. *Psychiatry Res.* **143**:51–61. [04]
- Jones, J. A. H., S. R. Sponheim, and A. W. MacDonald, III. 2010a. The Dot Pattern Expectancy Task: Reliability and Replication of Deficits in Schizophrenia. *Psychol. Assess.* **22**:131–141. [02]
- Jones, L., P. A. Holmans, M. L. Hamshere, et al. 2010b. Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. *PLoS One* **5**:e13950. [09]
- Jones, P., B. Rodgers, R. Murray, and M. Marmot. 1994. Child Development Risk Factors for Adult Schizophrenia in the British 1946 Birth Cohort. *Lancet* **344**:1398–1402. [06]
- Jones, P. B., and S. R. Marder. 2008. Psychosocial and Pharmacological Treatments for Schizophrenia. In: *Cambridge Textbook of Effective Treatments in Psychiatry*, ed. P. J. Tyrer and K. R. Silk, pp. 469–480. New York: Cambridge Univ. Press. [06]
- Jones, P. B., and J. Van Os. 1998. Predicting Schizophrenia in Teenagers: Pessimistic Results from the British 1946 Birth Cohort. *Schizophr. Res.* **29**:11. [09]
- Kahkonen, S., V. Mäkinen, I. P. Jaaskelainen, et al. 2005. Serotonergic Modulation of Mismatch Negativity. *Psychiatry Res.* **138**:61–74. [07]
- Kaitin, K. I., and J. A. DiMasi. 2011. Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009. *Clin. Pharmacol. Therap.* **89**:183–188. [17]

- Kaitin, K. I., and C. P. Milne. 2011. A Dearth of New Meds: Drugs to Treat Neuropsychiatric Disorders Have Become Too Risky for Big Pharma. *Sci. Am.* **305**:16–17. [17]
- Kaji, K., K. Norrby, A. Paca, et al. 2009. Virus-Free Induction of Pluripotency and Subsequent Excision of Reprogramming Factors. *Nature* **458**:771–775. [10]
- Kalmijn, S., E. J. Feskens, L. J. Launer, and D. Kromhout. 1997. Polyunsaturated Fatty Acids, Antioxidants, and Cognitive Function in Very Old Men. *Am. J. Epidemiol.* **145**:33–41. [07]
- Kandel, E. R., J. H. Schwartz, and T. M. Jessell. 2000. Principles of Neural Science. Smell and Taste: The Chemical Senses, L. B. Buck, series ed: McGraw-Hill. [10]
- Kane, J. M., M. Cohen, J. Zhao, L. M. Alphs, and J. Panagides. 2010a. Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients with Acute Exacerbation of Schizophrenia. *J. Clin. Psychopharmacol.* **30**:106–115. [04]
- Kane, J. M., D. C. D'Souza, A. A. Patkar, et al. 2010b. Armodafinil as Adjunctive Therapy in Adults with Cognitive Deficits Associated with Schizophrenia: A 4-Week, Double-Blind, Placebo-Controlled Study. *J. Clin. Psychiatry* **71**:1475–1481. [06]
- Kano, S., C. Colantuoni, F. Han, et al. 2012. Genome-Wide Profiling of Multiple Histone Methylations in Olfactory Cells: Further Implications for Cellular Susceptibility to Oxidative Stress in Schizophrenia. *Mol. Psychiatry* [10]
- Kapur, S., T. Arenovich, O. Agid, et al. 2005. Evidence for Onset of Antipsychotic Effects within the First 24 Hours of Treatment. *Am. J. Psychiatr.* **162**:939–946. [17]
- Kapur, S., R. Zipursky, C. Jones, G. Remington, and S. Houle. 2000. Relationship between Dopamine D(2) Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia. *Am. J. Psychiatr.* **157**:514–520. [07]
- Karaka, S., B. Bekci, and O. U. Erzen. 2003. Early Gamma Response in Human Neuroelectric Activity Is Correlated with Neuropsychological Test Scores. *Neurosci. Lett.* **340**:37–40. [04]
- Karksson, J. L. 1970. Genetic Association of Giftedness and Creativity with Schizophrenia. *Hereditas* **66**:177–182. [06]
- Kates, W. R. 2010. Investigating the Cognitive Antecedents of Schizophrenia. *Am. J. Psychiatr.* **167**:122–124. [09]
- Kato, M., and A. Serretti. 2010. Review and Meta-Analysis of Antidepressant Pharmacogenetic Findings in Major Depressive Disorder. *Mol. Psychiatry* **15**:473–500. [08]
- Keane, B. P., S. M. Silverstein, Y. Wang, and T. V. Papatomas. 2013. Reduced Depth Inversion Illusions in Schizophrenia Are State-Specific and Occur for Multiple Object Types and Viewing Conditions. *J. Abnorm. Psychol.* **122**:506–512. [01]
- Keefe, R. S., R. M. Bilder, S. M. Davis, et al. 2007. CATIE Investigators: Neurocognitive Working Group. Neurocognitive Effects of Antipsychotic Medications in Patients with Chronic Schizophrenia in the CATIE Trial. *Arch. Gen. Psychiatry* **64**:633–647. [14]
- Keefe, R. S., R. W. Buchanan, S. R. Marder, et al. 2013. Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far? *Schizophr. Bull.* **39**:417–435. [04, 06, 07]
- Keefe, R. S., C. E. Easley, and M. P. Poe. 2005. Defining a Cognitive Function Decrement in Schizophrenia. *Biol. Psychiatry* **57**:688–691. [14]
- Keefe, R. S., K. H. Fox, P. D. Harvey, et al. 2011a. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-Site Antipsychotic Schizophrenia Clinical Trial. *Schizophr. Res.* **125**:161–168. [14]

- Keefe, R. S., A. K. Malhotra, H. Y. Meltzer, et al. 2008. Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. *Neuropsychopharmacology* **33**:1217–1228. [14]
- Keefe, R. S., D. O. Perkins, H. Gu, et al. 2006. A Longitudinal Study of Neurocognitive Function in Individuals at Risk for Psychosis. *Schizophr. Res.* **88**:26–35. [07]
- Keefe, R. S., S. Vinogradov, A. Medalia, et al. 2012. Feasibility and Pilot Efficacy Results from the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial. *J. Clin. Psychiatry* **73**:1016–1022. [06]
- Keefe, R. S. E., and W. S. Fenton. 2007. How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment? *Schizophr. Bull.* **33**:912–920. [14]
- Keefe, R. S. E., T. E. Goldberg, P. D. Harvey, et al. 2004. The Brief Assessment of Cognition in Schizophrenia: Reliability, Sensitivity, and Comparison with a Standard Neurocognitive Battery. *Schizophr. Res.* **68**:283–297. [04]
- Keefe, R. S. E., S. Vinogradov, A. Medalia, et al. 2011b. Report from the Working Group Conference on Multi-Site Trial Design for Cognitive Remediation in Schizophrenia. *Schizophr. Bull.* **37**:1057–1065. [17]
- Kegeles, L. S., X. Mao, A. D. Stanford, et al. 2012. Elevated Prefrontal Cortex Gamma-Aminobutyric Acid and Glutamate-Glutamine Levels in Schizophrenia Measured *in Vivo* with Proton Magnetic Resonance Spectroscopy. *Arch. Gen. Psychiatry* **69**:449–459. [07]
- Kelleher, I., M. C. Clarke, C. Rawdon, J. Murphy, and M. Cannon. 2012a. Neurocognition in the Extended Psychosis Phenotype: Performance of a Community Sample of Adolescents with Psychotic Symptoms on the MATRICS Neurocognitive Battery. *Schizophr. Bull.* [09]
- Kelleher, I., D. Connor, M. C. Clarke, et al. 2012b. Prevalence of Psychotic Symptoms in Childhood and Adolescence: A Systematic Review and Meta-Analysis of Population-Based Studies. *Psychol. Med.* **42**:1857–1863. [06]
- Kelly, D. L., R. W. Buchanan, D. L. Boggs, and R. P. McMahon. 2009. A Randomized Double-Blind Trial of Atomoxetine for Cognitive Impairments in 32 People with Schizophrenia. *J. Clin. Psychiatry* **70**:518–525. [04]
- Kemp, A. S., N. R. Schooler, A. H. Kalali, et al. 2010. What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can Be Done About It? *Schizophr. Bull.* **36**:504–509. [01]
- Kempton, M. J., J. R. Geddes, U. Ettinger, S. C. Williams, and P. M. Grasby. 2008. Meta-Analysis, Database, and Meta-Regression of 98 Structural Imaging Studies in Bipolar Disorder. *Arch. Gen. Psychiatry* **65**:1017–1032. [07]
- Kendler, K. S., M. McGuire, A. M. Gruenberg, et al. 1993. The Roscommon Family Study III: Schizophrenia-Related Personality Disorder in Relatives. *Arch. Gen. Psychiatry* **50**:781–788. [05]
- Keri, S., and G. Benedek. 2009. Oxytocin Enhances the Perception of Biological Motion in Humans. *Cogn. Affect. Behav. Neurosci.* **9**:237–241. [07]
- Kern, R. S., S. M. Glynn, W. P. Horan, and S. R. Marder. 2009. Psychosocial Treatments to Promote Functional Recovery in Schizophrenia. *Schizophr. Bull.* **35**:347–361. [17]
- Kern, R. S., K. H. Nuechterlein, M. F. Green, et al. 2008. The MATRICS Consensus Cognitive Battery. Part 2: Co-Norming and Standardization. *Am. J. Psychiatr.* **165**:214–220. [06]

- Keshavan, M. S., S. Anderson, and J. W. Pettegrew. 1994. Is Schizophrenia Due to Excessive Synaptic Pruning in the Prefrontal Cortex? The Feinberg Hypothesis Revisited. *J. Psychiatr. Res.* **28**:239–265. [07]
- Keshavan, M. S., R. Tandon, N. N. Boutros, and H. A. Nasrallah. 2008. Schizophrenia, “Just the Facts”: What We Know in 2008. Part 3: Neurobiology. *Schizophr. Res.* **106**:89–107. [05]
- Kessler, R. C., S. Avenevoli, E. J. Costello, et al. 2012. Prevalence, Persistence, and Sociodemographic Correlates of DSM-IV Disorders in the National Comorbidity Survey Replication Adolescent Supplement. *Arch. Gen. Psychiatry* **69**:372–380. [06]
- Kessler, R. C., P. Berglund, O. Demler, et al. 2003. The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R). *JAMA* **289**:3095–3105. [16]
- Kessler, R. C., O. Demler, R. G. Frank, et al. 2005. Prevalence and Treatment of Mental Disorders, 1990 to 2003. *N. Engl. J. Med.* **352**:2515–2523. [16]
- Kessler, R. C., K. A. McLaughlin, J. G. Green, et al. 2010. Childhood Adversities and Adult Psychopathology in the WHO World Mental Health Surveys. *Br. J. Psychiatry* **197**:378–385. [09]
- Kety, S. S., W. Rosenthal, P. H. Wender, and F. Schulsinger. 1971. Mental Illness in the Biological and Adoptive Families of Adopted Schizophrenics. *Am. J. Psychiatry.* **128**:302–306. [02]
- Keuken, M. C., A. Hardie, B. T. Dorn, et al. 2011. The Role of the Left Inferior Frontal Gyrus in Social Perception: An rTMS Study. *Brain. Res.* **1383**:196–205. [07]
- Khandaker, G. M., J. H. Barnett, I. R. White, and P. B. Jones. 2011. A Quantitative Meta-Analysis of Population-Based Studies of Premorbid Intelligence and Schizophrenia. *Schizophr. Res.* **132**:220–227. [06, 14]
- Khandaker, G. M., J. Zimbron, C. Dalman, G. Lewis, and P. B. Jones. 2012a. Childhood Infection and Adult Schizophrenia: A Meta-Analysis of Population-Based Studies. *Schizophr. Res.* **139**:161–168. [06]
- Khandaker, G. M., J. Zimbron, G. Lewis, and P. B. Jones. 2012b. Prenatal Maternal Infection, Neurodevelopment and Adult Schizophrenia: A Systematic Review of Population-Based Studies. *Psychol. Med.* **16**:1–19. [06]
- Kilbourne, A. M., N. E. Morden, K. Austin, et al. 2009. Excess Heart-Disease-Related Mortality in a National Study of Patients with Mental Disorders: Identifying Modifiable Risk Factors. *Gen. Hosp. Psychiatry* **31**:555–563. [05]
- Kim, K., A. Doi, B. Wen, et al. 2010. Epigenetic Memory in Induced Pluripotent Stem Cells. *Nature* **467**:285–290. [10]
- Kingdon, D. G., and D. Turkington. 2004. Cognitive Therapy of Schizophrenia. New York: Guilford Press. [15]
- Kinon, B. J., L. Zhang, B. A. Millen, et al. 2011. A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients with DSM-IV Schizophrenia. *J. Clin. Psychopharmacol.* **31**:349–355. [04, 07]
- Kirkbride, J. B., J. Boydell, G. B. Ploubidis, et al. 2008. Testing the Association between the Incidence of Schizophrenia and Social Capital in an Urban Area. *Psychol. Med.* **38**:1083–1094. [01]
- Kirkbride, J. B., A. Errazuriz, T. J. Croudace, et al. 2012. Incidence of Schizophrenia and Other Psychoses in England, 1950–2009: A Systematic Review and Meta-Analyses. *PLoS One* **7**:e31660. [09]

- Kirkbride, J. B., P. Fearon, C. Morgan, et al. 2006. Heterogeneity in Incidence Rates of Schizophrenia and Other Psychotic Syndromes: Findings from the 3-Center Aesop Study. *Arch. Gen. Psychiatry* **63**:250–258. [09]
- Kirkpatrick, B. 2009. Schizophrenia as a Systemic Disease. *Schizophr. Bull.* **35**:381–382. [10]
- Kirkpatrick, B., R. W. Buchanan, D. E. Ross, and W. T. Carpenter, Jr. 2001. A Separate Disease within the Syndrome of Schizophrenia. *Arch. Gen. Psychiatry* **58**:165–171. [03]
- Kirkpatrick, B., W. S. Fenton, W. T. Carpenter, Jr., and S. R. Marder. 2006. The NIMH-MATRICES Consensus Statement on Negative Symptoms. *Schizophr. Bull.* **32**:214–219. [03]
- Kirov, G., D. Gumus, W. Chen, et al. 2008. Comparative Genome Hybridization Suggests a Role for NRXN1 and APBA2 in Schizophrenia. *Hum. Mol. Genet.* **17**:458–465. [05]
- Kirov, G., A. J. Pocklington, P. Holmans, et al. 2012. *De Novo* CNV Analysis Implicates Specific Abnormalities of Postsynaptic Signalling Complexes in the Pathogenesis of Schizophrenia. *Mol. Psychiatry* **17**:142–153. [09]
- Kirsch, I., B. J. Deacon, T. B. Huedo-Medina, et al. 2008. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. *PLoS Med.* **5**:e45, 260–268. [17]
- Knight, R. A., and S. M. Silverstein. 2001. A Process-Oriented Approach for Averting Confounds Resulting from General Performance Deficiencies in Schizophrenia. *J. Abnorm. Psychol.* **110**:15–30. [01, 02, 09]
- Knightbridge, S. M., R. King, and T. J. Rolfe. 2006. Using Participatory Action Research in a Community-Based Initiative Addressing Complex Mental Health Needs. *Aust. NZ J. Psychiatry* **40**:325–332. [15]
- Koethe, D., A. Giuffrida, D. Schreiber, et al. 2009a. Anandamide Elevation in Cerebrospinal Fluid in Initial Prodromal States of Psychosis. *Br. J. Psychiatry* **194**:371–372. [07]
- Koethe, D., C. Hoyer, and F. M. Leweke. 2009b. The Endocannabinoid System as a Target for Modelling Psychosis. *Psychopharmacology* **206**:551–561. [07]
- Kohler, C. G., W. Bilker, M. Hagendoorn, R. E. Gur, and R. C. Gur. 2000. Emotion Recognition Deficit in Schizophrenia: Association with Symptomatology and Cognition. *Biol. Psychiatry* **48**:127–136. [04]
- Kohler, C. G., T. H. Turner, W. B. Bilker, et al. 2003. Facial Emotion Recognition in Schizophrenia: Intensity Effects and Error Pattern. *Am. J. Psychiatr.* **160**:1768–1774. [04]
- Kohler, C. G., J. B. Walker, E. A. Martin, K. M. Healey, and P. J. Moberg. 2009. Facial Emotion Perception in Schizophrenia: A Meta-Analytic Review. *Schizophr. Bull.* **36**:1009–1019. [04]
- Kong, A., M. L. Frigge, G. Masson, et al. 2012. Rate of *De Novo* Mutations and the Importance of Father's Age to Disease Risk. *Nature* **488**:471–475. [08]
- Kontis, D., V. Huddy, C. Reeder, S. Landau, and T. Wykes. 2012. Effects of Age and Cognitive Reserve on Cognitive Remediation Therapy Outcome in Patients with Schizophrenia. *Am. J. Geriatr. Psychiatry* **21**:218–230. [06]
- Kopelowicz, A., C. J. Wallace, and R. Zarate. 1998. Teaching Psychiatric Inpatients to Re-Enter the Community: A Brief Method of Improving the Continuity of Care. *Psychiatr. Serv.* **49**:1313–1316. [15]

- Koren, D., L. J. Seidman, M. Goldsmith, and P. D. Harvey. 2006. Real World Cognitive- and Metacognitive-Dysfunction in Schizophrenia: A New Approach for Measuring (and Remediating) More “Right Stuff.” *Schizophr. Bull.* **32**:310–326. [04]
- Kornack, D. R., and P. Rakic. 1999. Continuation of Neurogenesis in the Hippocampus of the Adult Macaque Monkey. *PNAS* **96**:5768–5773. [07]
- Korostenskaja, M., K. Dapsys, A. Siurkute, et al. 2005. Effects of Olanzapine on Auditory P300 and Mismatch Negativity (MMN) in Schizophrenia Spectrum Disorders. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **29**:543–548. [07]
- Korostenskaja, M., V. V. Nikulin, D. Kicic, A. V. Nikulina, and S. Kahkonen. 2007. Effects of NMDA Receptor Antagonist Memantine on Mismatch Negativity. *Brain Res. Bull.* **72**:275–283. [07]
- Koseki, T., A. Mouri, T. Mamiya, et al. 2012. Exposure to Enriched Environments During Adolescence Prevents Abnormal Behaviours Associated with Histone Deacetylation in Phencyclidine-Treated Mice. *Int. J. Neuropsychopharmacol.* **15**:1489–1501. [09]
- Kosmidis, M. H., V. P. Bozikas, M. Giannakou, et al. 2007. Impaired Emotion Perception in Schizophrenia: A Differential Deficit. *Psychiatry Res.* **149**:279–284. [04]
- Kotov, R., L. T. Guey, E. J. Bromet, and J. E. Schwartz. 2010. Smoking in Schizophrenia: Diagnostic Specificity, Symptom Correlates, and Illness Severity. *Schizophr. Bull.* **36**:173–181. [17]
- Kotov, R., C. J. Ruggero, R. F. Krueger, et al. 2011. New Dimensions in the Quantitative Classification of Mental Illness. *Arch. Gen. Psychiatry* **68**:1003–1011. [02]
- Koutsouleris, N., G. J. Schmitt, C. Gaser, et al. 2009. Neuroanatomical Correlates of Different Vulnerability States for Psychosis and Their Clinical Outcomes. *Br. J. Psychiatry* **195**:218–226. [07]
- Kovelman, J. A., and A. B. Scheibel. 1984. A Neurohistological Correlate of Schizophrenia. *Biol. Psychiatry* **19**:1601–1917. [11]
- Krabbendam, L., B. Arts, J. van Os, and A. Aleman. 2005. Cognitive Functioning in Patients with Schizophrenia and Bipolar Disorder: A Quantitative Review. *Schizophr. Res.* **80**:137–149. [14]
- Krabbendam, L., and J. van Os. 2005. Schizophrenia and Urbanicity: A Major Environmental Influence—Conditional on Genetic Risk. *Schizophr. Bull.* **31**:795–799. [08, 09]
- Kraepelin, E. 1896. *Lehrbuch Für Studierende und Ärzte*. Leipzig: Barth. [14]
- . 1919/1971. *Dementia Praecox and Paraphrenia* (translated by R.M. Barclay). Huntington, NY: Robert E. Kreiger. [02, 03, 06, 15]
- Kryzhanovskaya, L. A., S. Schulz, C. McDougle, et al. 2009. Results from a Double-Blind Placebo-Controlled Trial of Olanzapine in Adolescents with Schizophrenia. *J. Am. Acad. Child Adol. Psychiatr.* **48**:60–70. [04]
- Kuepper, R., J. van Os, R. Lieb, H. U. Wittchen, and C. Henquet. 2011. Do Cannabis and Urbanicity Co-Participate in Causing Psychosis? Evidence from a 10-Year Follow-up Cohort Study. *Psychol. Med.* **41**:2121–2129. [09]
- Kuipers, L., J. Leff, and D. Lam. 2002. *Family Work for Schizophrenia: A Practical Guide* (2nd edition). London: Gaskell. [15]
- Kumari, V., D. Fannon, E. R. Peters, et al. 2011. Neural Changes Following Cognitive Behaviour Therapy for Psychosis: A Longitudinal Study. *Brain* **134**:2396–2407. [07]
- Kumari, V., D. Fannon, A. L. Sumich, and T. Sharma. 2007. Startle Gating in Antipsychotic-Naive First Episode Schizophrenia Patients: One Ear Is Better Than Two. *Psychiatry Res.* **151**:21–28. [07]

- Kumari, V., G. H. Gudjonsson, S. Raghuvanshi, et al. 2013. Reduced Thalamic Volume in Men with Antisocial Personality Disorder or Schizophrenia and a History of Serious Violence and Childhood Abuse. *Eur. Psychiatry* **28**:225–234. [01]
- Kumari, V., E. R. Peters, D. Fannon, et al. 2009. Dorsolateral Prefrontal Cortex Activity Predicts Responsiveness to Cognitive-Behavioral Therapy in Schizophrenia. *Biol. Psychiatry* **66**:594–602. [07]
- Kumra, A., J. Frazier, L. K. Jacobsen, et al. 1996. Childhood-Onset Schizophrenia. A Double-Blind Clozapine-Haloperidol Comparison. *Arch. Gen. Psychiatry* **53**:1090–1097. [04]
- Kumra, S., H. Kranzler, G. Gerbino-Rosen, et al. 2008. Clozapine and “High-Dose” Olanzapine in Refractory Early-Onset Schizophrenia: A 12-Week Randomized and Double-Blind Comparison. *Biol. Psychiatry* **63**:524–529. [04]
- Kurtz, M. M., and K. T. Mueser. 2008. A Meta-Analysis of Controlled Research on Social Skills Training for Schizophrenia. *J. Consult. Clin. Psychol.* **76**:491–504. [15, 17]
- Kurtz, M. M., and C. L. Richardson. 2012. Social Cognitive Training for Schizophrenia: A Meta-Analytic Investigation of Controlled Research. *Schizophr. Bull.* **38**:1092–1104. [15]
- Laan, W., D. E. Grobbee, J. P. Selten, et al. 2010. Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results from a Randomized, Double-Blind, Placebo-Controlled Trial. *J. Clin. Psychiatry* **71**:520–527. [07]
- Labrie, V., S. Pai, and A. Petronis. 2012. Epigenetics of Major Psychosis: Progress, Problems and Perspectives. *Trends Genet.* **28**:427–435. [09]
- Ladewig, J., J. Mertens, J. Kesavan, et al. 2012. Small Molecules Enable Highly Efficient Neuronal Conversion of Human Fibroblasts. *Nat. Methods* **9**:575–578. [10]
- Lahey, B. B., B. Applegate, J. K. Hakes, et al. 2012. Is There a General Factor of Prevalent Psychopathology During Adulthood? *J. Abnorm. Psychol.* **121**:971–977. [02]
- Lahti, A. C., and M. A. Reid. 2011. Is There Evidence for Neurotoxicity in the Prodromal and Early Stages of Schizophrenia? *Neuropsychopharmacology* **36**:1779–1780. [07]
- Lambert, M. J. 2005. Emerging Methods for Providing Clinicians with Timely Feedback on Treatment Effectiveness: An Introduction. *J. Clin. Psychol.* **61**:141–144. [15]
- Lancet Global Mental Health Group, D. Chisholm, A. J. Flisher, et al. 2007. Scale up Services for Mental Disorders: A Call for Action. *Lancet* **370(9594)**:1241–1252. [16]
- Landgraf, S., I. Amado, A. Berthoz, M. Krebs, and E. Van Der Meer. 2012. Cognitive Identify in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome. *Curr. Psychiatry Rev.* **8**:119–139. [01, 05]
- Langfeldt, G. 1939. The Schizophreniform States: A Katamnestic Study Based on Individual Re-Examinations: With Special Reference to Diagnostic and Prognostic Clues, and with a View to Presenting a Standard Material for Comparison with the Remissions Effected by Shock Treatment. Copenhagen: Munksgaard. [03]
- Lante, F., J. Meunier, J. Guiramand, et al. 2007. Neurodevelopmental Damage after Prenatal Infection: Role of Oxidative Stress in the Fetal Brain. *Free Radic. Biol. Med.* **42**:1231–1245. [07]
- Lau, A., and M. Tymianski. 2010. Glutamate Receptors, Neurotoxicity and Neurodegeneration. *Pflugers Arch.* **460**:525–542. [07]
- Lauber, C., M. Anthony, V. Ajdacic-Gross, and W. Rössler. 2004a. What About Psychiatrists’ Attitude to Mentally Ill People? *Eur. Psychiatry* **19**:423–427. [16]
- Lauber, C., A. Eichenberger, P. Luginbühl, C. Keller, and W. Rössler. 2003. Determinants of Burden in Caregivers of Patients with Exacerbating Schizophrenia. *Eur. Psychiatry* **18**:285–289. [16, 17]

- Lauber, C., C. Nordt, L. Falcató, and W. Rössler. 2001. Lay Recommendations on How to Treat Mental Disorders. *Soc. Psychiatry Psychiatr. Epidem.* **36**:553–556. [16]
- . 2002. Public Attitude to Compulsory Admission of Mentally Ill People. *Acta Psychiatr. Scand.* **105**:385–389. [16]
- . 2004b. Factors Influencing Social Distance toward People with Mental Illness. *Commun. Ment. Health J.* **40**:265–274. [17]
- Lauber, C., C. Nordt, N. Sartorius, L. Falcató, and W. Rössler. 2000. Public Acceptance of Restrictions on Mentally Ill People. *Acta Psychiatr. Scand.* **102**:26–32. [16]
- Laursen, T. M. 2011. Life Expectancy among Persons with Schizophrenia or Bipolar Affective Disorder. *Schizophr. Res.* **131**:101–104. [17]
- Laursen, T. M., E. Agero, and C. B. Pedersen. 2009. Bipolar Disorder, Schizoaffective Disorder, and Schizophrenia Overlap: A New Comorbidity Index. *J. Clin. Psychiatry* **70**:1432–1438. [02]
- Lavin, A., L. Nogueira, C. C. Lapish, et al. 2005. Mesocortical Dopamine Neurons Operate in Distinct Temporal Domains Using Multimodal Signaling. *J. Neurosci.* **25**:5013–5023. [12]
- Lavoie, S., M. M. Murray, P. Deppen, et al. 2008. Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients. *Neuropsychopharmacology* **33**:2187–2199. [07]
- Lawn, S. 2012. In It Together: Physical Health and Well-Being for People with Mental Illness. *Aust. NZ J. Psychiatry* **46**:14–17. [17]
- Lawrence, D., C. D. Holman, A. Jablensky, S. Fuller, and A. Stoney. 2001. Increasing Rates of Suicide in Western Australian Psychiatric Patients: A Record Linkage Study. *Acta Psychiatr. Scand.* **104**:443–451. [17]
- Lawrence, D., C. D. Holman, A. V. Jablensky, and M. Hobbs. 2003. Death Rate from Ischaemic Heart Disease in Western Australian Psychiatric Patients 1980–1998. *Br. J. Psychiatry* **182**:31–36. [17]
- Lawrie, S. M., C. Buechel, H. C. Whalley, et al. 2002. Reduced Fronto-Temporal Functional Connectivity in Schizophrenia Associated with Auditory Hallucinations. *Biol. Psychiatry* **51**:1008–1011. [04]
- Lederbogen, F., P. Kirsch, L. Haddad, et al. 2011. City Living and Urban Upbringing Affect Neural Social Stress Processing in Humans. *Nature* **474**:498–501. [08, 09, 12]
- Lee, H., D. Dvorak, H. Y. Kao, et al. 2012. Early Cognitive Experience Prevents Adult Deficits in a Neurodevelopmental Schizophrenia Model. *Neuron* **75**:714–724. [09, 13]
- Leeson, V. C., P. Sharma, M. Harrison, et al. 2011. IQ Trajectory, Cognitive Reserve and Clinical Outcome Following a First-Episode of Psychosis: A Three Year Longitudinal Study. *Schizophr. Bull.* **37**:768–777. [04]
- Leff, J., L. Kuipers, R. Berkowitz, and D. Sturgeon. 1985. A Controlled Trial of Social Intervention in the Families of Schizophrenic Patients: Two-Year Follow-Up. *Br. J. Psychiatry* **146**:594–600. [15]
- Lehman, A. F. 1998. The Role of Mental Health Service Research in Promoting Effective Treatment for Adults with Schizophrenia. *J. Ment. Health Policy Econ.* **1**:199–204. [16]
- Lehman, A. F., and D. M. Steinwachs. 1998. Patterns of Usual Care for Schizophrenia: Initial Results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. *Schizophr. Bull.* **24**:11–20. [01, 15]
- Lehrer, J. 2009. Accept Defeat: The Neuroscience of Screwing Up. *Wired Magazine* Jan 2010, http://www.wired.com/magazine/2009/12/fail_accept_defeat/all/1. [08]

- Lehtinen, V., J. Aaltonen, T. Koffert, V. Rääköläinen, and E. Syvälahti. 2000. Two-Year Outcome in First-Episode Psychosis Treated According to an Integrated Model. Is Immediate Neuroleptisation Always Needed? *Eur. Psychiatry* **15**:312–320. [01]
- Leicht, G., S. Karch, E. Karamatskos, et al. 2011. Alterations of the Early Auditory Evoked Gamma-Band Response in First-Degree Relatives of Patients with Schizophrenia: Hints to a New Intermediate Phenotype. *J. Psychiatr. Res.* **45**:699–705. [07]
- Lelliot, P., A. Beevor, G. Hogman, et al. 2001. Carers' and Users' Expectations of Services: User Version (CUES-U): A New Instrument to Measure the Experience of Users of Mental Health Services. *Br. J. Psychiatry* **179**:67–72. [16]
- Leonard, C. M., J. M. Kuldau, L. Maron, et al. 2008. Identical Neural Risk Factors Predict Cognitive Deficit in Dyslexia and Schizophrenia. *Neuropsychology* **22**:147–158. [01]
- Leucht, S., S. Heres, W. Kissling, and J. M. Davis. 2011. Evidence-Based Pharmacotherapy of Schizophrenia. *Int. J. Neuropsychopharmacol.* **14**:269–284. [05]
- Leucht, S., and R. Lasser. 2006. The Concepts of Remission and Recovery in Schizophrenia. *Pharmacopsychiatry* **39**:161–170. [17]
- Levinson, D. F. 2006. The Genetics of Depression: A Review. *Biol. Psychiatry* **60**:84–92. [08]
- Levkovitz, Y., S. Mendlovich, S. Riwkes, et al. 2010. A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia. *J. Clin. Psychiatry* **71**:138–149. [04, 07]
- Leweke, F., D. Koethe, C. W. Gerth, et al. 2007a. Double Blind, Controlled Clinical Trial of Cannabidiol Monotherapy Versus Amisulpiride in the Treatment of Acutely Psychotic Schizophrenia Patients. *Schizophr. Bull.* **33**:310. [07]
- Leweke, F. M., A. Giuffrida, D. Koethe, et al. 2007b. Anandamide Levels in Cerebrospinal Fluid of First-Episode Schizophrenic Patients: Impact of Cannabis Use. *Schizophr. Res.* **94**:29–36. [07]
- Lewinsohn, P. M. 1974. A Behavioral Approach to the Treatment of Depression. In: *The Psychology of Depression*, ed. R. M. Friedman and M. M. Katz, pp. 157–185. New York: Wiley. [15]
- Lewis, D. A., R. Y. Cho, C. S. Carter, et al. 2008. Subunit-Selective Modulation of GABA Type a Receptor Neurotransmission and Cognition in Schizophrenia. *Am. J. Psychiatr.* **165**:1585–1593. [07]
- Lewis, D. A., and G. Gonzalez-Burgos. 2008. Neuroplasticity of Neocortical Circuits in Schizophrenia. *Neuropsychopharmacology* **33**:141–165. [07]
- Lewis, D. A., T. Hashimoto, and D. W. Volk. 2005. Cortical Inhibitory Neurons and Schizophrenia. *Nat. Rev. Neurosci.* **6**:312–324. [13]
- Lewis, D. A., and B. Moghaddam. 2006. Cognitive Dysfunction in Schizophrenia: Convergence of Gamma-Aminobutyric Acid and Glutamate Alterations. *Arch. Neurol.* **63**:1372–1376. [07]
- Lewis, S. W., and J. Lieberman. 2008. CATIE and Cutlass: Can We Handle the Truth? *Br. J. Psychiatry* **192**:161–163. [01]
- Li, W., H. Zhou, R. Abujarour, et al. 2009. Generation of Human-Induced Pluripotent Stem Cells in the Absence of Exogenous Sox2. *Stem Cells* **27**:2992–3000. [10]
- Lieberman, R. P. 1979. Social and Political Challenges to the Development of Behavioral Programs in Organizations. In: *Trends in Behavior Therapy* ed. P. O. Sjoden et al. New York: Academic Press. [17]
- Lieberman, R. P., W. J. DeRisi, and K. T. Mueser. 1989. *Social Skills Training for Psychiatric Patients*. Needham Heights, MA: Allyn & Bacon. [15]

- Lieberman, R. P., and A. Kopelowicz. 2002. Teaching Persons with Severe Mental Disabilities to Be Their Own Case Managers. *Psychiatr. Serv.* **53**:1377–1379. [17]
- Lieberman, R. P., and K. T. Mueser. 1989. Psychosocial Treatment of Schizophrenia. In: *Comprehensive Textbook of Psychiatry* (5th edition), ed. H. I. Kaplan and B. J. Sadock, pp. 792–806. Baltimore: Williams & Wilkins. [15]
- Lieberman, R. P., K. T. Mueser, C. J. Wallace, et al. 1986. Training Skills in the Psychiatrically Disabled: Learning Coping and Competence. *Schizophr. Bull.* **12**:631–647. [15]
- Lichtenstein, P., B. H. Yip, C. Björk, et al. 2009. Common Genetic Determinants of Schizophrenia and Bipolar Disorder in Swedish Families: A Population-Based Study. *Lancet* **373**:234–239. [02, 05]
- Lieberman, J. A., K. Papadakis, J. Csernansky, et al. 2009. A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia. *Neuropsychopharmacology* **34**:1322–1329. [04]
- Lieberman, J. A., T. S. Stroup, J. P. McEvoy, et al. 2005. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. *N. Engl. J. Med.* **353**:1209–1223. [01]
- Light, G. A., and D. L. Braff. 2005. Stability of Mismatch Negativity Deficits and Their Relationship to Functional Impairments in Chronic Schizophrenia. *Am. J. Psychiatr.* **162**:1741–1743. [07]
- Light, G. A., J. L. Hsu, M. H. Hsieh, et al. 2006. Gamma Band Oscillations Reveal Neural Network Cortical Coherence Dysfunction in Schizophrenia Patients. *Biol. Psychiatry* **60**:1231–1240. [04]
- Lin, C. Y., A. Sawa, and H. Jaaro-Peled. 2012. Better Understanding of Mechanisms of Schizophrenia and Bipolar Disorder: From Human Gene Expression Profiles to Mouse Models. *Neurobiol. Dis.* **45**:48–56. [10]
- Lincoln, T. M., N. Peter, M. Schäfer, and M. S. 2009. Impact of Stress on Paranoia: An Experimental Investigation of Moderators and Mediators. *Psychol. Med.* **39**:1129–1139. [01]
- Lincoln, T. M., K. Wilhelm, and Y. Nestoriuc. 2007. Effectiveness of Psychoeducation for Relapse, Symptoms, Knowledge, Adherence and Functioning in Psychotic Disorders: A Meta-Analysis. *Schizophr. Res.* **96**:232–245. [15]
- Lindenmayer, J.-P. 2000. Treatment Refractory Schizophrenia. *Psychiatric Q.* **71**:373–384. [15]
- Lindenmayer, J. P., S. R. McGurk, K. T. Mueser, et al. 2008. A Randomized Controlled Trial of Cognitive Remediation among Inpatients with Persistent Mental Illness. *Psychiatr. Serv.* **59**:241–247. [15]
- Linehan, M. M. 1993. *Cognitive-Behavioral Treatment of Borderline Personality Disorder*. New York: Guilford Press. [15]
- Link, B. G., F. T. Cullen, E. Struening, P. E. Shrout, and B. P. Dohrenwend. 1989. A Modified Labeling Theory Approach to Mental Disorders: An Empirical Assessment. *Am. Sociol. Rev.* **54**:400–423. [17]
- Link, B. G., J. Mirotznik, and F. T. Cullen. 1991. The Effectiveness of Stigma Coping Orientations: Can Negative Consequences of Mental Illness Labeling Be Avoided? *J. Health Soc. Behav.* **32**:302–320. [17]
- Link, B. G., and J. C. Phelan. 2001. Conceptualizing Stigma. *Annu. Rev. Sociol.* **27**:363–385. [17]
- Linke, J., A. V. King, M. Rietschel, et al. 2012. Increased Medial Orbitofrontal and Amygdala Activation: Evidence for a Systems-Level Endophenotype of Bipolar I Disorder. *Am. J. Psychiatr.* **169**:316–325. [05]

- Lipina, T. V., M. Niwa, H. Jaaro-Peled, et al. 2010. Enhanced Dopamine Function in DISC1-L100p Mutant Mice: Implications for Schizophrenia. *Genes Brain Behav.* **9**:777–789. [13]
- Lipska, B. K., G. E. Jaskiw, S. Chrapusta, F. Karoum, and D. R. Weinberger. 1992. Ibotenic Acid Lesion of the Ventral Hippocampus Differentially Affects Dopamine and Its Metabolites in the Nucleus Accumbens and Prefrontal Cortex in the Rat. *Brain Res.* **585**:1–6. [11]
- Lisman, J. E. 2012. Excitation, Inhibition, Local Oscillations, or Large-Scale Loops: What Causes the Symptoms of Schizophrenia? *Curr. Opin. Neurobiol.* **22**:537–544. [13]
- Lisman, J. E., J. T. Coyle, R. W. Green, et al. 2008. Circuit-Based Framework for Understanding Neurotransmitter and Risk Gene Interactions in Schizophrenia. *Trends Neurosci.* **31**:234–242. [07, 13]
- Lodge, D. J., M. M. Behrens, and A. A. Grace. 2009. A Loss of Parvalbumin-Containing Interneurons Is Associated with Diminished Oscillatory Activity in an Animal Model of Schizophrenia. *J. Neurosci.* **29**:2344–2354. [11, 13]
- Loh, Y. H., O. Hartung, H. Li, et al. 2010. Reprogramming of T Cells from Human Peripheral Blood. *Cell Stem Cell* **7**:15–19. [10]
- Lohr, J. M., S. O. Lilienfeld, D. F. Tolin, and J. D. Herbert. 1999. Eye Movement Desensitization and Reprocessing: An Analysis of Specific Versus Non-Specific Treatment Factors. *J. Abnorm. Psychol.* **13**:185–207. [15]
- Lonergan, P. E., D. S. Martin, D. F. Horrobin, and M. A. Lynch. 2002. Neuroprotective Effect of Eicosapentaenoic Acid in Hippocampus of Rats Exposed to Gamma-Irradiation. *J. Biol. Chem.* **277**:20,804–20,811. [07]
- Lozada, A. F., X. Wang, N. V. Goukko, et al. 2012. Glutamatergic Synapse Formation Is Promoted by Alpha7-Containing Nicotinic Acetylcholine Receptors. *J. Neurosci.* **32**:7651–7661. [13]
- Luby, E. D., B. D. Cohen, G. Rosenbaum, J. S. Gottlieb, and R. Kelly. 1959. Study of a New Schizophrenomimetic Drug - Sernyl. *Arch. Neurol. Psychiat.* **81**:363–369. [11]
- Lucas, S., M. A. Hodge, A. Shores, J. Brennan, and A. Harris. 2009. Factors Associated with Functional Psychosocial Status after Diagnosis of First Episode Psychosis. *Early Interv. Psychiatry* **3**:35–43. [04]
- Luck, S. J., and J. M. Gold. 2008. The Construct of Attention in Schizophrenia. *Biol. Psychiatry* **64**:34–39. [02]
- Lucksted, A., A. Drapalski, C. Calmes, et al. 2011. Ending Self-Stigma: Pilot Evaluation of a New Intervention to Reduce Internalized Stigma among People with Mental Illnesses. *Psychiatr. Rehabil. J.* **35**:51–54. [15]
- Lucksted, A., W. McFarlane, D. Downing, and L. Dixon. 2012. Recent Developments in Family Psychoeducation as an Evidence-Based Practice. *J. Marital Fam. Ther.* **38**:101–121. [15]
- Ludewig, K., M. A. Geyer, and F. X. Vollenweider. 2003. Deficits in Prepulse Inhibition and Habituation in Never-Medicating, First-Episode Schizophrenia. *Biol. Psychiatry* **54**:121–128. [07]
- Lugnegård, T., M. Unenge Hallerbäck, F. Hjärthag, and C. Gillberg. 2013. Social Cognition Impairments in Asperger Syndrome and Schizophrenia. *Schizophr. Res.* **143**:277–284. [01]
- Lutkenhoff, E. S., T. G. van Erp, M. A. Thomas, et al. 2010. Proton MRS in Twin Pairs Discordant for Schizophrenia. *Mol. Psychiatry* **15**:308–318. [07]
- Ly, M., J. C. Motzkin, C. L. Philippi, et al. 2012. Cortical Thinning in Psychopathy. *Am. J. Psychiatr.* **169**:743–749. [01]

- Lynch, A. M., D. J. Loane, A. M. Minogue, et al. 2007. Eicosapentaenoic Acid Confers Neuroprotection in the Amyloid-Beta Challenged Aged Hippocampus. *Neurobiol. Aging* **28**:845–855. [07]
- Lynch, D., K. R. Laws, and P. J. McKenna. 2010. Cognitive Behavioural Therapy for Major Psychiatric Disorder: Does It Really Work? A Meta-Analytical Review of Well-Controlled Trials. *Psychol. Med.* **40**:9–24. [01]
- Lyon, H. M., S. Kaney, and R. P. Bentall. 1994. The Defensive Function of Persecutory Delusions. Evidence from Attribution Tasks. *Br. J. Psychiatry* **164**:637–646. [05]
- Lyoo, I. K., S. R. Dager, J. E. Kim, et al. 2010. Lithium-Induced Gray Matter Volume Increase as a Neural Correlate of Treatment Response in Bipolar Disorder: A Longitudinal Brain Imaging Study. *Neuropsychopharmacology* **35**:1743–1750. [07]
- Lysaker, P. H., K. D. Buck, and V. A. LaRocco. 2007. Clinical and Psychosocial Significance of Trauma History in the Treatment of Schizophrenia. *J. Psychosoc. Nurs. Ment. Health Serv.* **45**:44–51. [01]
- Lysaker, P. H., and J. T. Lysaker. 2010. Schizophrenia and Alterations in Self-Experience: A Comparison of 6 Perspectives. *Schizophr. Bull.* **36**:331–340. [01]
- Ma, J., and L. S. Leung. 2007. The Supramammillo-Septal-Hippocampal Pathway Mediates Sensorimotor Gating Impairment and Hyperlocomotion Induced by MK-801 and Ketamine in Rats. *Psychopharmacology* **191**:961–974. [07]
- MacCabe, J. H., M. P. Lambe, S. Cnattinghius, et al. 2008. Scholastic Achievement at Age 16 and Risk of Schizophrenia and Other Psychoses: A National Cohort Study. *Psychol. Med.* **38**:1133–1140. [14]
- . 2010. Excellent School Performance at Age 16 and Risk of Adult Bipolar Disorder: National Cohort Study. *Br. J. Psychiatry* **196**:109–115. [14, 17]
- MacCabe, J. H., S. Wicks, S. Löfving, et al. 2013. Decline in Cognitive Performance between Ages 13 and 18 Years and the Risk for Psychosis in Adulthood: A Swedish Longitudinal Cohort Study in Males. *JAMA Psychiatry* **70**:261–270. [15]
- MacDonald, A. W., III. 2009. Is More Cognitive Experimental Psychopathology of Schizophrenia Really Necessary? Challenges and Opportunities. In: *Neuropsychiatric Biomarkers, Endophenotypes, and Genes: Promises, Advances and Challenges*, ed. M. Ristner, vol. 1, pp. 141–154. New York: Springer. [02]
- MacDonald, A. W., III, and C. S. Carter. 2002. Cognitive Experimental Approaches to Investigating Impaired Cognition in Schizophrenia: A Paradigm Shift. *J. Clin. Exp. Neuropsychol.* **24**:873–882. [01, 02]
- MacDonald, A. W., III, C. S. Carter, J. G. Kerns, et al. 2005a. Specificity of Prefrontal Dysfunction and Context Processing Deficits to Schizophrenia in Never-Medicated Patients with First-Episode Psychosis. *Am. J. Psychiatr.* **162**:475–484. [02, 07]
- MacDonald, A. W., III, V. M. Goghari, B. M. Hicks, et al. 2005b. A Convergent-Divergent Approach to Context Processing, General Intellectual Functioning and the Genetic Liability to Schizophrenia. *Neuropsychology* **19**:814–821. [02]
- Mackeprang, T., K. T. Kristiansen, and B. Y. Glenthøj. 2002. Effects of Antipsychotics on Prepulse Inhibition of the Startle Response in Drug-Naive Schizophrenic Patients. *Biol. Psychiatry* **52**:863–873. [07]
- Malaspina, D., S. Harlap, S. Fennig, et al. 2001. Advancing Paternal Age and the Risk of Schizophrenia. *Arch. Gen. Psychiatry* **58**:361–367. [08]
- Malberg, J. E., A. J. Eisch, E. J. Nestler, and R. S. Duman. 2000. Chronic Antidepressant Treatment Increases Neurogenesis in Adult Rat Hippocampus. *J. Neurosci.* **20**:9104–9110. [07]
- Malhotra, A. K., T. Lencz, C. U. Correll, and J. M. Kane. 2007. Genomics and the Future of Pharmacotherapy in Psychiatry. *Int. Rev. Psychiatry* **19**:523–530. [07]

- Malhotra, A. K., J. P. Zhang, and T. Lencz. 2012. Pharmacogenetics in Psychiatry: Translating Research into Clinical Practice. *Mol. Psychiatry* **17**:760–769. [07, 17]
- Malhotra, D., and J. Sebat. 2011. CNVs: Harbingers of a Rare Variant Revolution in Psychiatric Genetics. *Cell* **148**:1223–1241. [05]
- Mallinckrodt, C. H., R. N. Tamura, and Y. Tanaka. 2011. Recent Developments in Improving Signal Detection and Reducing Placebo Response in Psychiatric Clinical Trials. *J. Psychiatr. Res.* **45**:1202–1207. [17]
- Manji, H. K., G. J. Moore, and G. Chen. 2000. Clinical and Preclinical Evidence for the Neurotrophic Effects of Mood Stabilizers: Implications for the Pathophysiology and Treatment of Manic-Depressive Illness. *Biol. Psychiatry* **48**:740–754. [07]
- Marchetto, M. C., C. Carroumeu, A. Acab, et al. 2010. A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells. *Cell* **143**:527–539. [10]
- Marco, E. J., O. M. Wolkowitz, S. Vinogradov, et al. 2002. Double-Blind Antiglucocorticoid Treatment in Schizophrenia and Schizoaffective Disorder: A Pilot Study. *World J. Biol. Psychiatry* **3**:156–161. [07]
- Marder, S. R. 2006. A Review of Agitation in Mental Illness: Treatment Guidelines and Current Therapies. *J. Clin. Psychiatry* **67**:13–21. [04]
- Marder, S. R., and W. Fenton. 2004. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS Initiative to Support the Development of Agents for Improving Cognition in Schizophrenia. *Schizophr. Res.* **72**:5–9. [07]
- Markon, K. E. 2010. Modeling Psychopathology Structure: A Symptom-Level Analysis of Axis I and II Disorders. *Psychol. Med.* **40**:273–288. [02]
- Marshall, C. T., Z. Guo, C. Lu, et al. 2005a. Human Adult Olfactory Neuroepithelial Derived Progenitors Retain Telomerase Activity and Lack Apoptotic Activity. *Brain. Res.* **1045**:45–56. [10]
- Marshall, M., S. W. Lewis, A. Lockwood, et al. 2005b. Association between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients: A Systematic Review. *Arch. Gen. Psychiatry* **62**:975–983. [06]
- Marsman, A., M. P. van den Heuvel, D. W. Klomp, et al. 2011. Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies. *Schizophr. Bull.* [07]
- Martin, B. C., and L. S. Miller. 1998. Expenditures for Treating Schizophrenia: A Population-Based Study of Georgia Medicaid Recipients. *Schizophr. Bull.* **24**:479–488. [01]
- Marx, C. E., R. S. E. Keefe, R. W. Buchanan, et al. 2009. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. *Neuropsychopharmacology* **34**:1885–1903. [04]
- Massatti, R. R., H. A. Seweeney, P. C. Panzano, and D. Roth. 2008. The De-Adoption of Innovative Mental Health Practices (IMHP): Why Organizations Choose Not to Sustain an IMHP. *Adm. Policy Ment. Health* **35**:50–65. [15]
- Masterton, G., and A. J. Mander. 1990. Psychiatric Emergencies. Scotland and the World Cup Finals. *Br. J. Psychiatry* **156**:475–478. [16]
- Matheson, S. L., A. M. Shepherd, R. M. Pinchbeck, K. R. Laurens, and V. J. Carr. 2013. Childhood Adversity in Schizophrenia: A Systematic Meta-Analysis. *Psychol. Med.* **43**:225–238. [01]
- Matigian, N., G. Abrahamsen, R. Sutharsan, et al. 2010. Disease-Specific, Neurosphere-Derived Cells as Models for Brain Disorders. *Dis. Model Mech.* **3**:785–798. [10]

- Mattay, V. S., T. E. Goldberg, F. Fera, et al. 2003. Catechol O-Methyltransferase Val158-Met Genotype and Individual Variation in the Brain Response to Amphetamine. *PNAS* **100**:6186–6191. [09]
- Mazereeuw, G., K. L. Lanctot, S. A. Chau, W. Swardfager, and N. Herrmann. 2012. Effects of Omega-3 Fatty Acids on Cognitive Performance: A Meta-Analysis. *Neurobiol. Aging* **33**:1482 e1417–1429. [07]
- McCabe, R., J. Bullenkamp, L. Hansson, et al. 2012. The Therapeutic Relationship and Adherence to Antipsychotic Medication in Schizophrenia. *PLoS One* **7**:e36080. [16]
- McCarley, R. W., D. F. Salisbury, Y. Hirayasu, et al. 2002. Association between Smaller Left Posterior Superior Temporal Gyrus Volume on Magnetic Resonance Imaging and Smaller Left Temporal P300 Amplitude in First-Episode Schizophrenia. *Arch. Gen. Psychiatry* **59**:321–331. [07]
- McClay, J. L., D. E. Adkins, K. Aberg, et al. 2011. Genome-Wide Pharmacogenomic Study of Neurocognition as an Indicator of Antipsychotic Treatment Response in Schizophrenia. *Neuropsychopharmacology* **36**:616–626. [07]
- McCormick, L. M., M. C. Brumm, J. N. Beadle, et al. 2012. Mirror Neuron Function, Psychosis, and Empathy in Schizophrenia. *Psychiatry Res.* **201**:233–239. [07]
- McCreadie, R. G., K. Phillips, J. A. Harvey, et al. 1991. The Nithsdale Schizophrenia Surveys. VIII: Do Relatives Want Family Intervention—and Does It Help? *Br. J. Psychiatry* **158**:110–113. [15]
- McCurdy, R. D., F. Feron, C. Perry, et al. 2006. Cell Cycle Alterations in Biopsied Olfactory Neuroepithelium in Schizophrenia and Bipolar I Disorder Using Cell Culture and Gene Expression Analyses. *Schizophr. Res.* **82**:163–173. [10]
- McDannald, M. A., J. P. Whitt, G. G. Calhoon, et al. 2011. Impaired Reality Testing in an Animal Model of Schizophrenia. *Biol. Psychiatry* **70**:1122–1126. [11]
- McFarlane, W. R. 2002. Multifamily Groups in the Treatment of Severe Psychiatric Disorders. New York: Guilford Press. [15]
- McFarlane, W. R., S. McNary, L. Dixon, H. Hornby, and E. Cimett. 2001. Predictors of Dissemination of Family Psychoeducation in Community Mental Health Centers in Maine and Illinois. *Psychiatr. Serv.* **52**:935–942. [15]
- McGahon, B. M., D. S. Martin, D. F. Horrobin, and M. A. Lynch. 1999. Age-Related Changes in Synaptic Function: Analysis of the Effect of Dietary Supplementation with Omega-3 Fatty Acids. *Neuroscience* **94**:305–314. [07]
- McGlashan, T. H. 2006. Is Active Psychosis Neurotoxic? *Schizophr. Bull.* **32**:609–613. [07]
- McGlashan, T. H., and R. E. Hoffman. 2000. Schizophrenia as a Disorder of Developmentally Reduced Synaptic Connectivity. *Arch. Gen. Psychiatry* **57**:637–648. [07]
- McGorry, P. D. 2007. Issues for DSM-V. Clinical Staging: A Heuristic Pathway to Valid Nosology and Safer, More Effective Treatment in Psychiatry. *Am. J. Psychiatr.* **164**:859–860. [09]
- McGorry, P. D., I. B. Hickie, A. R. Yung, C. Pantelis, and H. J. Jackson. 2006. Clinical Staging of Psychiatric Disorders: A Heuristic Framework for Choosing Earlier, Safer and More Effective Interventions. *Aust. NZ J. Psychiatry* **40**:616–622. [09]
- McGorry, P. D., B. Nelson, S. Goldstone, and A. R. Yung. 2010. Clinical Staging: A Heuristic and Practical Strategy for New Research and Better Health and Social Outcomes for Psychotic and Related Mood Disorders. *Can. J. Psychiatry* **55**:486–497. [03]

- McGowan, P. O., A. Sasaki, A. C. D'Alessio, et al. 2009. Epigenetic Regulation of the Glucocorticoid Receptor in Human Brain Associates with Childhood Abuse. *Nat. Neurosci.* **12**:342–348. [08]
- McGrath, J. 2007. The Surprisingly Rich Contours of Schizophrenia Epidemiology. *Arch. Gen. Psychiatry* **64**:14–16. [09]
- McGrath, J., and D. Castle. 1995. Does Influenza Cause Schizophrenia? A Five Year Review. *Aust. NZ J. Psychiatry* **29**:23–31. [08]
- McGrath, J., S. Saha, D. Chant, and J. Welham. 2008. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. *Epidemiol. Rev.* **30**:67–76. [01]
- McGrath, J., S. Saha, J. Welham, et al. 2004. A Systematic Review of the Incidence of Schizophrenia: The Distribution of Rates and the Influence of Sex, Urbanicity, Migrant Status and Methodology. *BMC Medical* **2**:13. [09]
- McGrath, J. J., D. W. Eyles, C. B. Pedersen, et al. 2010. Neonatal Vitamin D Status and Risk of Schizophrenia: A Population-Based Case-Control Study. *Arch. Gen. Psychiatry* **67**:889–894. [06]
- McGrath, J. J., and L. J. Richards. 2009. Why Schizophrenia Epidemiology Needs Neurobiology—and Vice Versa. *Schizophr. Bull.* **35**:577–581. [01, 08]
- McGrath, J. J., and E. S. Susser. 2009. New Directions in the Epidemiology of Schizophrenia. *Med. J. Aust.* **190**:S7–9. [13]
- McGurk, S. R., and K. T. Mueser. 2004. Cognitive Functioning, Symptoms, and Work in Supported Employment: A Review and Heuristic Model. *Schizophr. Res.* **70**:147–174. [15]
- McGurk, S. R., K. T. Mueser, T. DeRosa, and R. Wolfe. 2009. Work, Recovery, and Comorbidity in Schizophrenia: A Randomized Controlled Trial of Cognitive Remediation. *Schizophr. Bull.* **35**:319–335. [15]
- McGurk, S. R., K. T. Mueser, and A. Pascaris. 2005. Cognitive Training and Supported Employment for Persons with Severe Mental Illness: One Year Results from a Randomized Controlled Trial. *Schizophr. Bull.* **31**:898–909. [15]
- McGurk, S. R., E. W. Twamley, D. I. Sitzer, G. J. McHugo, and K. T. Mueser. 2007. A Meta-Analysis of Cognitive Remediation in Schizophrenia. *Am. J. Psychiatr.* **164**:1791–1802. [04, 15]
- McHugo, G. J., R. E. Drake, R. Whitley, et al. 2007. Fidelity Outcomes in the National Implementing Evidence-Based Practices Project. *Psychiatr. Serv.* **58**:1279–1284. [15]
- McLaughlin, K. A., J. G. Green, M. J. Gruber, et al. 2010. Childhood Adversities and Adult Psychiatric Disorders in the National Comorbidity Survey Replication II: Associations with Persistence of DSM-IV Disorders. *Arch. Gen. Psychiatry* **67**:124–132. [09]
- McLean, A. 1995. Empowerment and the Psychiatric Consumer/Ex-Patient Movement in the United States: Contradictions, Crisis and Change. *Soc. Sci. Med.* **40**:1053–1071. [15, 17]
- Mechelli, A., A. Riecher-Rossler, E. M. Meisenzahl, et al. 2011. Neuroanatomical Abnormalities That Predate the Onset of Psychosis: A Multicenter Study. *Arch. Gen. Psychiatry* **68**:489–495. [07]
- Meehl, P. E. 1962. Schizotaxia, Schizotypy, Schizophrenia. *Am. Psychol.* **17**:827–838. [02]
- . 1990. Toward an Integrated Theory of Schizotaxia, Schizotypy and Schizophrenia. *J. Pers. Disord.* **4**:1–99. [02]
- Meincke, U., G. A. Light, M. A. Geyer, D. L. Braff, and E. Gouzoulis-Mayfrank. 2004. Sensitization and Habituation of the Acoustic Startle Reflex in Patients with Schizophrenia. *Psychiatry Res.* **126**:51–61. [07]

- Meise, U., G. Kemmler, M. Kurz, and W. Rössler. 1996. Die Standortqualität als Grundlage Psychiatrischer Versorgungsplanung. *Gesundheitswesen* **58**:29–37. [16]
- Melle, I., T. K. Larsen, U. Haahr, et al. 2004. Reducing the Duration of Untreated First-Episode Psychosis: Effects on Clinical Presentation. *Arch. Gen. Psychiatry* **61**:143–150. [07]
- Meltzer, H. Y., L. Arvanitis, D. Bauer, and W. Rein. 2004. Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder. *Am. J. Psychiatr.* **161**:975–984. [07]
- Memory Pharmaceuticals Corp. 2008. Press Release (May 11, 2013): Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated with Schizophrenia. <http://www.thefreelibrary.com/Memory+Pharmaceuticals+Achieves+Enrollment+Goal+for+Phase+2+Study+of+...+a0189242108>. (accessed June 14, 2013). [04]
- Mendel, P., L. S. Meredith, M. Schoenbaum, C. D. Sherbourne, and K. B. Wells. 2008. Interventions in Organizational and Community Context: A Framework for Building Evidence on Dissemination and Implementation in Health Services Research. *Adm. Policy Ment. Health* **35**:21–37. [15]
- Mendrek, A., K. A. Kiehl, A. M. Smith, et al. 2005. Dysfunction of a Distributed Neural Circuitry in Schizophrenia Patients During a Working-Memory Performance. *Psychol. Med.* **35**:187–196. [07]
- Merck & Co. 2011. MK0249 for the Treatment of Cognitive Impairment in Patients with Schizophrenia (0249-016). *Natl. Library Med.* <http://www.clinicaltrials.gov/ct2/show/NCT00506077?term=NCT00506077&rank=1>. (accessed May 11, 2013). [04]
- Messias, E., B. Kirkpatrick, E. Bromet, et al. 2004. Summer Birth and Deficit Schizophrenia. A Pooled Analysis from 6 Countries. *Arch. Gen. Psychiatry* **61**:985–989. [03]
- Meyer, J. M., V. G. Davis, D. C. Goff, et al. 2008. Change in Metabolic Syndrome Parameters with Antipsychotic Treatment in the CATIE Schizophrenia Trial: Prospective Data from Phase 1. *Schizophr. Res.* **101**:273–286. [17]
- Meyer, U. 2011. Developmental Neuroinflammation and Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **42**:20–34. [07]
- Meyer, U., and J. Feldon. 2012. To Poly(I:C) or Not to Poly(I:C): Advancing Preclinical Schizophrenia Research through the Use of Prenatal Immune Activation Models. *Neuropharmacology* **62**(3):1308–1321. [11]
- Meyer, U., J. Feldon, and B. K. Yee. 2009. A Review of the Fetal Brain Cytokine Imbalance Hypothesis of Schizophrenia. *Schizophr. Bull.* **35**(5):959–972 [08]
- Meyer, U., S. Schwendener, J. Feldon, and B. K. Yee. 2006. Prenatal and Postnatal Maternal Contributions in the Infection Model of Schizophrenia. *Exp. Brain Res.* **173**:243–257. [11]
- Meyer, U., I. Weiner, G. M. McAlonan, and J. Feldon. 2011. The Neuropathological Contribution of Prenatal Inflammation to Schizophrenia. *Expert. Rev. Neurother.* **11**:29–32. [07]
- Meyer-Lindenberg, A. 2010a. From Maps to Mechanisms through Neuroimaging of Schizophrenia. *Nature* **468**:194–202. [09, 17]
- . 2010b. Imaging Genetics of Schizophrenia. *Dialog. Clin. Neurosci.* **12**:449–456. [08]
- . 2011. Neuroimaging and the Question of Neurodegeneration in Schizophrenia. *Prog. Neurobiol.* **95**:514–516. [09]

- Meyer-Lindenberg, A., J.-B. Poline, P. D. Kohn, et al. 2001. Evidence for Abnormal Cortical Functional Connectivity During Working Memory in Schizophrenia. *Am. J. Psychiatr.* **158**:1809–1817. [04, 12, 13]
- Meyer-Lindenberg, A., and H. Tost. 2012. Neural Mechanisms of Social Risk for Psychiatric Disorders. *Nat. Neurosci.* **15**:663–668. [08, 09, 17]
- Meyer-Lindenberg, A., and D. R. Weinberger. 2006. Intermediate Phenotypes and Genetic Mechanisms of Psychiatric Disorders. *Nat. Rev. Neurosci.* **7**:818–827. [09, 12]
- Meyer-Lindenberg, A. S., R. K. Olsen, P. D. Kohn, et al. 2005. Regionally Specific Disturbance of Dorsolateral Prefrontal-Hippocampal Functional Connectivity in Schizophrenia. *Arch. Gen. Psychiatry* **62**:379–386. [08, 09]
- Mier, D., P. Kirsch, and A. Meyer-Lindenberg. 2010. Neural Substrates of Pleiotropic Action of Genetic Variation in COMT: A Meta-Analysis. *Mol. Psychiatry* **15**:918–927. [08]
- Millar, J. K., J. C. Wilson-Annan, S. Anderson, et al. 2000. Disruption of Two Novel Genes by a Translocation Co-Segregating with Schizophrenia. *Hum. Mol. Genet.* **9**:1415–1423. [11]
- Miller, G. 2010. Is Pharma Running out of Brainy Ideas? *Science* **329**:502–504. [17]
- Miller, T. J., T. H. McGlashan, J. L. Rosen, et al. 2003. Prodromal Assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive Validity, Interrater Reliability, and Training to Reliability. *Schizophr. Bull.* **29**:703–715. [07]
- Miller, W. R., and S. Rollnick. 2002. *Motivational Interviewing: Preparing People for Change* (2nd edition). New York: Guilford Press. [17]
- Mishara, A. L., and T. E. Goldberg. 2004. A Meta-Analysis and Critical Review of the Effects of Conventional Neuroleptic Treatment on Cognition in Schizophrenia: Opening a Closed Book. *Biol. Psychiatry* **55**:1013–1022. [07, 14]
- Mitchell, K. J. 2007. The Genetics of Brain Wiring: From Molecule to Mind. *PLoS Biol.* **5**:e113. [13]
- . 2011a. The Genetics of Neurodevelopmental Disease. *Curr. Opin. Neurobiol.* **21**:197–203. [13]
- . 2011b. The Miswired Brain: Making Connections from Neurodevelopment to Psychopathology. *BMC Biol.* **9**:23. [13]
- Mitchell, K. J., Z. J. Huang, B. Moghaddam, and A. Sawa. 2011. Following the Genes: A Framework for Animal Modeling of Psychiatric Disorders. *BMC Biol.* **9**:76. [13]
- Mitchell, K. J., and D. J. Porteous. 2011. Rethinking the Genetic Architecture of Schizophrenia. *Psychol. Med.* **41**:19–32. [01, 13]
- Moghaddam, B., B. Adams, A. Verma, and D. Daly. 1997. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex. *J. Neurosci.* **17**:2921–2927. [11]
- Moghaddam, B., and D. Javitt. 2012. From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and Its Implication for Treatment. *Neuropsychopharmacology* **37**:4–15. [07]
- Mohamed, S., R. A. Rosenheck, M. S. Swartz, et al. 2008. Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. *Am. J. Psychiatr.* **165**:978–987. [14]
- Mojtabai, R., R. A. Nicholson, and B. N. Carpenter. 1998. Role of Psychosocial Treatments in Management of Schizophrenia: A Meta-Analytic Review of Controlled Outcome Studies. *Schizophr. Bull.* **24**:569–587. [15, 16]

- Mondelli, V., P. Dazzan, N. Hepgul, et al. 2010a. Abnormal Cortisol Levels During the Day and Cortisol Awakening Response in First-Episode Psychosis: The Role of Stress and of Antipsychotic Treatment. *Schizophr. Res.* **116**:234–242. [09]
- Mondelli, V., C. M. Pariante, S. Navari, et al. 2010b. Higher Cortisol Levels Are Associated with Smaller Left Hippocampal Volume in First-Episode Psychosis. *Schizophr. Res.* **119**:75–78. [09]
- Montoya, I. D., and F. Vocci. 2007. Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. *J. Dual Diagn.* **3**:113–150. [17]
- Moore, G. J., B. M. Cortese, D. A. Glitz, et al. 2009. A Longitudinal Study of the Effects of Lithium Treatment on Prefrontal and Subgenual Prefrontal Gray Matter Volume in Treatment-Responsive Bipolar Disorder Patients. *J. Clin. Psychiatry* **70**:699–705. [07]
- Moore, H. 2010. The Role of Rodent Models in the Discovery of New Treatments for Schizophrenia: Updating Our Strategy. *Schizophr. Bull.* **36**:1066–1072. [13]
- Moore, H., J. D. Jentsch, M. Ghajarnia, M. A. Geyer, and A. A. Grace. 2006. A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia. *Biol. Psychiatry* **60**:253–264. [11]
- Moore, T. H., S. Zammit, A. Lingford-Hughes, et al. 2007. Cannabis Use and Risk of Psychotic or Affective Mental Health Outcomes: A Systematic Review. *Lancet* **370**:319–328. [07, 09]
- Moran, M. 2006. U.S. Insurance Crisis Gets Pessimistic Prognosis. *Psychiatric News* **41**:16. [04]
- Morgan, C., J. Kirkbride, G. Hutchinson, et al. 2008. Cumulative Social Disadvantage, Ethnicity and First-Episode Psychosis: A Case-Control Study. *Psychol. Med.* **38**:1701–1715. [09]
- Morgan, C., and A. Kleinman. 2010. Social Science Perspectives: A Failure of the Sociological Imagination. In: Principles of Social Psychiatry, ed. C. Morgan and D. Bhugra. London: Wiley-Blackwell. [09]
- Morgan, V. A., J. Badcock, and A. Jablensky. 2006. Submission 277: Prepared on Behalf of the Australasian Society for Psychiatric Research, May 2005. In: The Senate Select Committee on Mental Health. A National Approach to Mental Health from Crisis to Community. Canberra: Commonwealth of Australia. http://www.aph.gov.au/Parliamentary_Business/Committees/Senate_Committees?url=mentalhealth_ctte/submissions/sub277.pdf. (accessed 13 June, 2013). [17]
- Morgan, V. A., G. M. Valuri, M. L. Croft, et al. 2011. Cohort Profile: Pathways of Risk from Conception to Disease: The Western Australian Schizophrenia High-Risk E-Cohort. *Int. J. Epidemiol.* **40**:1477–1485. [17]
- Morgan, V. A., A. Waterreus, A. Jablensky, et al. 2012. People Living with Psychotic Illness in 2010: The Second Australian National Survey of Psychosis. *Aust. NZ J. Psychiatry* **46**:735–752. [17]
- Moritz, S., N. Van Quaquebeke, and T. M. Lincoln. 2012. Jumping to Conclusions Is Associated with Paranoia but Not General Suspiciousness: A Comparison of Two Versions of the Probabilistic Reasoning Paradigm. *Schizophr. Res. Treat.* **2012**:Article ID 384039. [05]
- Morrison, A. P., P. French, S. L. Stewart, et al. 2012. Early Detection and Intervention Evaluation for People at Risk of Psychosis: Multisite Randomised Controlled Trial. *BMJ* **344**:e2233. [01, 06]

- Morrison, A. P., P. French, L. Walford, et al. 2004. Cognitive Therapy for the Prevention of Psychosis in People at Ultra-High Risk: Randomised Controlled Trial. *Br. J. Psychiatry* **185**:291–297. [07]
- Mors, O., P. B. Mortensen, and H. Ewald. 1999. A Population-Based Register Study of the Association between Schizophrenia and Rheumatoid Arthritis. *Schizophr. Res.* **40**:67–74. [01]
- Mortensen, P. B., M. G. Pedersen, and C. B. Pedersen. 2010. Psychiatric Family History and Schizophrenia Risk in Denmark: Which Mental Disorders Are Relevant? *Psychol. Med.* **40**:201–210. [02, 05]
- Mortensen, P. B., C. B. Pedersen, T. Westergaard, et al. 1999. Effects of Family History and Place and Season of Birth on the Risk of Schizophrenia. *N. Engl. J. Med.* **340**:603–608. [09]
- Motzkin, J. C., J. P. Newman, K. A. Kiehl, and M. Koenigs. 2011. Reduced Prefrontal Connectivity in Psychopathy. *J. Neurosci.* **31**:17,348–17,357. [01]
- Mowry, B. J., and J. Gratten. 2013. The Emerging Spectrum of Allelic Variation in Schizophrenia: Current Evidence and Strategies for the Identification and Functional Characterization of Common and Rare Variants. *Mol. Psychiatry* **18**:38–52. [07]
- Mueser, K. T., S. Aalto, D. R. Becker, et al. 2005. The Effectiveness of Skills Training for Improving Outcomes in Supported Employment. *Psychiatr. Serv.* **56**:1254–1260. [15]
- Mueser, K. T., A. S. Bellack, M. S. Douglas, and J. H. Wade. 1991. Prediction of Social Skill Acquisition in Schizophrenic and Major Affective Disorder Patients from Memory and Symptomatology. *Psychiatry Res.* **37**:281–296. [15]
- Mueser, K. T., R. E. Clark, M. Haines, et al. 2004. The Hartford Study of Supported Employment for Severe Mental Illness. *J. Consult. Clin. Psychol.* **72**:479–490. [15]
- Mueser, K. T., P. W. Corrigan, D. Hilton, et al. 2002. Illness Management and Recovery for Severe Mental Illness: A Review of the Research. *Psychiatr. Serv.* **53**:1272–1284. [15]
- Mueser, K. T., F. Deavers, D. L. Penn, and J. Cassisi. 2013a. Psychosocial Treatments for Schizophrenia. *Annu. Rev. Clin. Psychol.* **9**:465–497. [15]
- Mueser, K. T., S. M. Silverstein, and M. Farkas. 2013b. Should the Training of Clinical Psychologists Require Competence in the Treatment and Rehabilitation of Individuals with a Serious Mental Illness? *Psychiatr. Rehabil. J.* **36**:54–59. [15]
- Mueser, K. T., W. C. Torrey, D. Lynde, P. Singer, and R. E. Drake. 2003. Implementing Evidence-Based Practices for People with Severe Mental Illness. *Behav. Mod.* **27**:387–411. [15]
- Mueser, K. T., P. R. Yarnold, S. D. Rosenberg, et al. 2000. Substance Use Disorder in Hospitalized Severely Mentally Ill Psychiatric Patients: Prevalence, Correlates, and Subgroups. *Schizophr. Bull.* **26**:179–192. [17]
- Muller, N., D. Krause, S. Dehning, et al. 2010. Celecoxib Treatment in an Early Stage of Schizophrenia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial of Celecoxib Augmentation of Amisulpride Treatment. *Schizophr. Res.* **121**:118–124. [07]
- Munafo, M. R., S. M. Brown, and A. R. Hariri. 2008. Serotonin Transporter (5-HTTLPR) Genotype and Amygdala Activation: A Meta-Analysis. *Biol. Psychiatry* **63**:852–857. [08]
- Munafo, M. R., N. B. Freimer, W. Ng, et al. 2009. 5-HTTLPR Genotype and Anxiety-Related Personality Traits: A Meta-Analysis and New Data. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **150B**:271–281. [08]
- Munro, C. A., M. E. McCaul, D. F. Wong, et al. 2006. Sex Differences in Striatal Dopamine Release in Healthy Adults. *Biol. Psychiatry* **59**:966–974. [07]

- Murphy, K. C. 2002. Schizophrenia and Velo-Cardio-Facial Syndrome. *Lancet* **359**:426–430. [05]
- Murray, R. M. 2003. *The Epidemiology of Schizophrenia*. Cambridge, U.K., New York: Cambridge Univ. Press. [09]
- Murray, R. M., and S. W. Lewis. 1987. Is Schizophrenia a Neurodevelopmental Disorder? *BMJ (Clin. Res. Ed.)* **295**:681–682. [03, 08, 09]
- Murray, R. M., P. Sham, J. Van Os, et al. 2004. A Developmental Model for Similarities and Dissimilarities between Schizophrenia and Bipolar Disorder. *Schizophr. Res.* **71**:405–416. [09]
- Myin-Germeys, I., and J. van Os. 2008. Adult Adversity: Do Early Environment and Genotype Create Lasting Vulnerability for Adult Social Adversity in Psychosis? In: *Society and Psychosis*, ed. C. Morgan et al., pp. 127–142. Cambridge: Cambridge Univ. Press. [09]
- Myin-Germeys, I., J. van Os, J. E. Schwartz, A. A. Stone, and P. A. Delespaul. 2001. Emotional Reactivity to Daily Life Stress in Psychosis. *Arch. Gen. Psychiatry* **58**:1137–1144. [09]
- Naatanen, R., A. W. Gaillard, and S. Mantysalo. 1978. Early Selective-Attention Effect on Evoked Potential Reinterpreted. *Acta Psychol.* **42**:313–329. [07]
- National Collaborating Centre for Mental Health. 2009. *Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care* (updated edition). Natl. Clinical Guideline Nr. 82. London: British Psychological Society and The Royal College of Psychiatrists. [15]
- Need, A. C., R. S. Keefe, D. Ge, et al. 2009. Pharmacogenetics of Antipsychotic Response in the CATIE Trial: A Candidate Gene Analysis. *Eur. J. Hum. Genet.* **17**:946–957. [07]
- Nelson, B., A. Thompson, and A. R. Yung. 2012. Basic Self-Disturbance Predicts Psychosis Onset in the Ultra High Risk for Psychosis “Prodromal” Population. *Schizophr. Bull.* **38**:1277–1287. [01]
- . 2013. Not All First-Episode Psychosis Is the Same: Preliminary Evidence of Greater Basic Self-Disturbance in Schizophrenia Spectrum Cases. *Early Interv. Psychiatry* **7**:200–204. [01]
- Nelson, G., T. Aubry, and A. Lafrance. 2007. A Review of the Literature on the Effectiveness of Housing and Support, Assertive Community Treatment, and Intensive Case Management Interventions for Persons with Mental Illness Who Have Been Homeless. *Am. J. Orthopsychiat.* **77**:350–361. [15]
- Newman, K., C. Fox, D. Harding, J. Mehta, and W. Roth. 2004. *Rampage: The Social Roots of School Shootings*. New York: Basic Books. [01]
- Nordt, C., W. Rössler, and C. Lauber. 2006. Attitudes of Mental Health Professionals toward People with Schizophrenia and Major Depression. *Schizophr. Bull.* **32**:709–714. [16]
- Nuechterlein, K. H., D. M. Barch, J. M. Gold, et al. 2004. Identification of Separable Cognitive Factors in Schizophrenia. *Schizophr. Res.* **72**:29–39. [04]
- Nuechterlein, K. H., and M. E. Dawson. 1984. A Heuristic Vulnerability/Stress Model of Schizophrenic Episodes. *Schizophr. Bull.* **10**:300–312. [15]
- Nuechterlein, K. H., M. F. Green, R. S. Kern, et al. 2008. The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. *Am. J. Psychiatr.* **165**:203–213. [06]

- Nuechterlein, K. H., K. L. Subotnik, M. Gitlin, et al. 1999. Neurocognitive and Environmental Contributors to Work Recovery after Initial Onset of Schizophrenia: Answers from Path Analyses. In: International Congress on Schizophrenia Research. Santa Fe, NM. [04]
- Nutt, D., and G. Goodwin. 2011. ECNP Summit on the Future of CNS Drug Research in Europe 2011. *Eur. Neuropsychopharmacol.* **21**:495–499. [17]
- O’Doherty, J., M. L. Kringelbach, E. T. Rolls, J. Hornak, and C. Andrews. 2001. Abstract Reward and Punishment Representation in the Human Orbitofrontal Cortex. *Nat. Neurosci.* **4**:95–102. [05]
- O’Donnell, P. 2011. Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights from Animal Models. *Schizophr. Bull.* **37**:484–492. [13]
- . 2012. Cortical Disinhibition in the Neonatal Ventral Hippocampal Lesion Model of Schizophrenia: New Vistas on Possible Therapeutic Approaches. *Pharmacol. Ther.* **133**:19–25. [11]
- O’Donnell, P., J. H. Cabungcal, P. T. Piantadosi, et al. 2011. Oxidative Stress During Development in Prefrontal Cortical Interneurons in Developmental Animal Models of Schizophrenia. *Schizophr. Bull.* **37**:111. [11]
- O’Donovan, M. C., G. Kirov, and M. J. Owen. 2008. Phenotypic Variations on the Theme of CNVs. *Nat. Genet.* **40**:1392–1393. [08]
- OECD. 2012. Sick on the Job? Myths and Realities About Mental Health and Work. Paris: OECD Publishing. [16]
- Oh, G., and A. Petronis. 2008. Environmental Studies of Schizophrenia through the Prism of Epigenetics. *Schizophr. Bull.* **34**:1122–1129. [09]
- Oken, R. J., and M. Schulzer. 1999. At Issue: Schizophrenia and Rheumatoid Arthritis: The Negative Association Revisited. *Schizophr. Bull.* **25**:625–638. [01]
- Oliver, P. L. 2011. Challenges of Analysing Gene-Environment Interactions in Mouse Models of Schizophrenia. *ScientificWorldJournal* **11**:1411–1420. [13]
- Olney, J. W., and N. B. Farber. 1995a. Glutamate Receptor Dysfunction and Schizophrenia. *Arch. Gen. Psychiatry* **52**:998–1007. [07]
- . 1995b. NMDA Antagonists as Neurotherapeutic Drugs, Psychotogens, Neurotoxins, and Research Tools for Studying Schizophrenia. *Neuropsychopharmacology* **13**:335–345. [07]
- Ongur, D., J. E. Jensen, A. P. Prescott, et al. 2008. Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania. *Biol. Psychiatry* **64**:718–726. [07]
- Onstad, S., I. Skre, J. Edvardsen, and S. Torgersen. 1991. Mental Disorders in First-Degree Relatives of Schizophrenics. *Acta Psychiatr. Scand.* **83**:463–467. [02]
- O’Reilly, R., and Y. Munakata. 2000. Understanding the Mind by Simulating the Brain: Computational Explorations in Cognitive Neuroscience. Cambridge MA: MIT Press. [12]
- Oshima, I., Y. Mino, and Y. Inomata. 2003. Institutionalisation and Schizophrenia in Japan: Social Environments and Negative Symptoms: Nationwide Survey of In-Patients. *Br. J. Psychiatry* **183**:50–56. [01]
- . 2005. Effects of Environmental Deprivation on Negative Symptoms of Schizophrenia: A Nationwide Survey in Japan’s Psychiatric Hospitals. *Psychiatry Res.* **136**:163–171. [01]
- Oswald, L. M., D. F. Wong, M. McCaul, et al. 2005. Relationships among Ventral Striatal Dopamine Release, Cortisol Secretion, and Subjective Responses to Amphetamine. *Neuropsychopharmacology* **30**:821–832. [07]

- Ota, M., M. Ishikawa, N. Sato, et al. 2012. Glutamatergic Changes in the Cerebral White Matter Associated with Schizophrenic Exacerbation. *Acta Psychiatr. Scand.* **126**:72–78. [07]
- Othman, M., C. Lu, K. Klueber, W. Winstead, and F. Roisen. 2005. Clonal Analysis of Adult Human Olfactory Neurosphere Forming Cells. *Biotech. Histochem.* **80**:189–200. [10]
- Owen, M. J., N. M. Williams, and M. C. O'Donovan. 2004. The Molecular Genetics of Schizophrenia: New Findings Promise New Insights. *Mol. Psychiatry* **9**:14–27. [08]
- Ozyurt, B., M. Sarsilmaz, N. Akpolat, et al. 2007. The Protective Effects of Omega-3 Fatty Acids against MK-801-Induced Neurotoxicity in Prefrontal Cortex of Rat. *Neurochem. Int.* **50**:196–202. [07]
- Pacher, P., S. Batkai, and G. Kunos. 2006. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. *Pharmacol. Rev.* **58**:389–462. [07]
- Pajonk, F. G., T. Wobrock, O. Gruber, et al. 2010. Hippocampal Plasticity in Response to Exercise in Schizophrenia. *Arch. Gen. Psychiatry* **67**:133–143. [17]
- Pang, Y., S. Rodts-Palenik, Z. Cai, W. A. Bennett, and P. G. Rhodes. 2005. Suppression of Glial Activation Is Involved in the Protection of Il-10 on Maternal *E. coli* Induced Neonatal White Matter Injury. *Brain Res. Dev. Brain Res.* **157**:141–149. [07]
- Pang, Z. P., N. Yang, T. Vierbuchen, et al. 2011. Induction of Human Neuronal Cells by Defined Transcription Factors. *Nature* **476**:220–223. [10]
- Pantelis, C., D. Velakoulis, P. D. McGorry, et al. 2003. Neuroanatomical Abnormalities before and after Onset of Psychosis: A Cross-Sectional and Longitudinal MRI Comparison. *Lancet* **361**:281–288. [07]
- Pantelis, C., M. Yucel, S. J. Wood, et al. 2005. Structural Brain Imaging Evidence for Multiple Pathological Processes at Different Stages of Brain Development in Schizophrenia. *Schizophr. Bull.* **31**:672–696. [07, 11]
- Papassotiropoulos, A., K. Henke, E. Stefanova, et al. 2011. A Genome-Wide Survey of Human Short-Term Memory. *Mol. Psychiatry* **16**:184–192. [08]
- Pariante, C. M., K. Vassilopoulou, D. Velakoulis, et al. 2004. Pituitary Volume in Psychosis. *Br. J. Psychiatry* **185**:5–10. [09]
- Parnas, J., P. Vianin, D. Saebye, et al. 2001. Visual Binding Abilities in the Initial and Advanced Stages of Schizophrenia. *Acta Psychiatr. Scand.* **103**:171–180. [01, 07]
- Pasca, S. P., T. Portmann, I. Voineagu, et al. 2011. Using iPSC-Derived Neurons to Uncover Cellular Phenotypes Associated with Timothy Syndrome. *Nat. Med.* **17**:1657–1662. [10]
- Patil, S. T., L. Zhang, F. Martenyi, et al. 2007. Activation of mGlu2/3 Receptors as a New Approach to Treat Schizophrenia: A Randomized Phase 2 Clinical Trial. *Nat. Med.* **13**:1102–1107. [07, 11]
- Patterson, P. H. 2009. Immune Involvement in Schizophrenia and Autism: Etiology, Pathology and Animal Models. *Behav. Brain Res.* **204**:313–321. [08]
- Patterson, T. L., S. Goldman, C. L. McKibbin, T. Hughs, and D. V. Jeste. 2001. UCSD Performance-Based Skills Assessment: Development of a New Measure of Everyday Functioning for Severely Mentally Ill Adults. *Schizophr. Bull.* **27**:235–245. [04]
- Paul, G. L. 1986. Principles and Methods to Support Cost-Effective Quality Operations: Assessment in Residential Treatment Settings, Part 1. Champaign: Research Press. [15]
- Paul, G. L., and R. J. Lentz. 1977. Psychosocial Treatment of Chronic Mental Patients: Milieu Versus Social-Learning Programs. Cambridge, MA: Harvard Univ. Press. [15, 17]

- Paulus, F. M., S. Krach, J. Bedenbender, et al. 2013. Partial Support for ZNF804A Genotype-Dependent Alterations in Prefrontal Connectivity. *Hum. Brain Mapp.* **34**:304–313. [09]
- Pedersen, C. A., C. M. Gibson, S. W. Rau, et al. 2011. Intranasal Oxytocin Reduces Psychotic Symptoms and Improves Theory of Mind and Social Perception in Schizophrenia. *Schizophr. Res.* **132**:50–53. [07]
- Pedersen, C. B., and P. B. Mortensen. 2001. Evidence of a Dose-Response Relationship between Urbanicity During Upbringing and Schizophrenia Risk. *Arch. Gen. Psychiatry* **58**:1039–1046. [08, 09]
- Peleg-Raibstein, D., and J. Feldon. 2008. Effects of Withdrawal from an Escalating Dose of Amphetamine on Conditioned Fear and Dopamine Response in the Medial Prefrontal Cortex. *Behav. Brain Res.* **186**:12–22. [13]
- Penadés, R., N. Pujol, R. Catalán, et al. 2013. Brain Effects of Cognitive Remediation Therapy in Schizophrenia: A Structural and Functional Neuroimaging Study. *Biol. Psychiatry* **73**:1015–1023. [01]
- Penn, D. L., P. W. Corrigan, R. P. Bentall, J. M. Racenstein, and L. Newman. 1997. Social Cognition in Schizophrenia. *Psychol. Bull.* **121**:114–132. [04]
- Penschuck, S., P. Flagstad, M. Didriksen, M. Leist, and A. T. Michael-Titus. 2006. Decrease in Parvalbumin-Expressing Neurons in the Hippocampus and Increased Phencyclidine-Induced Locomotor Activity in the Rat Methylazoxymethanol (MAM) Model of Schizophrenia. *Eur. J. Neurosci.* **23**:279–284. [11]
- Penzes, P., M. E. Cahill, K. A. Jones, J. E. VanLeeuwen, and K. M. Woolfrey. 2011. Dendritic Spine Pathology in Neuropsychiatric Disorders. *Nat. Neurosci.* **14**:285–293. [12]
- Peralta, V., and M. J. Cuesta. 2001. How Many and Which Are the Psychopathological Dimensions of Schizophrenia? Issues Influencing Their Ascertainment. *Schizophr. Res.* **49**:269–285. [02, 03]
- Perkins, R. 2001. What Constitutes Success? The Relative Priority of Service Users' and Clinicians' Views of Mental Health Services. *Br. J. Psychiatry* **179**:9–10. [16]
- Perry, A., S. Bentin, I. Shalev, et al. 2010. Intranasal Oxytocin Modulates EEG Mu/Alpha and Beta Rhythms During Perception of Biological Motion. *Psychoneuroendocrinology* **35**:1446–1453. [07]
- Perry, V. H. 2007. Stress Primes Microglia to the Presence of Systemic Inflammation: Implications for Environmental Influences on the Brain. *Brain Behav. Immun.* **21**:45–46. [07]
- Pescosolido, B. A., J. K. Martin, A. Lang, and S. Olafsdottir. 2008. Rethinking Theoretical Approaches to Stigma: A Framework Integrating Normative Influences on Stigma (FINIS). *Soc. Sci. Med.* **67**:431–440. [17]
- Petersen, L., M. Nordentoft, P. Jeppesen, et al. 2005. Improving 1-Year Outcome in First-Episode Psychosis: Opus Trial. *Br. J. Psychiatry Suppl.* **48**:s98–103. [07]
- Petronis, A. 2010. Epigenetics as a Unifying Principle in the Aetiology of Complex Traits and Diseases. *Nature* **465**:721–727. [09]
- Pezawas, L., and A. Meyer-Lindenberg. 2010. Imaging Genetics: Progressing by Leaps and Bounds. *NeuroImage* **53**:801–803. [08]
- Pfammatter, M., U. M. Junghan, and H. D. Brenner. 2006. Efficacy of Psychological Therapy in Schizophrenia: Conclusions from Meta-Analyses. *Schizophr. Bull.* **32**(Suppl. 1):S64–S68. [15]
- Pfisterer, U., A. Kirkeby, O. Torper, et al. 2011. Direct Conversion of Human Fibroblasts to Dopaminergic Neurons. *PNAS* **108**:10343–10348. [10]

- Pharoah, F., J. Mari, J. Rathbone, and W. Wong. 2010. Family Intervention for Schizophrenia. *Cochrane Database Syst. Rev.* **12**:CD000088. [15]
- Phillips, W. A., and S. M. Silverstein. 2003. Convergence of Biological and Psychological Perspectives on Cognitive Coordination in Schizophrenia. *Behav. Brain Sci.* **26**:65–137. [01, 02, 07]
- . 2013. The Coherent Organization of Mental Life Depends on Mechanisms for Context-Sensitive Gain-Control That Are Impaired in Schizophrenia. *Front. Psychol.* **4**:307. [01]
- Picton, T. W., C. Alain, L. Otten, W. Ritter, and A. Achim. 2000. Mismatch Negativity: Different Water in the Same River. *Audiol. Neurootol.* **5**:111–139. [07]
- Pidsley, R., and J. Mill. 2011. Epigenetic Studies of Psychosis: Current Findings, Methodological Approaches, and Implications for Postmortem Research. *Biol. Psychiatry* **69**:146–156. [09]
- Pilling, S., P. Bebbington, E. Kuipers, et al. 2002. Psychological Treatments in Schizophrenia: I. Meta-Analysis of Family Intervention and Cognitive Behaviour Therapy. *Psychol. Med.* **32**:763–782. [17]
- Pilowsky, L. S., D. C. Costa, P. J. Ell, et al. 1993. Antipsychotic Medication, D2 Dopamine Receptor Blockade and Clinical Response: A 123i IBZM SPET (Single Photon Emission Tomography) Study. *Psychol. Med.* **23**:791–797. [07]
- Pineda, J. A., D. Brang, E. Hecht, et al. 2008. Positive Behavioral and Electrophysiological Changes Following Neurofeedback Training in Children with Autism. *Res. Autism Spectr. Disord.* **2**:557–581. [07]
- Piomelli, D., C. Pilon, B. Giros, et al. 1991. Dopamine Activation of the Arachidonic Acid Cascade as a Basis for D1/D2 Receptor Synergism. *Nature* **353**:164–167. [07]
- Pitschel-Walz, G., S. Leucht, J. Bäuml, W. Kissling, and R. R. Engel. 2001. The Effect of Family Interventions on Relapse and Rehospitalization in Schizophrenia: A Meta-Analysis. *Schizophr. Bull.* **27**:73–92. [15]
- Planck, M. 1949. The Meaning and Limits of Exact Science. *Science* **110**:325. [05]
- Poduri, A., and D. Lowenstein. 2011. Epilepsy Genetics: Past, Present, and Future. *Curr. Opin. Genet. Dev.* **21**:325–332. [13]
- Pollmacher, T., M. Haack, A. Schuld, T. Kraus, and D. Hinze-Selch. 2000. Effects of Antipsychotic Drugs on Cytokine Networks. *J. Psychiatr. Res.* **34**:369–382. [07]
- Pompili, M., X. Amador, P. Girardi, et al. 2007. Suicide Risk in Schizophrenia: Learning from the Past to Change the Future. *Ann Gen Psychiatry* **6**:1–22. [17]
- Pool, D., W. Bloom, D. Mielke, J. J. Roniger, and D. Callant. 1976. A Controlled Evaluation of Lozitan in Seventy-Five Adolescent Schizophrenia Patients. *Curr. Ther. Res. Clin. Exp.* **19**:99–104. [04]
- Porteous, D. J., J. K. Millar, N. J. Brandon, and A. Sawa. 2011. DISC1 at 10: Connecting Psychiatric Genetics and Neuroscience. *Trends Molec. Med.* **17**:699–706. [08]
- Posthuma, D., E. J. Mulder, D. I. Boomsma, and E. J. de Geus. 2002. Genetic Analysis of IQ, Processing Speed and Stimulus-Response Incongruency Effects. *Biol. Psychol.* **61**:157–182. [07]
- Powell, S. B., and M. A. Geyer. 2002. Developmental Markers of Psychiatric Disorders as Identified by Sensorimotor Gating. *Neurotox. Res.* **4**:489–502. [07]
- Power, P. J., R. J. Bell, R. Mills, et al. 2003. Suicide Prevention in First Episode Psychosis: The Development of a Randomised Controlled Trial of Cognitive Therapy for Acutely Suicidal Patients with Early Psychosis. *Aust. NZ J. Psychiatry* **37**:414–420. [07]

- President's New Freedom Commission on Mental Health. 2003. Achieving the Promise: Transforming Mental Health Care in America: Final Report. http://www.promoting-excellence.org/downloads/mass/presidents_summary.pdf. (accessed June 11, 2013). [15, 17]
- Prikryl, R., M. Mikl, H. Prikrylova Kucerova, et al. 2012. Does Repetitive Transcranial Magnetic Stimulation Have a Positive Effect on Working Memory and Neuronal Activation in Treatment of Negative Symptoms of Schizophrenia? *Neuro. Endocrinol. Lett.* **33**:90–97. [09]
- Proctor, E. K., J. Landsverk, G. A. Aarons, et al. 2009. Implementation Research in Mental Health Services: An Emerging Science with Conceptual, Methodological, and Training Challenges. *Adm. Policy Ment. Health* **36**:24–34. [15]
- Pruessner, J. C., F. Champagne, M. J. Meaney, and A. Dagher. 2004. Dopamine Release in Response to a Psychological Stress in Humans and Its Relationship to Early Life Maternal Care: A Positron Emission Tomography Study Using [11C]Raclopride. *J. Neurosci.* **24**:2825–2831. [08]
- Psychiatric GWAS Consortium Steering Committee. 2009. A Framework for Interpreting Genome-Wide Association Studies of Psychiatric Disorders. *Mol. Psychiatry* **14**:10–17. [08]
- Pukrop, R., F. Schultze-Lutter, S. Ruhrmann, et al. 2006. Neurocognitive Functioning in Subjects at Risk for a First Episode of Psychosis Compared with First- and Multiple-Episode Schizophrenia. *J. Clin. Exp. Neuropsychol.* **28**:1388–1407. [07]
- Purcell, S. M., N. R. Wray, J. L. Stone, et al. 2009. Common Polygenic Variation Contributes to Risk of Schizophrenia and Bipolar Disorder. *Nature* **460**:748–752. [07, 09]
- Qiang, L., R. Fujita, T. Yamashita, et al. 2011. Directed Conversion of Alzheimer's Disease Patient Skin Fibroblasts into Functional Neurons. *Cell* **146**:359–371. [10]
- Quednow, B. B., I. Frommann, J. Berning, et al. 2008. Impaired Sensorimotor Gating of the Acoustic Startle Response in the Prodrome of Schizophrenia. *Biol. Psychiatry* **64**:766–773. [07]
- Racenstein, J. M., M. Harrow, R. Reed, et al. 2002. The Relationship between Positive Symptoms and Instrumental Work Functioning in Schizophrenia: A 10-Year Follow-up Study. *Schizophr. Res.* **56**:95–103. [15]
- Raj, A., and A. van Oudenaarden. 2008. Nature, Nurture, or Chance: Stochastic Gene Expression and Its Consequences. *Cell* **135**:216–226. [13]
- Rajesh, D., S. J. Dickerson, J. Yu, et al. 2011. Human Lymphoblastoid B-Cell Lines Reprogrammed to EBV-Free Induced Pluripotent Stem Cells. *Blood* **118**:1797–1800. [10]
- Ralph, R. O. 2000. Recovery. *Psychiatric Rehab. Skills* **4**:480–517. [15]
- Ramsden, S., F. M. Richardson, G. Josse, et al. 2011. Verbal and Non-Verbal Intelligence Changes in the Teenage Brain. *Nature* **479**:113–116. [17]
- Ransohoff, R. M., and V. H. Perry. 2009. Microglial Physiology: Unique Stimuli, Specialized Responses. *Annu. Rev. Immunol.* **27**:119–145. [07]
- Rapaport, M. H., K. K. Delrahim, C. J. Bresee, et al. 2005. Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia. *Biol. Psychiatry* **57**:1594–1596. [07]
- Rasetti, R., F. Sambataro, Q. Chen, et al. 2011. Altered Cortical Network Dynamics: A Potential Intermediate Phenotype for Schizophrenia and Association with ZNF804A. *Arch. Gen. Psychiatry* **68**:1207–1217. [09]
- Rasser, P. E., U. Schall, J. Todd, et al. 2011. Gray Matter Deficits, Mismatch Negativity, and Outcomes in Schizophrenia. *Schizophr. Bull.* **37**:131–140. [07]

- Rawson, N. E., G. Gomez, B. Cowart, et al. 1997. Selectivity and Response Characteristics of Human Olfactory Neurons. *J. Neurophysiol.* **77**:1606–1613. [10]
- RDoC. 2011. NIMH Research Domain Criteria. <http://www.nimh.nih.gov/research-funding/rdoc/nimh-research-domain-criteria-rdoc.shtml>. (accessed June 4, 2013). [03, 05]
- Realmuto, G., W. Erickson, A. Yellin, J. H. Hopwood, and L. Greenberg. 1984. Clinical Comparison of Thiothixene and Thiorizadine in Schizophrenia Adolescents. *Am. J. Psychiatr.* **141**:440–442. [04]
- Reddy, F., W. D. Spaulding, M. A. Jansen, A. A. Menditto, and S. Pickett. 2010. Psychologists' Roles and Opportunities in Rehabilitation and Recovery for Serious Mental Illness: A Survey of Council of University Directors of Clinical Psychology (CUDCP) Clinical Psychology Training and Doctoral Education. *Train. Educ. Prof. Psychol.* **4**:254–263. [15]
- Reeder, C., E. Newton, S. Frangou, and T. Wykes. 2004. Which Cognitive Skills Should We Target to Effect Social Functioning Change? A Study of a Cognitive Remediation Therapy Programme. *Schizophr. Bull.* **30**:87–100. [01]
- Regier, D. A., C. T. Kaelber, D. S. Rae, et al. 1998. Limitations of Diagnostic Criteria and Assessment Instrument for Mental Disorders. Implications for Research and Policy. *Arch. Gen. Psychiatry* **55**:109–115. [16]
- Regier, D. A., E. A. Kuhl, and D. J. Kupfer. 2013. The DSM-5: Classification and Criteria Changes. *World Psychiatry* **12**:92–99. [16]
- Regier, D. A., W. E. Narrow, D. S. Rae, et al. 1993. The *De Facto* US Mental and Addictive Disorders Service System. Epidemiologic Catchment Area Prospective 1-Year Prevalence Rates of Disorders and Services. *Arch. Gen. Psychiatry* **50**:85–94. [16]
- Reichenberg, A., A. Caspi, H. Harrington, et al. 2010. Static and Dynamic Cognitive Deficits in Childhood Preceding Adult Schizophrenia: A 30-Year Study. *Am. J. Psychiatr.* **167**:160–169. [09, 14, 17]
- Reichenberg, A., M. Weiser, J. Rabinowitz, et al. 2002. A Population-Based Cohort Study of Premorbid Intellectual, Language, and Behavioral Functioning in Patients with Schizophrenia, Schizoaffective Disorder, and Nonpsychotic Bipolar Disorder. *Am. J. Psychiatr.* **159**:2027–2035. [14, 17]
- Reid, M. A., L. E. Stoeckel, D. M. White, et al. 2010. Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia. *Biol. Psychiatry* **68**:625–633. [07]
- ReliaSoft. 2012. Fault Tree Diagrams and System Analysis: Reliawiki. http://reliawiki.com/index.php/Fault_Tree_Diagrams_and_System_Analysis. (accessed May 25, 2012). [02]
- Remijne, P. L., M. M. Nielen, H. B. Uylings, and D. J. Veltman. 2005. Neural Correlates of a Reversal Learning Task with an Affectively Neutral Baseline: An Event-Related fMRI Study. *NeuroImage* **26**:609–618. [05]
- Renes, R. A., L. Vermeulen, R. S. Kahn, H. Aarts, and N. E. van Haren. 2013. Abnormalities in the Establishment of Feeling of Self-Agency in Schizophrenia. *Schizophr. Res.* **143**:50–54. [01]
- Reser, J. E. 2007. Schizophrenia and Phenotypic Plasticity: Schizophrenia May Represent a Predictive, Adaptive Response to Severe Environmental Adversity That Allows Both Bioenergetic Thrift and a Defensive Behavioral Strategy. *Med. Hypotheses* **69**:383–394. [01]

- Resnick, S. G., R. A. Rosenheck, L. Dixon, and A. F. Lehman. 2005. Correlates for Family Contact with the Mental Health System: Allocation of a Scarce Resource. *Ment. Health Serv. Res.* **7**:113–121. [15]
- Resnick, S. G., R. A. Rosenheck, and A. F. Lehmann. 2004. An Exploratory Analysis of Correlates of Recovery. *Psychiatr. Serv.* **55**:540–547. [16]
- Restrepo, D., Y. Okada, J. H. Teeter, et al. 1993. Human Olfactory Neurons Respond to Odor Stimuli with an Increase in Cytoplasmic Ca²⁺. *Biophys. J.* **64**:1961–1966. [10]
- Revheim, N., P. D. Butler, I. Schechter, et al. 2006. Reading Impairment and Visual Processing Deficits in Schizophrenia. *Schizophr. Res.* **87**:238–245. [01]
- Richardson, A. J. 1994. Dyslexia, Handedness and Syndromes of Psychosis-Proneness. *Int. J. Psychophysiol.* **18**:251–263. [01]
- Richfield, E. K., J. B. Penney, and A. B. Young. 1989. Anatomical and Affinity State Comparisons between Dopamine D1 and D2 Receptors in the Rat Central Nervous System. *Neuroscience* **30**:767–777. [12]
- Richland, N. M., and R. K. McNamara. 2008. Serotonin and Dopamine Interactions in Psychosis Prevention. *Prog. Brain Res.* **172**:141–153. [07]
- Ridler, K., J. M. Veijola, P. Tanskanen, et al. 2006. Fronto-Cerebellar Systems Are Associated with Infant Motor and Adult Executive Functions in Healthy Adults but Not in Schizophrenia. *PNAS* **103**:15651–15656. [06]
- Rietschel, M., M. Mattheisen, J. Frank, et al. 2010. Genome-Wide Association-, Replication-, and Neuroimaging Study Implicates Homer1 in the Etiology of Major Depression. *Biol. Psychiatry* **68**:578–585. [08]
- Riley, E. M., D. McGovern, D. Mockler, et al. 2000. Neuropsychological Functioning in First-Episode Psychosis: Evidence of Specific Deficits. *Schizophr. Res.* **43**:47–55. [04]
- Ring, K. L., L. M. Tong, M. E. Balestra, et al. 2012. Direct Reprogramming of Mouse and Human Fibroblasts into Multipotent Neural Stem Cells with a Single Factor. *Cell Stem Cell* **11**:100–109. [10]
- Ripke, S., A. R. Sanders, K. S. Kendler, et al. 2011. Genome-Wide Association Study Identifies Five New Schizophrenia Loci. *Nat. Genet.* **43**:969–976. [08]
- Risch, N., and K. Merikangas. 1996. The Future of Genetic Studies of Complex Human Diseases. *Science* **273**:1516–1517. [08]
- Ritsner, M. S., A. Gibel, T. Shleifer, and I. Boguslavsky. 2010. Pregnenolone and Dehydroepiandrosterone as an Adjunctive Treatment in Schizophrenia and Schizoaffective Disorder. *J. Clin. Psychiatry* **71**:1351–1362. [04]
- Robertson, S. A., A. S. Care, and R. J. Skinner. 2007. Interleukin 10 Regulates Inflammatory Cytokine Synthesis to Protect against Lipopolysaccharide-Induced Abortion and Fetal Growth Restriction in Mice. *Biol. Reprod.* **76**:738–748. [07]
- Robinson, D. G., M. G. Woerner, J. M. Alvir, et al. 1999. Predictors of Relapse Following Response from a First Episode of Schizophrenia or Schizoaffective Disorder. *Arch. Gen. Psychiatry* **56**:241–247. [06]
- Robinson, D. G., M. G. Woerner, M. McMeniman, A. Mendelowitz, and R. M. Bilder. 2004. Symptomatic and Functional Recovery from a First Episode of Schizophrenia or Schizoaffective Disorder. *Am. J. Psychiatr.* **161**:473–479. [06]
- Rocha, K. K., A. M. Ribeiro, K. C. Rocha, et al. 2012. Improvement in Physiological and Psychological Parameters after 6 Months of Yoga Practice. *Conscious Cogn.* **21**:843–850. [07]
- Roder, C. H., J. M. Hoogendam, and F. M. van der Veen. 2010. fMRI, Antipsychotics and Schizophrenia. Influence of Different Antipsychotics on BOLD-Signal. *Curr. Pharm. Des.* **16**:2012–2025. [07]

- Roder, V., D. R. Mueller, and S. J. Schmidt. 2011a. Effectiveness of Integrated Psychological Therapy (IPT) for Schizophrenia Patients: A Research Update. *Schizophr. Bull.* **37**(Suppl. 2):S71–S79. [15]
- Roder, V., D. R. Müller, H. D. Brenner, and W. D. Spaulding. 2011b. Integrated Psychological Therapy (IPT) for the Treatment of Neurocognition, Social Cognition, and Social Competency in Schizophrenia Patients. Cambridge, MA: Hogrefe. [15]
- Roe, D. 2001. Progressing from “Patienthood” to “Personhood” across the Multi-Dimensional Outcomes in Schizophrenia and Related Disorders. *J. Nerv. Ment. Dis.* **189**:691–699. [06]
- Roe, D., and M. Chopra. 2003. Beyond Coping with Mental Illness: Toward Personal Growth. *Am. J. Orthopsychiat.* **73**:334–344. [15]
- Rogers, E. 2003. Diffusion of Innovations (5th edition). New York: Free Press. [15]
- Rogers, E. S., J. Chamberlin, M. L. Ellison, and T. Crean. 1997. A Consumer-Constructed Scale to Measure Empowerment among Users of Mental Health Services. *Psychiatr. Serv.* **48**:1042–1047. [16]
- Roisen, F. J., K. M. Klueber, C. L. Lu, et al. 2001. Adult Human Olfactory Stem Cells. *Brain. Res.* **890**:11–22. [10]
- Rorick-Kehn, L. M., B. G. Johnson, J. L. Burkey, et al. 2007. Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: *In Vitro* Characterization of Agonist (-)-(1r,4S,5S,6S)-4-Amino-2-Sulfonylbicyclo[3.1.0]-Hexane-4,6-Dicarboxylic Acid (LY404039). *J. Pharmacol. Exp. Ther.* **321**:308–317. [07]
- Rose, G. 1985. Sick Individuals and Sick Populations. *Int. J. Epidemiol.* **14**:32–38. [09]
- Rosen, A., K. T. Mueser, and M. Teeson. 2007. Assertive Community Treatment: Issues from Scientific and Clinical Literature with Implications for Practice. *J. Rehabil. Res. Dev.* **44**:813–826. [15]
- Rosenberg, D. R., and D. A. Lewis. 1995. Postnatal Maturation of the Dopaminergic Innervation of Monkey Prefrontal and Motor Cortices: A Tyrosine Hydroxylase Immunohistochemical Analysis. *J. Comp. Neurol.* **358**:383–400. [13]
- Roser, P., F. X. Vollenweider, and W. Kawohl. 2010. Potential Antipsychotic Properties of Central Cannabinoid (CB1) Receptor Antagonists. *World J. Biol. Psychiatry* **11**:208–219. [07]
- Rössler, W. 2000. Schizophrenie: Psychosoziale Einflussfaktoren. In: *Psychiatrie Der Gegenwart V*, ed. N. Sartorius, pp. 181–192. Heidelberg: Springer. [16]
- . 2006. Psychiatric Rehabilitation Today: An Overview. *World Psychiatry* **5**:151–157. [16, 17]
- . 2012. Stress, Burnout, and Job Dissatisfaction in Mental Health Workers. *Eur. Arch. Psychiatry Clin. Neurosci.* **262**:S65–S69. [16]
- Rössler, W., M. P. Hengartner, V. Ajdacic-Gross, H. Haker, and J. Angst. 2013. Lifetime and 12-Month Prevalence Rates of Sub-Clinical Psychosis Symptoms in a Community Cohort of 50-Year-Old Individuals. *Eur. Psychiatry* **28**:202–307. [16]
- Rössler, W., M. P. Hengartner, V. Ajdacic-Gross, et al. 2011. Sub-Clinical Psychosis Symptoms in Young Adults Are Risk Factors for Subsequent Common Mental Disorders. *Schizophr. Res.* **131**:18–23. [16]
- Rössler, W., M. P. Hengartner, J. Angst, and V. Ajdacic-Grosset. 2012. Linking Substance Use with Symptoms of Subclinical Psychosis in a Community Cohort over 30 Years. *Addiction* **107**:1174–1184. [16]
- Rössler, W., A. Riecher, W. Löffler, and B. Fätkenheuer. 1991. Community Care in Child Psychiatry: An Empirical Approach Using the Concept of Travel Time. *Soc. Psychiatry Psychiatr. Epidem.* **26**:28–33. [16]

- Rössler, W., A. Riecher-Rössler, J. Angst, et al. 2007. Psychotic Experiences in the General Population: A Twenty-Year Prospective Community Study. *Schizophr. Res.* **92**:1–14. [01, 16]
- Rounis, E., K. E. Stephan, L. Lee, et al. 2006. Acute Changes in Frontoparietal Activity after Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in a Cued Reaction Time Task. *J. Neurosci.* **26**:9629–9638. [09]
- Rowland, L. M., K. Kontson, J. West, et al. 2012. *In Vivo* Measurements of Glutamate, GABA, and NAAG in Schizophrenia. *Schizophr. Bull.* doi: 10.1093/schbul/sbs1092. [07]
- Rujescu, D., A. Ingason, S. Cichon, et al. 2008. Disruption of the Neurexin 1 Gene Is Associated with Schizophrenia. *Hum. Mol. Genet.* **18**:988–996. [05]
- Rund, B. R. 1998. A Review of Longitudinal Studies of Cognitive Function in Schizophrenia Patients. *Schizophr. Bull.* **24**: [07]
- Rupp, A., and S. J. Keith. 1993. The Costs of Schizophrenia: Assessing the Burden. *Psychiatr. Clin. North Am.* **16**:413–423. [01]
- Rüsch, N., P. W. Corrigan, and A. Wassel. 2009. Self-Stigma, Group Identification, Perceived Legitimacy of Discrimination and Mental Health Service Use. *Br. J. Psychiatry* **195**:551–552. [16]
- Russell-Smith, S. N., M. T. Maybery, and D. M. Bayliss. 2010. Are the Autism and Positive Schizotypy Spectra Diametrically Opposed in Local Versus Global Processing? *J. Autism Dev. Disord.* **40**:968–977. [01]
- Rutten, B. P., and J. Mill. 2009. Epigenetic Mediation of Environmental Influences in Major Psychotic Disorders. *Schizophr. Bull.* **35**:1045–1056. [07, 09]
- Rutter, M. 1985. Resilience in the Face of Adversity. Protective Factors and Resistance to Psychiatric Disorder. *Br. J. Psychiatry* **147**:598–611. [06]
- Sabb, F. W., T. G. van Erp, M. E. Hardt, et al. 2010. Language Network Dysfunction as a Predictor of Outcome in Youth at Clinical High Risk for Psychosis. *Schizophr. Res.* **116**:173–183. [07]
- Sachs, G., D. Steger-Wuchse, I. Kryspin-Exner, R. C. Gur, and H. Katschnig. 2004. Facial Recognition Deficits and Cognition in Schizophrenia. *Schizophr. Res.* **68**:27–35. [04]
- Sackett, D. L., W. S. Richardson, W. Rosenberg, and R. B. Haynes. 1997. Evidence-Based Medicine. New York: Churchill Livingstone. [15]
- Saldivia, S., B. Vicente, R. Kohn, P. Rioseco, and S. Torres. 2004. Use of Mental Health Services in Chile. *Psychiatr. Serv.* **55**:71–76. [16]
- Salisbury, D. F., N. Kuroki, K. Kasai, M. E. Shenton, and R. W. McCarley. 2007. Progressive and Interrelated Functional and Structural Evidence of Post-Onset Brain Reduction in Schizophrenia. *Arch. Gen. Psychiatry* **64**:521–529. [07]
- Salisbury, D. F., M. E. Shenton, C. B. Griggs, A. Bonner-Jackson, and R. W. McCarley. 2002. Mismatch Negativity in Chronic Schizophrenia and First-Episode Schizophrenia. *Arch. Gen. Psychiatry* **59**:686–694. [07]
- Salize, H. J., M. R., J. Bullenkamp, et al. 2009. Cost of Treatment in Six European Countries. *Schizophr. Res.* **111**:70–77. [01, 16]
- Salize, H. J., R. McCabe, J. Bullenkamp, et al. 2009. Cost of Treatment in Six European countries. *Schiz. Res.* **111**:70–77. [16]
- Salize, H. J., and W. Rössler. 1996. The Cost of Comprehensive Care of People with Schizophrenia Living in the Community. A Cost Evaluation from a German Catchment Area. *Br. J. Psychiatry* **169**:42–48. [16]

- Salkever, D. S., M. C. Karakus, E. P. Slade, et al. 2007. Measures and Predictors of Community-Based Employment and Earnings of Persons with Schizophrenia in a Multisite Study. *Psychiatr. Serv.* **58**:315–324. [05]
- Sampson, R. J., and W. B. Groves. 1989. Community Structure and Crime: Testing Social Disorganization Theory. *Am. J. Sociol.* **94**:774–802. [01]
- Sandefur, R., and E. O. Laumann. 1998. A Paradigm for Social Capital. *Rational. Soc.* **10**:481–501. [01]
- Sass, L. A., and J. Parnas. 2009. Schizophrenia, Consciousness, and the Self. *Schizophr. Bull.* **29**:427–444. [01]
- Sato, M. 2006. Renaming Schizophrenia: A Japanese Perspective. *World Psychiatry* **5**:53–55. [05]
- Sattler, R., Y. Ayukawa, L. Coddington, et al. 2011. Human Nasal Olfactory Epithelium as a Dynamic Marker for CNS Therapy Development. *Exp. Neurol.* **232**:203–211. [10]
- Sawa, A., and N. G. Cascella. 2009. Peripheral Olfactory System for Clinical and Basic Psychiatry: A Promising Entry Point to the Mystery of Brain Mechanism and Biomarker Identification in Schizophrenia. *Am. J. Psychiatr.* **166**:137–139. [10]
- Sawamura, N., T. Ando, Y. Maruyama, et al. 2008. Nuclear DISC1 Regulates Cre-Mediated Gene Transcription and Sleep Homeostasis in the Fruit Fly. *Mol. Psychiatry* **13**:1138–1148, 1069. [10]
- Saxena, S., E. Gorbis, J. O'Neill, et al. 2009. Rapid Effects of Brief Intensive Cognitive-Behavioral Therapy on Brain Glucose Metabolism in Obsessive-Compulsive Disorder. *Mol. Psychiatry* **14**:197–205. [07]
- Schall, U., S. V. Catts, F. Karayanidis, and P. B. Ward. 1999. Auditory Event-Related Potential Indices of Fronto-Temporal Information Processing in Schizophrenia Syndromes: Valid Outcome Prediction of Clozapine Therapy in a Three-Year Follow-Up. *Int. J. Neuropsychopharmacol.* **2**:83–93. [07]
- Scharinger, C., U. Rabl, H. H. Sitte, and L. Pezawas. 2010. Imaging Genetics of Mood Disorders. *NeuroImage* **53**:810–821. [08]
- Scheff, T. 1966. *Being Mentally Ill: A Sociology Theory*. Chicago: Aldine. [17]
- Schenkel, L. S., and S. Silverstein. 2004. Dimensions of Premorbid Functioning in Schizophrenia: A Review of Neuromotor, Cognitive, Social, and Behavioral Domains. *Genet. Soc. Gen. Psychol. Monogr.* **130**:241–270. [01]
- Schiffman, J., J. A. Maeda, K. Hayashi, et al. 2006. Premorbid Childhood Ocular Alignment Abnormalities and Adult Schizophrenia-Spectrum Disorder. *Schizophr. Res.* **81**:253–260. [01]
- Schnack, H. G., M. Nieuwenhuis, E. M. Neeltje, et al. submitted. Can Structural MRI Aid in Clinical Classification? A Machine Learning Study in Two Independent Samples of Patients with Schizophrenia, Bipolar Disorder and Healthy Subjects. [17]
- Schneider, K. 1959. *Clinical Psychopathology* (translated by M. W. Hamilton and E. W. Anderson). New York: Grune & Stratton. [03]
- Schork, N. J., T. A. Greenwood, and D. L. Braff. 2007. Statistical Genetics Concepts and Approaches in Schizophrenia and Related Neuropsychiatric Research. *Schizophr. Bull.* **33**:95–104. [03]
- Schubert, E. W., K. M. Henriksson, and T. F. McNeil. 2005. A Prospective Study of Offspring of Women with Psychosis: Visual Dysfunction in Early Childhood Predicts Schizophrenia-Spectrum Disorders in Adulthood. *Acta Psychiatr. Scand.* **112**:385–393. [01]
- Schultze-Lutter, F. 2009. Subjective Symptoms of Schizophrenia in Research and the Clinic: The Basic Symptom Concept. *Schizophr. Bull.* **35**:5–8. [17]

- Schulze, B., and W. Rössler. 2005. Caregiver Burden in Mental Illness: Review of Measurement, Findings and Interventions in 2004–2005. *Curr. Opin. Psychiatry* **18**:684–691. [17]
- Schwartz, J. M., P. W. Stoessel, L. R. Baxter, Jr., K. M. Martin, and M. E. Phelps. 1996. Systematic Changes in Cerebral Glucose Metabolic Rate after Successful Behavior Modification Treatment of Obsessive-Compulsive Disorder. *Arch. Gen. Psychiatry* **53**:109–113. [07]
- Schwartz, S., and E. Susser. 2006. Relationships among Causes. In: *Psychiatric Epidemiology: Searching for the Causes of Mental Disorders*, ed. E. Susser et al., pp. 62–74. Oxford: Oxford Univ. Press. [09]
- Scott, A., B. A. Wowra, and R. McCarter. 1999. Validation of the Empowerment Scale with an Outpatient Mental Health Population. *Psychiatr. Serv.* **50**:959–961. [16]
- Seamans, J. K., D. Durstewitz, B. R. Christie, C. F. Stevens, and T. J. Sejnowski. 2001a. Dopamine D1/D5 Receptor Modulation of Excitatory Synaptic Inputs to Layer V Prefrontal Cortex Neurons. *PNAS* **98**:301–306. [12]
- Seamans, J. K., N. Gorelova, D. Durstewitz, and C. R. Yang. 2001b. Bidirectional Dopamine Modulation of Gabaergic Inhibition in Prefrontal Cortical Pyramidal Neurons. *J. Neurosci.* **21**:3628–3638. [12]
- Sebat, J., D. L. Levy, and S. E. McCarthy. 2009. Rare Structural Variants in Schizophrenia: One Disorder, Multiple Mutations; One Mutation, Multiple Disorders. *Trends Genet.* **25**:528–535. [01, 07]
- Seeman, P. 2011. All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2(High) Receptors. *CNS Neurosci. Ther.* **17**:118–132. [13]
- Seeman, P., and H. C. Guan. 2009. Glutamate Agonist LY404,039 for Treating Schizophrenia Has Affinity for the Dopamine D2(High) Receptor. *Synapse* **63**:935–939. [07]
- Seeman, P., J. Schwarz, J. F. Chen, et al. 2006. Psychosis Pathways Converge via D2high Dopamine Receptors. *Synapse* **60**:319–346. [12]
- Seidman, L. J., A. J. Giuliano, E. C. Meyer, et al. 2010. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. *Arch. Gen. Psychiatry* **67**:578–588. [02, 07]
- Seidman, L. J., H. W. Thermenos, R. A. Poldrack, et al. 2006. Altered Brain Activation in Dorsolateral Prefrontal Cortex in Adolescents and Young Adults at Genetic Risk for Schizophrenia: An fMRI Study of Working Memory. *Schizophr. Res.* **85**:58–72. [07]
- Seki, T., S. Yuasa, M. Oda, et al. 2010. Generation of Induced Pluripotent Stem Cells from Human Terminally Differentiated Circulating T Cells. *Cell Stem Cell* **7**:11–14. [10]
- Selten, J. P., and E. Cantor-Graae. 2005. Social Defeat: Risk Factor for Schizophrenia? *Br. J. Psychiatry* **187**:101–102. [09]
- Serretti, A., M. Kato, D. De Ronchi, and T. Kinoshita. 2007. Meta-Analysis of Serotonin Transporter Gene Promoter Polymorphism (5-HTTLPR) Association with Selective Serotonin Reuptake Inhibitor Efficacy in Depressed Patients. *Mol. Psychiatry* **12**:247–257. [08]
- Sesack, S. R., and D. B. Carr. 2002. Selective Prefrontal Cortex Inputs to Dopamine Cells: Implications for Schizophrenia. *Physiol. Behav.* **77**:513–517. [07]
- Sesack, S. R., D. B. Carr, N. Omelchenko, and A. Pinto. 2003. Anatomical Substrates for Glutamate-Dopamine Interactions: Evidence for Specificity of Connections and Extrasynaptic Actions. *Ann. NY Acad. Sci.* **1003**:36–52. [07]

- Seshadri, S., A. Kamiya, Y. Yokota, et al. 2010. Disrupted-in-Schizophrenia-1 Expression Is Regulated by Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1-Neuregulin Cascade. *PNAS* **107**:5622–5627. [08]
- Shahbazian, M. D., B. Antalffy, D. L. Armstrong, and H. Y. Zoghbi. 2002. Insight into Rett Syndrome: MeCP2 Levels Display Tissue- and Cell-Specific Differences and Correlate with Neuronal Maturation. *Hum. Mol. Genet.* **11**:115–124. [10]
- Sharp, F. R., M. Tomitaka, M. Bernaudin, and S. Tomitaka. 2001. Psychosis: Pathological Activation of Limbic Thalamocortical Circuits by Psychomimetics and Schizophrenia? *Trends Neurosci.* **24**:330–334. [07]
- Shaw, P., D. Greenstein, J. Lerch, et al. 2006a. Intellectual Ability and Cortical Development in Children and Adolescents. *Nature* **440**:676–679. [13]
- Shaw, P., A. Sporn, N. Gogtay, et al. 2006b. Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison. *Arch. Gen. Psychiatry* **63**:721–730. [04]
- Sheldon, K. M., T. Kasser, K. Smith, and T. Share. 2002. Personal Goals and Psychological Growth: Testing an Intervention to Enhance Goal Attainment and Personality Integration. *J. Pers.* **70**:5–31. [15]
- Shelley, A. M., P. B. Ward, S. V. Catts, et al. 1991. Mismatch Negativity: An Index of a Preattentive Processing Deficit in Schizophrenia. *Biol. Psychiatry* **30**:1059–1062. [07]
- Shen, S., B. Lang, C. Nakamoto, et al. 2008. Schizophrenia-Related Neural and Behavioral Phenotypes in Transgenic Mice Expressing Truncated DISC1. *J. Neurosci.* **28**:10,893–10,904. [13]
- Sicard, M. N., C. C. Zai, A. K. Tiwari, et al. 2010. Polymorphisms of the HTR2C Gene and Antipsychotic-Induced Weight Gain: An Update and Meta-Analysis. *Pharmacogenomics* **11**:1561–1571. [07]
- Siegle, G. J., C. S. Carter, and M. E. Thase. 2006. Use of fMRI to Predict Recovery from Unipolar Depression with Cognitive Behavior Therapy. *Am. J. Psychiatr.* **163**:735–738. [09]
- Sigurdsson, T., K. L. Stark, M. Karayiorgou, J. A. Gogos, and J. A. Gordon. 2010. Impaired Hippocampal-Prefrontal Synchrony in a Genetic Mouse Model of Schizophrenia. *Nature* **464**:763–767. [09, 11, 13]
- Sikich, L., R. Hamer, R. Bashford, B. Sheitman, and J. Lieberman. 2004. A Pilot Study of Risperidone, Olanzapine and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial. *Neuropsychopharmacology* **29**:133–145. [04]
- Silverstein, S. M. 1993. Methodological and Empirical Considerations in Assessing the Validity of Psychoanalytic Theories of Hypnosis. *Genet. Soc. Gen. Psychol. Monogr.* **119**:5–54. [01]
- . 2000. Psychiatric Rehabilitation of Schizophrenia: Unresolved Issues, Current Trends and Future Directions. *Appl. Prev. Psychol.* **9**:227–248. [06]
- . 2008. Measuring Specific, Rather Than Generalized, Cognitive Deficits and Maximizing between-Group Effect Size in Studies of Cognition and Cognitive Change. *Schizophr. Bull.* **34**:645–655. [01, 09]
- . 2010. Failures of Dynamic Coordination in Disease States, and Their Implications for Normal Brain Function. In: *Dynamic Coordination in the Brain: From Molecules to Mind*, ed. C. von der Malsburg et al., Strüngmann Forum Report, J. Lupp, series ed., vol. 5, pp. 245–265. Cambridge, MA: MIT Press. [01]
- Silverstein, S. M., S. D. All, J. L. Thompson, et al. 2012a. Absolute Level of Gamma Synchrony Is Increased in First Episode Schizophrenia During Face Processing. *J. Exp. Psychopath.* **3**:702–723. [04]

- Silverstein, S. M., and A. S. Bellack. 2008. A Scientific Agenda for the Concept of Recovery as It Applies to Schizophrenia. *Clin. Psychol. Rev.* **28**:1108–1124. [01, 06, 15, 17]
- Silverstein, S. M., S. Berten, B. Essex, et al. 2009a. An fMRI Examination of Visual Integration in Schizophrenia. *J. Integr. Neurosci.* **8**:175–202. [01, 02]
- Silverstein, S. M., M. Hatashita-Wong, B. A. Solak, et al. 2005. Effectiveness of a Two-Phase Cognitive Rehabilitation Intervention for Severely Impaired Schizophrenia Patients. *Psychol. Med.* **35**:829–837. [01]
- Silverstein, S. M., M. Hatashita-Wong, S. M. Wilkniss, et al. 2006a. Behavioral Rehabilitation of the Treatment-Refractory Schizophrenia Patient: Conceptual Foundations, Interventions and Outcome Data. *Psychol. Serv.* **3**:145–169. [17]
- Silverstein, S. M., and B. P. Keane. 2009. Perceptual Organization in Schizophrenia: Plasticity and State-Related Change. *Learn. Percept.* **1**:229–261. [01]
- . 2011. Perceptual Organization Impairment in Schizophrenia and Associated Brain Mechanisms; Review of Research from 2005–2010. *Schizophr. Bull.* **37**:690–699. [07]
- Silverstein, S. M., B. P. Keane, D. M. Barch, et al. 2012b. Optimization and Validation of a Visual Integration Test for Schizophrenia Research. *Schizophr. Bull.* **38**:125–134. [02]
- Silverstein, S. M., B. P. Keane, Y. Wang, et al. 2013a. Visual Context Sensitivity Predicts Clinical State and Short-Term Treatment Responsiveness in Schizophrenia. *Front. Psychol.*, in press. [01]
- Silverstein, S. M., I. Kovacs, R. Corry, and C. Valone. 2000. Perceptual Organization, the Disorganization Syndrome and Context Processing in Chronic Schizophrenia. *Schizophr. Res.* **43**:11–20. [02]
- Silverstein, S. M., and D. R. Palumbo. 1995. Nonverbal Perceptual Organization Output Disability and Schizophrenia Spectrum Symptomatology. *Psychiatry* **58**:66–81. [01]
- Silverstein, S. M., W. D. Spaulding, A. A. Menditto, et al. 2009b. Attention Shaping: A Reward-Based Learning Method to Enhance Skills Training Outcomes in Schizophrenia. *Schizophr. Bull.* **35**:222–232. [15]
- Silverstein, S. M., P. J. Uhlhaas, B. Essex, et al. 2006b. Perceptual Organization in First Episode Schizophrenia and Ultra-High-Risk States. *Schizophr. Res.* **83**:41–52. [01]
- Silverstein, S. M., Y. Wang, and B. P. Keane. 2012c. Cognitive and Neuroplasticity Mechanisms by Which Congenital or Early Blindness May Confer a Protective Effect against Schizophrenia. *Front Psychol.* **3**:624. [01]
- Silverstein, S. M., Y. Wang, and M. W. Roché. 2013b. Base Rates, Blindness, and Schizophrenia. *Front. Psychol.* **4**:157. [01]
- Simmers, A. J., and P. J. Bex. 2001. Deficit of Visual Contour Integration in Dyslexia. *Invest. Ophthalmol. Vis. Sci.* **42**:2737–2742. [01]
- Simon, H. A. 1973. The Organization of Complex Systems. In: *Hierarchy Theory: The Challenge of Complex Systems*, ed. H. H. Pattee, pp. 1–27. New York: George Braziller. [01]
- Singh, F., J. Pineda, and K. S. Cadenhead. 2011. Association of Impaired EEG Mu Wave Suppression, Negative Symptoms and Social Functioning in Biological Motion Processing in First Episode of Psychosis. *Schizophr. Res.* **130**:182–186. [07]
- Singh, S. M., P. McDonald, B. Murphy, and R. O'Reilly. 2004. Incidental Neurodevelopmental Episodes in the Etiology of Schizophrenia: An Expanded Model Involving Epigenetics and Development. *Clin. Genet.* **65**:435–440. [13]

- Sklar, P., S. Ripke, L. J. Scott, et al. 2011. Large-Scale Genome-Wide Association Analysis of Bipolar Disorder Identifies a New Susceptibility Locus near *Odz4*. *Nat. Genet.* **43**:977–983. [09]
- Sluzki, C. E. 2007. Interfaces: Toward a New Generation of Systemic Models in Family Research and Practice. *Fam. Process.* **46**:173–184. [09]
- Smith, R. G., R. L. Kember, J. Mill, et al. 2009. Advancing Paternal Age Is Associated with Deficits in Social and Exploratory Behaviors in the Offspring: A Mouse Model. *PLoS ONE* **4**:e8456. [08]
- Smith, S. M., and P. T. Yanos. 2009. Psychotherapy for Schizophrenia in an Act Team Context. *Clinical Case Stud.* **8**:454–462. [01]
- Smith, T. E., J. W. Hull, S. Romanelli, E. Fertuck, and K. A. Weiss. 1999. Symptoms and Neurocognition as Rate Limiters in Skills Training for Psychotic Patients. *Am. J. Psychiatr.* **156**:1817–1818. [15]
- Snitz, B. E., A. W. MacDonald, III, and C. S. Carter. 2006. Cognitive Deficits in Unaffected First-Degree Relatives of Schizophrenia Patients: A Meta-Analytic Review of Putative Endophenotypes. *Schizophr. Bull.* **32**:179–194. [02, 04]
- Soares, D. C., B. C. Carlyle, N. J. Bradshaw, and D. J. Porteous. 2011. DISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness. *ACS Chem. Neurosci.* **2**:609–632. [13]
- Soldner, F., D. Hockemeyer, C. Beard, et al. 2009. Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors. *Cell* **136**:964–977. [10]
- Son, E. Y., J. K. Ichida, B. J. Wainger, et al. 2011. Conversion of Mouse and Human Fibroblasts into Functional Spinal Motor Neurons. *Cell Stem Cell* **9**:205–218. [10]
- Sørensen, H. J., D. Saebuy, A. Urfer-Parnas, E. L. Mortensen, and J. Parnas. 2012. Premorbid Intelligence and Educational Level in Bipolar and Unipolar Disorders: A Danish Draft Board Study. *J. Affect. Disord.* **136**:1188–1191. [14, 17]
- Spaulding, W. D., M. E. Sullivan, and J. S. Poland. 2003. Treatment and Rehabilitation of Severe Mental Illness. New York: Guilford Press. [15, 17]
- Spearman, C. 1904. "General Intelligence," Objectively Determined and Measured. *Am. J. Psychol.* **15**:201–293. [02]
- Spencer, E., V. Kafantaris, M. Padron-Gaylo, C. Rosenberg, and M. Campell. 1992. Haloperidol in Schizophrenia Children: Early Findings from a Study in Progress. *Psychopharmacol. Bull.* **28**:183–186. [04]
- Spencer, K. M., P. G. Nestor, R. Perlmutter, et al. 2004. Neural Synchrony Indexes Disordered Perception and Cognition in Schizophrenia. *PNAS* **101**:17,288–17,293. [04]
- Spieker, E. A., R. S. Astur, J. T. West, J. A. Griego, and L. M. Rowland. 2012. Spatial Memory Deficits in a Virtual Reality Eight-Arm Radial Maze in Schizophrenia. *Schizophr. Res.* **135**:84–89. [17]
- Staerk, J., M. M. Dawlaty, Q. Gao, et al. 2010. Reprogramming of Human Peripheral Blood Cells to Induced Pluripotent Stem Cells. *Cell Stem Cell* **7**:20–24. [10]
- Stangl, D., and S. Thuret. 2009. Impact of Diet on Adult Hippocampal Neurogenesis. *Genes Nutr.* **4**:271–282. [17]
- Steen, R. G., C. Mull, R. McClure, R. M. Hamer, and J. A. Lieberman. 2006. Brain Volume in First-Episode Schizophrenia: Systematic Review and Meta-Analysis of Magnetic Resonance Imaging Studies. *Br. J. Psychiatry* **188**:510–518. [09]
- Stein, L. I., and A. B. Santos. 1998. Assertive Community Treatment of Persons with Severe Mental Illness. New York: Norton. [15]

- Steindler, D. A., and D. W. Pincus. 2002. Stem Cells and Neurogenesis in the Adult Human Brain. *Lancet* **359**:1047–1054. [07]
- Stephan, K. E., K. J. Friston, and C. D. Frith. 2009. Dysconnection in Schizophrenia: From Abnormal Synaptic Plasticity to Failures of Self-Monitoring. *Schizophr. Bull.* **35**:509–527. [13]
- Stirling, J., C. White, S. Lewis, et al. 2003. Neurocognitive Function and Outcome in First-Episode Schizophrenia: A 10-Year Follow-up of an Epidemiological Cohort. *Schizophr. Res.* **65**:75–86. [04]
- Stone, J. M., F. Day, H. Tsagaraki, et al. 2009. Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume. *Biol. Psychiatry* **66**:533–539. [07]
- Stone, W. S., and L. Iguchi. 2011. Do Apparent Overlaps between Schizophrenia and Autistic Spectrum Disorders Reflect Superficial Similarities or Etiological Commonalities? *N. Am. J. Med. Sci.* **4**:124–133. [01]
- Strauss, J. S. 1969. Hallucinations and Delusions as Points on Continuum Function. Rating Scale Evidence. *Arch. Gen. Psychiatry* **21**:581–586. [03]
- Strauss, J. S., and W. T. Carpenter, Jr. 1972. The Prediction of Outcome in Schizophrenia I. Characteristics of Outcome. *Arch. Gen. Psychiatry* **27**:739–746. [15, 17]
- . 1975. The Key Clinical Dimensions of the Functional Psychoses. *Publ. Assoc. Res. Nerv. Ment. Dis.* **54**:9–17. [03]
- . 1977. Prediction of Outcome in Schizophrenia III. Five-Year Outcome and Its Predictors. *Arch. Gen. Psychiatry* **34**:159–163. [15]
- . 1981. Schizophrenia. New York: Plenum Medical Books. [03]
- Strauss, J. S., W. T. Carpenter, Jr., and J. J. Bartko. 1974. The Diagnosis and Understanding of Schizophrenia. Part III. Speculations on the Processes That Underlie Schizophrenic Symptoms and Signs. *Schizophr. Bull.* **Winter**:61–69. [03]
- Strauss, M. E. 2001. Demonstrating Specific Cognitive Deficits: A Psychometric Perspective. *J. Abnorm. Psychol.* **110**:6–14. [02]
- Sturgeon, D., G. Turpin, L. Kuipers, R. Berkowitz, and J. Leff. 1984. Physiological Responses of Schizophrenic Patients to High and Low Expressed Emotion Relatives: A Follow-up Study. *Br. J. Psychiatry* **145**:62–69. [01]
- Sturman, D. A., D. R. Mandell, and B. Moghaddam. 2010. Adolescents Exhibit Behavioral Differences from Adults During Instrumental Learning and Extinction. *Behav. Neurosci.* **124**:16–25. [13]
- Sturman, D. A., and B. Moghaddam. 2011. The Neurobiology of Adolescence: Changes in Brain Architecture, Functional Dynamics, and Behavioral Tendencies. *Neurosci. Biobehav. Rev.* **35**:1704–1712. [13]
- . 2012. Striatum Processes Reward Differently in Adolescents Versus Adults. *PNAS* **109**:1719–1724. [13]
- Sullivan, G., N. Duan, S. Mukherjee, et al. 2005. The Role of Services Researchers in Facilitating Intervention Research. *Psychiatr. Serv.* **56**:537–542. [15]
- Sullivan, P. F. 2007. Spurious Genetic Associations. *Biol. Psychiatry* **61**:1121–1126. [08]
- Sullivan, P. F., M. J. Daly, and M. O'Donovan. 2012a. Genetic Architectures of Psychiatric Disorders: The Emerging Picture and Its Implications. *Nat. Rev. Genet.* **13**:537–551. [09, 13]
- Sullivan, P. F., K. S. Kendler, and M. C. Neale. 2003. Schizophrenia as a Complex Trait: Evidence from a Meta-Analysis of Twin Studies. *Arch. Gen. Psychiatry* **60**:1187–1192. [07, 08]

- Sullivan, P. F., C. Magnusson, A. Reichenberg, et al. 2012b. Family History of Schizophrenia and Bipolar Disorder as Risk Factors for Autism. *Arch. Gen. Psychiatry* **69**:1099–1103. [05, 06]
- Sullivan, P. F., M. C. Neale, and K. S. Kendler. 2000. Genetic Epidemiology of Major Depression: Review and Meta-Analysis. *Am. J. Psychiatr.* **157**:1552–1562. [08]
- Swerdlow, N. R. 2011. Are We Studying and Treating Schizophrenia Correctly? *Schizophr. Res.* **130**:1–10. [07]
- Swerdlow, N. R., D. L. Braff, and M. A. Geyer. 1999. Cross-Species Studies of Sensorimotor Gating of the Startle Reflex. *Ann. NY Acad. Sci.* **877**:202–216. [07]
- Swerdlow, N. R., S. Caine, D. Braff, and M. Geyer. 1992. The Neural Substrates of Sensorimotor Gating of the Startle Reflex: A Review of Recent Findings and Their Implications. *J. Psychopharmacol.* **6**:176–190. [07]
- Swerdlow, N. R., N. Halim, F. M. Hanlon, A. Platten, and P. P. Auerbach. 2001. Lesion Size and Amphetamine Hyperlocomotion after Neonatal Ventral Hippocampal Lesions: More Is Less. *Brain Res. Bull.* **55**:71–77. [11]
- Swerdlow, N. R., S. A. Lelham, A. N. Sutherland Owens, et al. 2009a. Pramipexole Effects on Startle Gating in Rats and Normal Men. *Psychopharmacology* **205**:689–698. [07]
- Swerdlow, N. R., G. A. Light, K. S. Cadenhead, et al. 2006. Startle Gating Deficits in a Large Cohort of Patients with Schizophrenia: Relationship to Medications, Symptoms, Neurocognition, and Level of Function. *Arch. Gen. Psychiatry* **63**:1325–1335. [07]
- Swerdlow, N. R., N. Stephany, J. M. Shoemaker, et al. 2002. Effects of Amantadine and Bromocriptine on Startle and Sensorimotor Gating: Parametric Studies and Cross-Species Comparisons. *Psychopharmacology* **164**:82–92. [07]
- Swerdlow, N. R., D. P. van Bergeijk, F. Bergsma, E. Weber, and J. Talledo. 2009b. The Effects of Memantine on Prepulse Inhibition. *Neuropsychopharmacology* **34**:1854–1864. [07]
- Swerdlow, N. R., M. Weber, Y. Qu, G. A. Light, and D. L. Braff. 2008. Realistic Expectations of Prepulse Inhibition in Translational Models for Schizophrenia Research. *Psychopharmacology* **199**:331–388. [07]
- Symond, M. P., A. W. Harris, E. Gordon, and L. M. Williams. 2005. “Gamma Synchrony” in First-Episode Schizophrenia: A Disorder of Temporal Connectivity? *Am. J. Psychiatr.* **162**:459–465. [04, 07]
- Szoke, A., A. Trandafir, M.-E. Dupont, et al. 2008. Longitudinal Studies of Cognition in Schizophrenia: Meta-Analysis. *Br. J. Psychiatry* **192**:248–257. [04]
- Tackett, J. L., A. L. Silberschmidt, R. F. Krueger, and S. R. Sponheim. 2008. A Dimensional Model of Personality Disorder: Incorporating DSM Cluster A Characteristics. *J. Abnorm. Psychol.* **117**:454–459. [02]
- Tajinda, K., K. Ishizuka, C. Colantuoni, et al. 2010. Neuronal Biomarkers from Patients with Mental Illnesses: A Novel Method through Nasal Biopsy Combined with Laser-Captured Microdissection. *Mol. Psychiatry* **15**:231–232. [10]
- Takahashi, K., and S. Yamanaka. 2006. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* **126**:663–676. [10]
- Talamo, B. R., R. Rudel, K. S. Kosik, et al. 1989. Pathological Changes in Olfactory Neurons in Patients with Alzheimer’s Disease. *Nature* **337**:736–739. [10]
- Talledo, J. A., A. N. Sutherland Owens, T. Schortinghuis, and N. R. Swerdlow. 2009. Amphetamine Effects on Startle Gating in Normal Women and Female Rats. *Psychopharmacology* **204**:165–175. [07]

- Tan, P.-N., M. Steinbach, and V. Kumar. 2005. Introduction to Data Mining: Addison-Wesley. [05]
- Tan, Z. S., W. S. Harris, A. S. Beiser, et al. 2012. Red Blood Cell Omega-3 Fatty Acid Levels and Markers of Accelerated Brain Aging. *Neurology* **78**:658–664. [07]
- Tandon, R., and W. T. Carpenter, Jr. 2012. DSM-5 Status of Psychotic Disorders. *Schizophr. Bull.* **38**:369–370. [02]
- Tandon, R., M. S. Keshavan, and H. Nasrallah. 2008. Schizophrenia, “Just the Facts”: What We Know in 2008 Part 1: Overview. *Schizophr. Res.* **100**:4–19. [05, 13]
- Tandon, R., H. A. Nasrallah, and M. S. Keshavan. 2011. “Just the Facts”: Meandering in Schizophrenia’s Many Forests. *Schizophr. Res.* **128**:5–6. [07]
- Tarasenko, M., M. Sullivan, A. Ritchie, and W. Spaulding. 2012. Effects of Eliminating Psychiatric Rehabilitation from the Secure Levels of a Mental Health Service System. *Psychol. Serv.* Epub ahead of print. [17]
- Tarrier, N., C. Barrowclough, G. Haddock, and J. McGovern. 1999. The Dissemination of Innovative Cognitive-Behavioural Psychosocial Treatments for Schizophrenia. *J. Ment. Health* **8**:569–582. [15]
- Tarrier, N., R. Beckett, S. Harwood, et al. 1993. A Trial of Two Cognitive Behavioural Methods of Treating Drug-Resistant Residual Psychotic Symptoms in Schizophrenic Patients: I. Outcome. *Br. J. Psychiatry* **162**:524–532. [15]
- Taylor, M. J., S. Sen, and Z. Bhagwagar. 2010. Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region. *Biol. Psychiatry* **68**:536–543. [08]
- Tayoshi, S., S. Sumitani, K. Taniguchi, et al. 2009. Metabolite Changes and Gender Differences in Schizophrenia Using 3-Tesla Proton Magnetic Resonance Spectroscopy (1H-MRS). *Schizophr. Res.* **108**:69–77. [07]
- Teague, G. B., K. T. Mueser, and C. A. Rapp. 2012. Advances in Fidelity Measurement for Mental Health Services Research: Four Measures. *Psychiatr. Serv.* **63**:765–771. [15]
- Thaker, G. 2008. Neurophysiological Endophenotypes across Bipolar and Schizophrenia Psychosis. *Schizophr. Bull.* **34**:760–773. [03]
- Theberge, J., Y. Al-Semaan, P. C. Williamson, et al. 2003. Glutamate and Glutamine in the Anterior Cingulate and Thalamus of Medicated Patients with Chronic Schizophrenia and Healthy Comparison Subjects Measured with 4.0-T Proton MRS. *Am. J. Psychiatr.* **160**:2231–2233. [07]
- Theodoridou, A., F. Schlatter, V. Ajdacic, W. Rössler, and M. Jäger. 2012. Therapeutic Relationship in the Context of Perceived Coercion in a Psychiatric Population. *Psychiatry Res.* **200**:939–944. [16]
- Thermenos, H. W., L. J. Seidman, H. Breiter, et al. 2004. Functional Magnetic Resonance Imaging During Auditory Verbal Working Memory in Nonpsychotic Relatives of Persons with Schizophrenia: A Pilot Study. *Biol. Psychiatry* **55**:490–500. [07]
- Thornberry, T. P. 1987. Toward an Interactional Theory of Delinquency. *Criminology* **25**:863–891. [01]
- Tienari, P., L. C. Wynne, A. Sorri, et al. 2004. Genotype-Environment Interaction in Schizophrenia-Spectrum Disorder: Long-Term Follow-up Study of Finnish Adoptees. *Br. J. Psychiatry* **184**:216–222. [01, 09]
- Tiihonen, J., J. Lönnqvist, K. Wahlbeck, et al. 2009. 11-Year Follow-up of Mortality in Patients with Schizophrenia: A Population-Based Cohort Study (FIN11 Study). *Lancet* **374**:620–627. [05]
- Ting, J. T., J. Peca, and G. Feng. 2012. Functional Consequences of Mutations in Postsynaptic Scaffolding Proteins and Relevance to Psychiatric Disorders. *Annu. Rev. Neurosci.* **35**:49–71. [13]

- Toch, H., and K. Adams. 1989. *The Disturbed Violent Offender*. New Haven: Yale Univ. Press. [01]
- Tost, H., and A. Meyer-Lindenberg. 2012. Puzzling over Schizophrenia: Schizophrenia, Social Environment and the Brain. *Nat. Med.* **18**:211–213. [09, 12]
- Touloupoulou, T., T. E. Goldberg, I. R. Mesa, et al. 2010. Impaired Intellect and Memory: A Missing Link between Genetic Risk and Schizophrenia? *Arch. Gen. Psychiatry* **67**:905–913. [14]
- Townsend, L. A., and R. M. Norman. 2004. Course of Cognitive Functioning in First Episode Schizophrenia Spectrum Disorders. *Expert. Rev. Neurother.* **4**:61–68. [04]
- Toyokawa, S., M. Uddin, K. C. Koenen, and S. Galea. 2012. How Does the Social Environment “Get into the Mind”? Epigenetics at the Intersection of Social and Psychiatric Epidemiology. *Soc. Sci. Med.* **74**:67–74. [09]
- Trantham-Davidson, H., L. C. Neely, A. Lavin, and J. K. Seamans. 2004. Mechanisms Underlying Differential D1 Versus D2 Dopamine Receptor Regulation of Inhibition in Prefrontal Cortex. *J. Neurosci.* **24**:10652–10659. [12]
- Trikalinos, T. A., E. E. Ntzani, D. G. Contopoulos-Ioannidis, and J. P. Ioannidis. 2004. Establishment of Genetic Associations for Complex Diseases Is Independent of Early Study Findings. *Eur. J. Hum. Genet.* **12**:762–769. [08]
- Trojanowski, J. Q., P. D. Newman, W. D. Hill, and V. M. Lee. 1991. Human Olfactory Epithelium in Normal Aging, Alzheimer’s Disease, and Other Neurodegenerative Disorders. *J. Comp. Neurol.* **310**:365–376. [10]
- Tryson, G. S., and G. Winograd. 2001. Goal Consensus and Collaboration. *Psychotherapy* **38**:385–389. [15]
- Tseng, K. Y., R. A. Chambers, and B. K. Lipska. 2009. The Neonatal Ventral Hippocampal Lesion as a Heuristic Neurodevelopmental Model of Schizophrenia. *Behav. Brain Res.* **204**:295–305. [11]
- Tseng, K. Y., B. L. Lewis, T. Hashimoto, et al. 2008. A Neonatal Ventral Hippocampal Lesion Causes Functional Deficits in Adult Prefrontal Cortical Interneurons. *J. Neurosci.* **28**:12691–12699. [11]
- Tseng, K. Y., and P. O’Donnell. 2007. Dopamine Modulation of Prefrontal Cortical Interneurons Changes During Adolescence. *Cereb. Cortex* **17**:1235–1240. [13]
- Tsukada, H., H. Ohba, S. Nishiyama, and T. Kakiuchi. 2011. Differential Effects of Stress on [(1)(1)C]Raclopride and [(1)(1)C]MNPA Binding to Striatal D(2)/D(3) Dopamine Receptors: A PET Study in Conscious Monkeys. *Synapse* **65**:84–89. [07]
- Tulsky, D. S., and L. R. Price. 2003. The Joint WAIS-III and WMS-III Factor Structure: Development and Cross-Validation of a Six-Factor Model of Cognitive Functioning. *Psychol. Assess.* **15**:149–162. [04]
- Turetsky, B. I., M. E. Calkins, G. A. Light, et al. 2007. Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures. *Schizophr. Bull.* **33**:69–94. [03]
- Turetsky, B. I., C. G. Hahn, K. Borgmann-Winter, and P. J. Moberg. 2009. Scents and Nonsense: Olfactory Dysfunction in Schizophrenia. *Schizophr. Bull.* **35**:1117–1131. [10]
- Turetsky, B. I., and P. J. Moberg. 2009. An Odor-Specific Threshold Deficit Implicates Abnormal Intracellular Cyclic Amp Signaling in Schizophrenia. *Am. J. Psychiatr.* **166**:226–233. [10]
- Turner, E. E., N. Fedtsova, and D. V. Jeste. 1997. Cellular and Molecular Neuropathology of Schizophrenia: New Directions from Developmental Neurobiology. *Schizophr. Res.* **27**:169–180. [12]

- Twamley, E. W., C. Z. Burton, and L. Vella. 2011. Compensatory Cognitive Training for Psychosis: Who Benefits? Who Stays in Treatment? *Schizophr. Bull.* **37**(Suppl. 2):S55–62. [07]
- Twamley, E. W., G. N. Savla, C. H. Zurhellen, R. K. Heaton, and D. V. Jeste. 2008. Development and Pilot Testing of a Novel Compensatory Cognitive Training Intervention for People with Psychosis. *Am. J. Psychiatr. Rehabil.* **11**:144–163. [07]
- Uhlhaas, P. J., F. Roux, W. Singer, et al. 2009. The Development of Neural Synchrony Reflects Late Maturation and Restructuring of Functional Networks in Humans. *PNAS* **106**:9866–9871. [13]
- Uhlhaas, P. J., S. M. Silverstein, W. A. Phillips, and P. G. Lovell. 2004. Evidence for Impaired Visual Context Processing in Schizotypy with Thought Disorder. *Schizophr. Res.* **68**:249–260. [02]
- Uhlhaas, P. J., and W. Singer. 2010. Abnormal Neural Oscillations and Synchrony in Schizophrenia. *Nat. Rev. Neurosci.* **11**:100–113. [04, 12]
- . 2012. Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks. *Neuron* **75**:963–980. [13]
- Umbricht, D., D. Javitt, G. Novak, et al. 1998. Effects of Clozapine on Auditory Event-Related Potentials in Schizophrenia. *Biol. Psychiatry* **44**:716–725. [07]
- . 1999. Effects of Risperidone on Auditory Event-Related Potentials in Schizophrenia. *Int. J. Neuropsychopharmacol.* **2**:299–304. [07]
- Umbricht, D. S., J. A. Bates, J. A. Lieberman, J. M. Kane, and D. C. Javitt. 2006. Electrophysiological Indices of Automatic and Controlled Auditory Information Processing in First-Episode, Recent-Onset and Chronic Schizophrenia. *Biol. Psychiatry* **59**:762–772. [07]
- Vacic, C., S. McCarthy, Malhotra D, et al. 2011. Duplications of the Neuropeptide Receptor Gene VIPR2 Confer Significant Risk for Schizophrenia. *Nature* **471**:499–503. [05]
- Vaidya, V. A., G. J. Marek, G. K. Aghajanian, and R. S. Duman. 1997. 5-HT_{2A} Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex. *J. Neurosci.* **17**:2785–2795. [07]
- Valkonen-Korhonen, M., M. Purhonen, I. M. Tarkka, et al. 2003. Altered Auditory Processing in Acutely Psychotic Never-Medicating First-Episode Patients. *Brain Res. Cogn. Brain Res.* **17**:747–758. [07]
- van Berckel, B. N., B. Oranje, J. M. van Ree, M. N. Verbaten, and R. S. Kahn. 1998. The Effects of Low Dose Ketamine on Sensory Gating, Neuroendocrine Secretion and Behavior in Healthy Human Subjects. *Psychopharmacology* **137**:271–281. [07]
- Vancampfort, D., M. Probst, L. Helvik Skjaerven, et al. 2012. Systematic Review of the Benefits of Physical Therapy within a Multidisciplinary Care Approach for People with Schizophrenia. *Phys. Ther.* **92**:11–23. [07]
- Van Craenenbroeck, K., K. De Bosscher, W. Vanden Berghe, P. Vanhoenacker, and G. Haegeman. 2005. Role of Glucocorticoids in Dopamine-Related Neuropsychiatric Disorders. *Mol. Cell Endocrinol.* **245**:10–22. [07]
- Van Den Bossche, M. J., M. Johnstone, M. Strazisar, et al. 2012. Rare Copy Number Variants in Neuropsychiatric Disorders: Specific Phenotype or Not? *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **159B**:812–822. [09]
- van den Buuse, M. 2010. Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects. *Schizophr. Bull.* **36**:246–270. [13]

- van der Gaag, M., D. H. Nieman, J. Rietdijk, et al. 2012. Cognitive Behavioral Therapy for Subjects at Ultrahigh Risk for Developing Psychosis: A Randomized Controlled Clinical Trial. *Schizophr. Bull.* **38**:1180–1188. [01]
- Van Oel, J., M. M. Sitskoorn, M. P. M. Cremer, and R. S. Kahn. 2002. School Performance as a Premorbid Marker for Schizophrenia: A Twin Study. *Schizophr. Bull.* **28**:401–414. [14, 17]
- van Os, J. 2004. Does the Urban Environment Cause Psychosis? *Br. J. Psychiatry* **184**:287–288. [07]
- van Os, J., and S. Kapur. 2009. Schizophrenia. *Lancet* **374**:635–645. [15]
- van Os, J., G. Kenis, and B. P. Rutten. 2010. The Environment and Schizophrenia. *Nature* **468**:203–212. [09]
- van Os, J., R. J. Linscott, I. Myin-Germeys, P. Delespaul, and L. Krabbendam. 2009. A Systematic Review and Meta-Analysis of the Psychosis Continuum: Evidence for a Psychosis Proneness-Persistence-Impairment Model of Psychotic Disorder. *Psychol. Med.* **39**:179–195. [05, 09, 16]
- van Os, J., C. B. Pedersen, and P. B. Mortensen. 2004. Confirmation of Synergy between Urbanicity and Familial Liability in the Causation of Psychosis. *Am. J. Psychiatry* **161**:2312–2314. [09]
- van Os, J., B. P. Rutten, and R. Poulton. 2008. Gene–Environment Interactions in Schizophrenia: Review of Epidemiological Findings and Future Directions. *Schizophr. Bull.* **34**:1066–1082. [08, 09]
- van Winkel, R. 2011. Family-Based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-Up. *Arch. Gen. Psychiatry* **68**:148–157. [09]
- van Winkel, R., B. P. Rutten, O. Peerbooms, et al. 2010. Mthfr and Risk of Metabolic Syndrome in Patients with Schizophrenia. *Schizophr. Res.* **121**:193–198. [17]
- Varese, F., F. Smeets, M. Drukker, et al. 2012. Childhood Adversities Increase the Risk of Psychosis: A Meta-Analysis of Patient-Control, Prospective- and Cross-Sectional Cohort Studies. *Schizophr. Bull.* **38**:661–671. [09]
- Varghese, D., J. Scott, J. Welham, et al. 2011. Psychotic-Like Experiences in Major Depression and Anxiety Disorders: A Population-Based Survey in Young Adults. *Schizophr. Bull.* **37**:389–393. [09]
- Varker, T., and G. J. Devilly. 2012. An Analogue Trial of Inoculation/Resilience Training for Emergency Services Personnel: Proof of Concept. *J. Anxiety Disord.* **26**:696–701. [06]
- Vauth, R., P. W. Corrigan, M. Clauss, et al. 2005. Cognitive Strategies Versus Self-Management Skills as Adjunct to Vocational Rehabilitation. *Schizophr. Bull.* **31**:55–66. [15]
- Velligan, D. I., P. M. Diamond, N. J. Maples, et al. 2008. Comparing the Efficacy of Interventions That Use Environmental Supports to Improve Outcomes in Patients with Schizophrenia. *Schizophr. Res.* **102**:312–319. [07]
- Velligan, D. I., P. M. Diamond, J. Mintz, et al. 2006. The Use of Individually Tailored Environmental Supports to Improve Medication Adherence and Outcomes in Schizophrenia. *Schizophr. Bull.* **32**:483–489. [15]
- Velligan, D. I., T. J. Prihoda, J. L. Ritch, et al. 2002. A Randomized Single-Blind Pilot Study of Compensatory Strategies in Schizophrenia Outpatients. *Schizophr. Bull.* **28**:283–292. [15]
- Ventura, J., S. A. Wilson, R. C. Wood, and G. S. Helleman. 2013. Cognitive Training at Home in Schizophrenia Is Feasible. *Schizophr. Res.* **143**:397–398. [01]

- Verdoux, H., and J. van Os. 2002. Psychotic Symptoms in Non-Clinical Populations and the Continuum of Psychosis. *Schizophr. Res.* **54**:59–65. [14]
- Verhaeghe, N., J. De Maeseneer, L. Maes, C. Van Heeringen, and L. Annemans. 2011. Effectiveness and Cost-Effectiveness of Lifestyle Interventions on Physical Activity and Eating Habits in Persons with Severe Mental Disorders: A Systematic Review. *Int. J. Behav. Nutr. Phys. Act.* **8**:28. [17]
- Vértes, P. E., A. F. Alexander-Bloch, N. Gogtay, et al. 2012. Simple Models of Human Brain Functional Networks. *PNAS* **109**:5868–5873. [06]
- Vesell, E. S. 1978. Twin Studies in Pharmacogenetics. *Hum. Genet. Suppl.* **19**:30. [07]
- Vierbuchen, T., A. Ostermeier, Z. P. Pang, et al. 2010. Direct Conversion of Fibroblasts to Functional Neurons by Defined Factors. *Nature* **463**:1035–1041. [10]
- Vijayraghavan, S., M. Wang, S. G. Birnbaum, G. V. Williams, and A. F. Arnsten. 2007. Inverted-U Dopamine D1 Receptor Actions on Prefrontal Neurons Engaged in Working Memory. *Nat. Neurosci.* **10**:376–384. [09, 12]
- Vinogradov, S., M. Fisher, and E. de Villers-Sidani. 2012. Cognitive Training for Impaired Neural Systems in Neuropsychiatric Illness. *Neuropsychopharmacology* **37**:43–76. [07]
- Volavka, J., and L. Citrome. 2011. Pathways to Aggression in Schizophrenia Affect Results of Treatment. *Schizophr. Bull.* **37**:921–929. [01]
- Vollenweider, F. X., M. Barro, P. A. Csomor, and J. Feldon. 2006. Clozapine Enhances Prepulse Inhibition in Healthy Humans with Low but Not with High Prepulse Inhibition Levels. *Biol. Psychiatry* **60**:597–603. [07]
- Vonk, R., A. C. van der Schot, G. C. M. van Baal, et al. 2012. Premorbid School Performance in Twins Concordant and Discordant for Bipolar Disorder. *J. Affect. Disord.* **136**:294–303. [14, 17]
- Waddington, J. L. 1993. Schizophrenia: Developmental Neuroscience and Pathobiology. *Lancet* **341**:531–536. [11]
- Walker, E., N. Lewis, R. Loewy, and S. Palyo. 1999. Motor Dysfunction and Risk for Schizophrenia. *Dev. Psychopathol.* **11**:509–523. [01]
- Walker, E., V. Mittal, and K. Tessner. 2008. Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia. *Annu. Rev. Clin. Psychol.* **4**:189–216. [07]
- Walker, E. F., P. A. Brennan, M. Esterberg, et al. 2010. Longitudinal Changes in Cortisol Secretion and Conversion to Psychosis in At-Risk Youth. *J. Abnorm. Psychol.* **119**:401–408. [07]
- Walker, E. F., D. J. Walder, and F. Reynolds. 2001. Developmental Changes in Cortisol Secretion in Normal and at-Risk Youth. *Dev. Psychopathol.* **13**:721–732. [07]
- Wallace, C. J., R. Tauber, and J. Wilde. 1999. Teaching Fundamental Workplace Skills to Persons with Serious Mental Illness. *Psychiatr. Serv.* **50**:1147–1153. [15]
- Walport, M., and P. Brest. 2011. Sharing Research Data to Improve Public Health. *Lancet* **377**:537–539. [09]
- Wand, G. S., L. M. Oswald, M. E. McCaul, et al. 2007. Association of Amphetamine-Induced Striatal Dopamine Release and Cortisol Responses to Psychological Stress. *Neuropsychopharmacology* **32**:2310–2320. [07]
- Wang, S. J., H. M. Hung, and R. O'Neill. 2011. Regulatory Perspectives on Multiplicity in Adaptive Design Clinical Trials Throughout a Drug Development Program. *J. Biopharm. Stat.* **21**:846–859. [17]
- Warren, L., P. D. Manos, T. Ahfeldt, et al. 2010. Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. *Cell Stem Cell* **7**:618–630. [10]

- Weickert, T. W., T. E. Goldberg, A. Mishara, et al. 2004. Catechol-O-Methyltransferase Val(108/158)Met Genotype Predicts Working Memory Response to Antipsychotic Medications. *Biol. Psychiatry* **56**:677–682. [07]
- Weinberger, D. R. 1987. Implications of Normal Brain Development for the Pathogenesis of Schizophrenia. *Arch. Gen. Psychiatry* **44**:660–669. [03, 07, 08, 09, 12]
- Weiser, M., and S. Noy. 2005. Interpreting the Association between Cannabis Use and Increased Risk for Schizophrenia. *Dialog. Clin. Neurosci.* **7**:81–85. [07]
- Welham, J., M. Isohanni, P. Jones, and J. McGrath. 2009. The Antecedents of Schizophrenia: A Review of Birth Cohort Studies. *Schizophr. Bull.* **35**:603–623. [09]
- Wells, K., J. Miranda, M. L. Bruce, M. Alegria, and N. Wallerstein. 2004. Bridging Community Intervention and Mental Health Services Research. *Am. J. Psychiatr.* **161**:955–963. [15]
- White, J. G., E. Southgate, J. N. Thomson, and S. Brenner. 1986. The Structure of the Nervous System of the Nematode *Caenorhabditis Elegans*. *Phil. Trans. R. Soc. Lond. B* **314**:1–340. [10]
- Whitford, T. J., T. F. D. Farrow, C. J. Rennie, et al. 2006. Longitudinal Changes in Regional Grey Matter Volume and Corresponding EEG Power in First-Episode Psychosis. *Aust. NZ J. Psychiatry* **40**:A122–A123. [04]
- Whyte, J. 1998. Distinctive Methodological Challenges. In: *Assessing Medical Rehabilitation Practices : The Promise of Outcomes Research*, ed. M. J. Fuhrer, pp. 43–59. Baltimore: Paul H. Brookes. [01]
- Whyte, M. C., C. Brett, L. K. Harrison, et al. 2006. Neuropsychological Performance over Time in People at High Risk of Developing Schizophrenia and Controls. *Biol. Psychiatry* **59**:730–739. [07]
- Wicks, S., A. Hjern, and C. Dalman. 2010. Social Risk or Genetic Liability for Psychosis? A Study of Children Born in Sweden and Reared by Adoptive Parents. *Am. J. Psychiatr.* **167**:1240–1246. [09]
- Wicks, S., A. Hjern, D. Gunnell, G. Lewis, and C. Dalman. 2005. Social Adversity in Childhood and the Risk of Developing Psychosis: A National Cohort Study. *Am. J. Psychiatr.* **162**:1652–1657. [09]
- Wienberg, M., B. Y. Glenthøj, K. S. Jensen, and B. Oranje. 2010. A Single High Dose of Escitalopram Increases Mismatch Negativity without Affecting Processing Negativity or P300 Amplitude in Healthy Volunteers. *J. Psychopharmacol.* **24**:1183–1192. [07]
- Wiersma, D., F. J. Nienhuis, C. J. Slooff, and R. Giel. 1998. Natural Course of Schizophrenic Disorders: A 15-Year Follow-up of a Dutch Incidence Cohort. *Schizophr. Bull.* **24**:75–85. [06]
- Wilke, R. A., and M. E. Dolan. 2011. Genetics and Variable Drug Response. *JAMA* **306**:306–307. [07]
- Williams, G. V., and P. S. Goldman-Rakic. 1995. Modulation of Memory Fields by Dopamine D1 Receptors in Prefrontal Cortex. *Nature* **376**:572–575. [09]
- Williams, L. M., P. Das, B. J. Liddell, et al. 2006. Mode of Functional Connectivity in Amygdala Pathways Dissociates Level of Awareness for Signals of Fear. *J. Neurosci.* **26**:9264–9271. [04]
- . 2007a. Fronto-Limbic and Autonomic Disjunctions to Negative Emotion Distinguish Schizophrenia Subtypes. *Psychiatry Res.* **155**:29–44. [04]
- Williams, L. M., T. J. Whitford, G. Flynn, et al. 2007b. General and Social Cognition in First Episode Schizophrenia: Identification of Separable Factors and Prediction of Functional Outcome Using the Integneuro Test Battery. *Schizophr. Res.* **99**:182–191. [04]

- Williams, L. M., T. J. Whitford, E. Gordon, et al. 2009a. Neural Synchrony in Patients with a First Episode of Schizophrenia: Tracking Relations with Grey Matter and Symptom Profile. *J. Psychiatry Neurosci.* **34**:21–29. [07]
- Williams, L. M., T. J. Whitford, M. Nagy, et al. 2009b. Emotion-Elicited Gamma Synchrony in Patients with First-Episode Schizophrenia: A Neural Correlate of Social Cognition Outcomes. *J. Psychiatry Neurosci.* **34**:303–313. [04, 07]
- Wilson, B. A. 1991. Long-Term Prognosis of Patients with Severe Memory Disorders. *Neuropsychol. Rehabil.* **1**:117–134. [01]
- . 1997. Cognitive Rehabilitation : How It Is and How It Might Be. *J. Int. Neuropsychol. Soc.* **3**:487–496. [01]
- Wittchen, H. U. 2000. Epidemiological Research in Mental Disorders: Lessons for the Next Decade of Research: The Nape Lecture 1999. *Acta Psychiatr. Scand.* **101**:2–10. [16]
- Wolf, R. C., N. Vasic, F. Sambataro, et al. 2009. Temporally Anticorrelated Brain Networks During Working Memory Performance Reveal Aberrant Prefrontal and Hippocampal Connectivity in Patients with Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **33**:1464–1473. [09]
- Wolf, R. C., N. Vasic, and H. Walter. 2006. The Concept of Working Memory in Schizophrenia: Current Evidence and Future Perspectives. *Fortschr. Neurol. Psychiatr.* **74**:449–468. [01]
- Wolfson, M., S. E. Wallace, N. Masca, et al. 2010. Datashield: Resolving a Conflict in Contemporary Bioscience: Performing a Pooled Analysis of Individual-Level Data without Sharing the Data. *Int. J. Epidemiol.* **39**:1372–1382. [09]
- Wood, J., Y. Kim, and B. Moghaddam. 2012. Disruption of Prefrontal Cortex Large Scale Neuronal Activity by Different Classes of Psychotomimetic Drugs. *J. Neurosci.* **32**:3022–3031. [13]
- Wood, S., A. Yung, P. McGorry, and C. Pantelis. 2011. Neuroimaging and Treatment Evidence for Clinical Staging in Psychotic Disorders: From the At-Risk Mental State to Chronic Schizophrenia. *Biol. Psychiatry* **70**:619–625. [05]
- Woodberry, K. A., A. J. Giuliano, and L. J. Seidman. 2008. Premorbid IQ in Schizophrenia: A Meta-Analytic Review. *Am. J. Psychiatr.* **165**:579–587. [14]
- Woodward, N. D., K. Jayathilake, and H. Y. Meltzer. 2007. COMT Val108/158met Genotype, Cognitive Function, and Cognitive Improvement with Clozapine in Schizophrenia. *Schizophr. Res.* **90**:86–96. [07]
- Woodward, N. D., S. E. Purdon, H. Y. Meltzer, and D. H. Zald. 2005. A Meta-Analysis of Neuropsychological Change to Clozapine, Olanzapine, Quetiapine, and Risperidone in Schizophrenia. *Int. J. Neuropsychopharmacol.* **8**:457–472. [04]
- Woolf, C. M. 1997. Does the Genotype for Schizophrenia Often Remain Unexpressed Because of Canalization and Stochastic Events During Development? *Psychol. Med.* **27**:659–668. [13]
- World Health Organization. 2010. International Classification of Diseases (ICD-10). Geneva: World Health Organization. [05]
- Wright, A. G. C., K. M. Thomas, C. J. Hopwood, et al. 2012. The Hierarchical Structure of DSM-5 Pathological Personality Traits. *J. Abnorm. Psychol.* **121**:951–917. [02]
- Wright, E. R. 1997. The Impact of Organizational Factors on Mental Health Professionals' Involvement with Families. *Psychiatr. Serv.* **48**:921–927. [15]
- Wu, E. Q., H. G. Birnbaum, L. Shi, et al. 2005. The Economic Burden of Schizophrenia in the United States in 2002. *J. Clin. Psychiatry* **66**:1122–1129. [01]
- Wyatt, R. J. 1991. Neuroleptics and the Natural Course of Schizophrenia. *Schizophr. Bull.* **17**:325–351. [04]

- Wykes, T. 1998. What Are We Changing with Neurocognitive Rehabilitation? Illustrations from Two Single Cases of Changes in Neuropsychological Performance and Brain Systems as Measured by SPECT. *Schizophr. Res.* **34**:77–86. [01]
- . 2010. Cognitive Remediation Therapy Needs Funding. *Nature* **468**:165–166. [04]
- Wykes, T., M. Brammer, J. Mellers, et al. 2002. The Effects on the Brain of a Psychological Treatment, Cognitive Remediation Therapy (CRT): An fMRI Study. *Br. J. Psychiatry* **181**:144–152. [01]
- Wykes, T., V. Huddy, C. Cellard, S. R. McGurk, and P. Czobor. 2011. A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes. *Am. J. Psychiatr.* **168**:472–485. [01, 04, 05, 06, 07, 15, 17]
- Wykes, T., E. Newton, S. Landau, et al. 2007. Cognitive Remediation Therapy (CRT) for Young Early Onset Patients with Schizophrenia: An Exploratory Randomized Controlled Trial. *Schizophr. Res.* **94**:221–230. [07]
- Wykes, T., and C. Reeder. 2005. Cognitive Remediation Therapy for Schizophrenia: Theory and Practice. London: Routledge. [15]
- Wykes, T., C. Reeder, C. Huddy, et al. 2012. Developing Models of How Cognitive Improvements Change Functioning: Mediation, Moderation and Moderated Mediation. *Schizophr. Res.* **138**:88–93. [01]
- Wykes, T., C. Steel, B. Everitt, and N. Tarrier. 2008. Cognitive Behavior Therapy for Schizophrenia: Effect Sizes, Clinical Models, and Methodological Rigor. *Schizophr. Bull.* **34**:523–537. [01, 05, 15]
- Wynn, J. K., M. F. Green, J. Sprock, et al. 2007. Effects of Olanzapine, Risperidone and Haloperidol on Prepulse Inhibition in Schizophrenia Patients: A Double-Blind, Randomized Controlled Trial. *Schizophr. Res.* **95**:134–142. [07]
- Xu, B., I. Ionita-Laza, J. L. Roos, et al. 2012. De Novo Gene Mutations Highlight Patterns of Genetic and Neural Complexity in Schizophrenia. *Nat. Genet.* [09]
- Yan, J. 2013. NIMH Tries to Jumpstart Drug Innovations. *Psychiatric News* **48**:8–10. [17]
- Yang, C. R., and J. K. Seamans. 1996. Dopamine D1 Receptor Actions in Layer V–VI Rat Prefrontal Cortex Neurons In Vitro: Modulation of Dendritic-Somatic Signal Integration. *J. Neurosci* **16**:1922–1935. [12]
- Yang, N., Y. H. Ng, Z. P. Pang, T. C. Sudhof, and M. Wernig. 2011. Induced Neuronal Cells: How to Make and Define a Neuron. *Cell Stem Cell* **9**:517–525. [10]
- Yanos, P. T., D. Roe, M. L. West, S. M. Smith, and P. H. Lysaker. 2012. Group-Based Treatment for Internalized Stigma among Persons with Severe Mental Illness: Findings from a Randomized Controlled Trial. *Psychol. Serv.* **9**:248–258. [15]
- Yazawa, M., B. Hsueh, X. Jia, et al. 2011. Using Induced Pluripotent Stem Cells to Investigate Cardiac Phenotypes in Timothy Syndrome. *Nature* **471**:230–234. [10]
- Yoo, A. S., A. X. Sun, L. Li, et al. 2011. MicroRNA-Mediated Conversion of Human Fibroblasts to Neurons. *Nature* **476**:228–231. [10]
- Young, C. E., and C. R. Yang. 2004. Dopamine D1/D5 Receptor Modulates State-Dependent Switching of Soma-Dendritic Ca²⁺ Potentials via Differential Protein kinase A and C Activation in Rat Prefrontal Cortical Neurons. *J. Neurosci.* **24**:8–23. [12]
- Young, J. W., X. Zhou, and M. A. Geyer. 2010. Animal Models of Schizophrenia. *Curr. Top. Behav. Neurosci.* **4**:391–433. [13]
- Yu, J., K. Hu, K. Smuga-Otto, et al. 2009. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences. *Science* **324**:797–801. [10]
- Yu, J., M. A. Vodyanik, K. Smuga-Otto, et al. 2007. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. *Science* **318**:1917–1920. [10]

- Yung, A., L. Phillips, P. McGorry, et al. 2002. Comprehensive Assessment of At-Risk Mental States (CAARMS). Melbourne: The PACE Clinic, University of Melbourne. [07]
- Yung, A. R., and P. D. McGorry. 1996. The Initial Prodrome in Psychosis: Descriptive and Qualitative Aspects. *Aust. NZ J. Psychiatry* **30**:587–599. [09]
- Yung, A. R., and B. Nelson. 2011. Young People at Ultra High Risk for Psychosis: A Research Update. *Early Interv. Psychiatry* **5**(Suppl. 1):52–57. [01, 09]
- Yung, A. R., B. Nelson, C. Stanford, et al. 2008. Validation of “Prodromal” Criteria to Detect Individuals at Ultra High Risk of Psychosis: 2 Year Follow-Up. *Schizophr. Res.* **105**:10–17. [02]
- Yung, A. R., H. P. Yuen, G. Berger, et al. 2007. Declining Transition Rate in Ultra High Risk (Prodromal) Services: Dilution or Reduction of Risk? *Schizophr. Bull.* **33**:673–681. [02]
- Zald, D. H., and J. V. Pardo. 1997. Emotion, Olfaction, and the Human Amygdala: Amygdala Activation During Aversive Olfactory Stimulation. *PNAS* **94**:4119–4124. [10]
- Zammit, S., P. Allebeck, A. S. David, et al. 2004. A Longitudinal Study of Premorbid IQ Score and Risk of Developing Schizophrenia, Bipolar Disorder, Severe Depression, and Other Nonaffective Psychoses. *Arch. Gen. Psychiatry* **61**:354–360. [14, 17]
- Zammit, S., G. Lewis, C. Dalman, and P. Allebeck. 2010a. Examining Interactions between Risk Factors for Psychosis. *Br. J. Psychiatry* **197**:207–211. [09]
- Zammit, S., G. Lewis, J. Rasbash, et al. 2010b. Individuals, Schools, and Neighborhood: A Multilevel Longitudinal Study of Variation in Incidence of Psychotic Disorders. *Arch. Gen. Psychiatry* **67**:914–922. [08]
- Zanelli, J., A. Reichenberg, K. Morgan, et al. 2010. Specific and Generalized Neuropsychological Deficits: A Comparison of Patients with Various First-Episode Psychosis Presentations. *Am. J. Psychiatr.* **167**:78–85. [14]
- Zhang, J. P., T. Lencz, and A. K. Malhotra. 2010. D2 Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. *Am. J. Psychiatr.* **167**:763–772. [07]
- Zhang, X., K. M. Klueber, Z. Guo, et al. 2006. Induction of Neuronal Differentiation of Adult Human Olfactory Neuroepithelial-Derived Progenitors. *Brain. Res.* **1073-1074**:109–119. [10]
- Zhang, X., K. M. Klueber, Z. Guo, C. Lu, and F. J. Roisen. 2004. Adult Human Olfactory Neural Progenitors Cultured in Defined Medium. *Exp. Neurol.* **186**:112–123. [10]
- Zheng, P., X. X. Zhang, B. S. Bunney, and W. X. Shi. 1999. Opposite Modulation by Cortical N-Methyl-D-Aspartate Receptor-Mediated Responses by Low and High Concentrations of Dopamine. *Neuroscience* **91**:527–535. [12]
- Ziermans, T., P. Schothorst, M. Magnee, H. van Engeland, and C. Kemner. 2011. Reduced Prepulse Inhibition in Adolescents at Risk for Psychosis: A 2-Year Follow-up Study. *J. Psychiatry Neurosci.* **36**:127–134. [07]
- Zuardi, A. W., J. E. Hallak, S. M. Dursun, et al. 2006. Cannabidiol Monotherapy for Treatment-Resistant Schizophrenia. *J. Psychopharmacol.* **20**:683–686. [07]
- Zuckerman, L., M. Rehavi, R. Nachman, and I. Weiner. 2003. Immune Activation During Pregnancy in Rats Leads to a Postpubertal Emergence of Disrupted Latent Inhibition, Dopaminergic Hyperfunction, and Altered Limbic Morphology in the Offspring: A Novel Neurodevelopmental Model of Schizophrenia. *Neuropsychopharmacology* **28**:1778–1789. [11]